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ABSTRACT
The phosphorylation of the heterotrimeric guanine nucleotide binding proteins has 
received increasing attention as a possible mode of controlling intracellular signalling. Here 
further evidence is submitted which helps to confirm the occurrence of such 
phosphorylation events in rat hepatocytes, to identify the phosphorylation site in a-Gi_2, to 
examine the effects of insulin on the phosphorylation and to investigate any changes in the 
phosphorylation characteristics in animal models of type I and type II diabetes.
Using the antiserum 1867 it was possible to immunoprecipitate specifically the 
phosphorylated form of guanine nucleotide binding protein a-Gj.2 from rat hepatocytes. By 
carrying out two dimensional phosphopeptide mapping and phosphoamino acid analysis of 
the protein it was found that phosphorylation occurred at two different serines and that one 
of the sites was most probably a protein kinase C (PKC) phosphorylation site whilst the 
other, although being protein kinase A (PKA)-dependent, was phosphorylated by an 
unknown kinase. By the use of the enzymes trypsin and Staphylococcus aureus V8, and 
theoretical analysis of possible phosphopeptides and their migration in the two-dimensional 
chromatography, it was possible to predict the phosphorylation site for the PKC-mediated 
phosphorylation as either serine 47 or serine 144, with serine 144 being the most likely 
candidate. The identification of the other phosphorylation site was not possible from the 
data produced. These sites were also found to occur in a-G i_2 from hepatocytes in 
streptozotocin-tneated Sprague Dawley rats and in both lean and obese Zucker rats.
The incubation of hepatocytes from Sprague Dawley rats with insulin produced 
both a time and concentration dependent inhibition of the 32P-labelling of a-Gi-2 with the 
inhibition becoming significant after 2 minutes and insulin being effective at 1 nM. As it is 
known that the phosphorylation of a-Gi-2 in rat hepatocytes is under the control of a futile 
cycle the point of action of insulin was investigated by the use of a range of ligands that 
interacted with the inositol phosphate and cAMP signalling pathways and hence stimulated 
the phosphorylation of a-Gi-2. From these studies it was found that insulin was able to 
inhibit some of the ligand-induced phosphorylation of a-Gi-2 and this indicated that insulin 
interacted with at least two components of the cycle, that is a kinase and a phosphatase. 
Interestingly, insulin also enhanced the phosphorylation induced by glucagon and the 
insulin inhibition of phosphorylation was reversed by amylin which also caused a cAMP- 
dependent phosphorylation. Evidence was also found that a cAMP-dependent 
phosphorylation of a-Gi-2 may occur even when the cAMP system is not being stimulated.
The induction of type I diabetes in Sprague Dawley rats with streptozotocin 
caused a loss of the insulin-induced inhibition of a-Gi-2 phosphorylation and also reduced 
the levels of phosphorylation of a-Gi-2 achieved by 8-bromo-cAMP, PMA and glucagon 
and abolished the insulin enhancement of glucagon stimulated phosphorylation.
In the obese Zucker rat model of type II diabetes and their lean litter mates, 
insulin did not effect the phosphorylation of a-Gi-2 and the enhancement of glucagon 
stimulated phosphorylations was lost. The compound BRL 49653, which normalises 
glucose handling in animal models of diabetes, did not effect the ligand induced 
phosphorylations of a-Gi-2 other than abolishing the significant insulin inhibition of 
glucagon stimulated phosphorylation in the lean animals.
In conclusion, the activated insulin receptor does interact with a-Gi-2 and 
although the result of this interaction on cellular signalling is not known it does seem likely 
that it is not involved in the control of glucose homeostasis but some other aspect of insulin 
signalling.
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IRS 1 Insulin receptor substrate 1
mr Mass-charge ratio
NIDDM Non-insulin-dependent diabetes mellitus (type II diabetes)
PDE Phosphodiesterase
PI Phosphatidyl inositol
PIP2 Phosphatidylinositol 4,5-bisphosphate
PKA cAMP-dependent protein kinase (protein kinase A)
PKC Protein kinase C
PKG Cyclic guanosine 3 '5 '-monophosphate-dependent protein kinase
PLA2 Phospholipase A2
PLC Phospholipase C
PLD Phospholipase D
PMA Phorbol 12-myristate 13-acetate
PTPase Phosphotyrosine phosphatase
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM Standard error of the mean
SH2 src homology domain 2
SH3 src homology domain 2
TPCK Tosylphenylalanylchloromethane
Tris 2-amino-2 -hydroxymethyl-propane-1,3-diol
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Introduction
1.1 General Introduction
Recent years have seen an explosion in the knowledge and understanding of the 
transfer of information between cells, and from extra- to intracellular signals. Techniques 
such as receptor binding assays, patch clamping, secondary messenger assays, molecular 
biology, computer imaging, and monoclonal antibody technology have provided the means 
to probe what are now known to be complicated, subtle, and intricate systems of 
intracellular communications.
The interaction of biologically active compounds with cell surface receptors can 
effect cellular responses in three possible ways (see Martens, 1992; Michell, 1987). The 
affects can be produced by the opening of ion channels, the phosphorylation of intracellular 
proteins (see section 1.2.4) or the generation of a secondary messenger such as inositol 
phosphates (InsP) or cyclic nucleotides (e.g. adenosine 3',5f-monophosphate [cAMP]; see 
sections 1.2.3.2 and 1.2.3.1) which again can lead to the phosphorylation of proteins. The 
procedure for the production of secondary messengers requires three components namely; 
receptors (see section 1.2.1); mediators (see section 1.2.2); and effectors (see section 1.2.3; 
e.g. see Berridge & Irvine, 1989; Gilman, 1987; Neer & Clapham, 1988; Neubig & 
Thomsen, 1989; Rana & Hokin, 1990; see also Rodbell, 1992). The effectors then produce 
the intracellular secondary messengers (i.e. cAMP [see section 1.2.3.1] or InsP / DAG [see 
section 1.2.3.2]) which in turn can activate a series of dependent kinases (e.g. cAMP- 
dependent PKA [see section 1.2.4.1] and DAG-dependent PKC [see section 1.2.4.2]) 
resulting in the phosphorylation of intracellular proteins.
1 .2  Cellular Signalling
1 .2 .1  Receptors
Cell surface receptors can be divided broadly into four classes and each class can 
then be further subdivided. The four receptor classes are those which form ligand gated ion 
channels (e.g. nicotinic acetylcholine, GABA, glycine), G-protein linked receptors (e.g. 
adrenergic, muscarinic), species expressing tyrosine kinase activity (e.g. insulin [see 
section 1.4], insulin-like growth factor, epidermal growth factor, platelet derived growth 
factor) and guanylate cyclase expressing receptors (e.g. atrial natriuretic peptide; see Neubig 
& Thomsen, 1989).
The ligand gated ion channel receptors are multi-subunit membrane spanning 
proteins which, upon the binding of a specific ligand, undergo a conformational change that 
allows a channel between the subunits to open and specific ions to flow across the cell 
membrane (see Michell, 1987; Neubig & Thomsen, 1989).
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The G-protein (see section 1.2.2) linked receptors share a common structure. 
The receptor protein is folded to form seven transmembrane domains with the N-terminal on 
the extracellular face and the C-terminal on the intracellular surface (see Findlay & 
Eliopoulos, 1990; Iismaa & Shine, 1992; Martens, 1992; Reithmann, Gierschik & Jakobs, 
1990). The receptor contains a ligand binding site formed from the transmembrane loops 
and a G-protein interaction site formed by a specific sequence of amino acids in the third 
intracellular loop (see Martens, 1992).
The G-protein linked receptors can be divided into several sub-groups depending 
on the cellular responses that are mediated by the G-protein they activate (see section 1.2.2; 
Neubig & Thomsen, 1989).
1.2.2 Mediators - the G-proteins
The G-proteins are a super-family of proteins which bind guanosine 5'- 
triphosphate (GTP) and have GTPase activity to produce the diphosphate form (GDP; see 
Linder & Gilman, 1992; Egan & Weinberg, 1993). Many such proteins have now been 
identified and these can be divided into two basic groups by molecular weight and structure. 
Both groups are involved in the transduction of extracellular signals but their composition 
and modes of action are different (see Reithmann et al., 1990). One group consists of a 
family of closely related heterotrimeric proteins which are formed from a  (17 different 
subunits, 36 - 52 kDa), p (4 different subunits, 35 - 37 kDa) and y (5 different subunits, 6 - 
8 kDa) subunits giving a protein of a final molecular weight in the range of 77 - 87 kDa (see 
section 1.2.2.2, table 1.1 and figure 1.1; see Gilman, 1987; Reithmann et al., 1990; Taylor, 
1990; Yamane & Fung, 1993). The other group does not have a heterotrimeric structure 
and because of their molecular weight (20 - 30 kDa) and tertiary structure have been termed 
'small1, 'mini' or monomeric G-proteins. Indeed, more than fifty 'small* G-proteins have 
been found in mammalian tissues (see Bokoch, 1993; Yamane & Fung, 1993).
Based on sequence homology, the 'small' G-proteins have been divided into four 
families ras, rho, rab and arf{see Bokoch, 1993). The ras family are involved in receptor 
mediated signalling, controlling cell proliferation and differentiation. The rho family in 
cytoskeletal assembly and the rab and a//proteins in the regulation of transport vesicles (see 
Balch, 1990; Bokoch, 1993; Egan & Weinberg, 1993).
Both the heterotrimeric and 'small' G-proteins can undergo covalent 
modifications, such as ADP-ribosylation, prenylation, acylation and phosphorylation 
(Jakobs, Bauer & Watanabe, 1985; Lounsbury et al., 1993; Morris et al., 1994; Sagi- 
Eisenberg, 1989) which are critical for their activity and cellular distribution (see Parenti et 
al., 1993; Yamane & Fung, 1993).
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Figure 1.1: Phylogenetic trees of the heterotrimeric guanine nucleotide binding protein
subunits
Phylogenetic trees of a, p and y subunits of the heterotrimeric guanine nucleotide binding 
proteins (taken from Bimbaumer, 1992).
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Table 1.1: Isoforms of G-protein subunits.
Effector Intracellular
F cDNA MW Toxin SDS AC PLC PDE K+ Ca2+ Messenger
as s 46.5 CT 52 + +Ca +L Tca m p  I m p
as olf 44.5 CT 45 + tcAMP
aq q 42 +P t n >3 T d a g
aq 11 41.4 42 +P T1P3 T d a g
aq 14 41.5 42 +P T1P3 T d a g
aq 16 43.5 43 +P T1P3 T d a g
aq 12 44.0 43 ? ?
aq 13 44.0 43 ? ?
cti ol 40.0 PT 39 +? -L,N iM P
cti o2 40.0 PT 39 +? -L,N -Im p
cti gust PT +A icAMP
ai t-cone 40.1 PT 40 +G icGMP
cti t-rod 40.0 PT 39 +G -IcGMP
ai il 40.4 PT/CT 41 - +ir,A -IcAMP TMP
ai i2 40.5 PT/CT 40 - +ir,A TcAMP Tm p
cti i3 40.5 PT/CT 41 - +ir,A icAMP TMP
cti z 40.9 41 - -IcAMP
P 1 37.4 - 36
P 2 37.3 - 35
P 3 37.2 36?
P 4 36?
Y 1 8.4 - 8
Y 2 7.9 6
Y 3 8
Y 4 5-10
Y 5
Location
Ubiquitous 
Olfactory 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Brain 
Brain 
Taste buds 
Retinal cones 
Retinal rods 
Ubiquitous* 
Ubiquitous 
Ubiquitous 
Brain 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Brain 
Retina 
Ubiquitous 
Brain 
?
F = G-protein family (see figure 1.1); cDNA = cDNA clone, ol and o2 are splice variants 
of a©; MW = predicted molecular weight (kDa) based on genetic sequence; Toxin = toxin 
sensitivity of the protein, PT = pertussis toxin sensitive, CT = cholera toxin sensitive, 
CT/PT = cholera and pertussis toxin sensitive; SDS = observed molecular weight (kDa) on 
SDS-PAGE; Effectors: AC = adenylyl cyclase, PLC = phospholipase C (+p, activation of 
P isoform; +?, activates PLC but isoform is unknown; ?, effects PLC but effects unknown), 
PDE = phosphodiesterase (A = cAMP, G = cGMP), K+ = potassium channel (Ca = calcium 
activated, ir = inwardly rectifying potassium channel, A = ATP-inhibited potassium 
channel), Ca2+ = calcium channel (L = L-type, N = N-type) [+ = positive effect (activation); 
- = negative effect (inhibition)]; Intracellular messenger, IP3 = D-myo-inositol 1,4,5- 
trisphosphate, DAG = diacylglycerol, cAMP = cyclic adenosine 3',5'-monophosphate, 
cGMP = cyclic guanosine 3',5'-monophosphate, MP = membrane potential [T increases, I 
decreases]; Location, tissue distribution of the isoforms (* not in hepatocytes); py-subunits 
form non - dissociating subunit which can activate adenylyl cyclases II and IV, inhibit 
adenylyl cyclase I, activate phospholipases C and A2, and stimulate the phosphorylation of 
receptors (see Bimbaumer, 1992; Conklin & Bourne, 1993; Reithmann et al., 1990).
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1 .2 .2 .1  Mode o f  activation o f heterotrimeric G-proteins
The heterotrimeric G-proteins are found associated with the cytoplasmic face of 
the plasma membrane (see Spiegel et al., 1991). The exact orientation of the heterotrimer 
within the membrane is unknown and initially it was thought that the p-subunit of the 
protein provided the main anchorage (see Neer & Clapham, 1988; Reithmann et al., 1990) 
but there is now evidence that it is the a  and y-subunits that provide attachment (Spiegel et 
al., 1991). The a-subunit possess the ability to bind guanosine 5'- triphosphate (GTP) and 
exhibits GTPase activity to produce the diphosphate form (GDP; see Reithmann et al., 
1990). The binding of a ligand to its cell surface receptor produces a conformational change 
in the receptor leading to activation of a G-protein. The activated G-protein then interacts 
with its effector molecules (see section 1.2.3). One ligand /  receptor complex can activate 
several G-proteins which in turn can activate a number of effectors and so produce signal 
amplification (see Bimbaumer, Abramowitz & Brown, 1990; Neer & Clapham, 1988; 
Reithmann et al., 1990; Yamane & Fung, 1993; Lamb & Pugh Jr, 1992). Initially it was 
thought that the termination of the G-protein signal, namely the hydrolysis of GTP, was 
under the control of the GTPase activity of the a-subunit but recent evidence indicates that 
the effector may also play a role in termination of the signal. Early experiments on GTP 
hydrolysis by the a-subunit in reconstituted systems indicated that the rate of hydrolysis 
was slower than would be expected for the physiological processes that were being 
controlled but it has now been found that if the hydrolysis rates are measured in the 
presence of the effector then the rates are significantly increased so reducing hydrolysis 
times to a physiological level (see figure 1.2; see Bourne & Stryer, 1992).
In the inactive state, GDP is bound to the a  subunit, and this gives the G-protein 
a high affinity for py subunits the binding of which increases the a-subunit’s affinity for 
GDP. Interaction with the activated receptor results in the release of GDP from the a- 
subunit producing an a-subunit with an empty nucleotide binding site. In the absence of 
GTP, the activated receptor binds tightly to the apy complex. This then precipitates the 
binding of GTP to the a-subunit, which then undergoes a conformational change causing it 
to dissociate rapidly from the py-subunits and the receptor (see Conklin & Bourne, 1993). 
The GTP-a subunit has a low affinity for receptors and py-subunits, but a high affinity for 
the its effector (e.g. ion channels, adenylyl cyclase, phospholipase C [see section 1.2.3; see 
Reithmann et al., 1990). The py subunits represent a stable heterodimer that does not 
dissociate under physiological conditions. After dissociation of the heterotrimer, the Py- 
subunit remains associated with the membrane. In contrast, the activated a-subunit either 
remains associated with the plasma membrane (Buss et al., 1987) or released into the 
cytoplasm (see Crouch & Hendry, 1993; Rodbell, 1985; Spiegel et al., 1991). The a- 
subunit is deactivated as a result of the hydrolysis of GTP to GDP. The GDP-bound a- 
subunit has a high affinity for py-subunits, with which it re-associates, and a low affinity 
for effectors and receptors (see Reithmann et al., 1990).
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Figure 1.2: Diagrammatic representation of the activation of heterotrimeric G-proteins
Diagrammatic representation of the activation of heterotrimeric G-proteins. Panel 1 show 
the binding of hormone /  transmitter (H) to the receptor (R). The G-protein (aPy) is in an 
inactive state with GDP bound to the a-subunit. Panel 2: Hormone (H) has bound to the 
receptor (R) which undergoes a conformational change. The receptor (R) interacts with the 
G-protein (apy) and catalyses the exchange of GDP for GTP. Panel 3: The GTP bound a- 
subunit dissociates from the py-subunit and interacts with the effector (E). Panel 4: The a- 
subunit hydrolyses GTP to GDP and dissociates from the effector (E). Panel 1: The GDP 
bound a-subunit binds to the py-subunit.
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There is evidence that one type of a-subunit may interact with different receptors 
and that an effector can interact with several different classes of G-proteins (see Iismaa & 
Shine, 1992). Membrane binding or interaction of the a-subunit with the cytoskeleton may 
produce compartmentalisation and so prevent interaction with non - localised effectors (see 
Neer & Clapham, 1988; Rodbell, 1992).
1 .2 .2 .2 Heterotrimeric G-protein isoforms and interaction with effectors
Initially, within the cell, at least two major classes of G-protein were identified 
and the different activities of the G-proteins was thought to be mainly associated with the a  
subunit. The first class of G-protein was defined as having a stimulatory effect on adenylyl 
cyclase and was called Gs. The second class was defined as having an inhibitory effect on 
adenylyl cyclase and was called Gi. However, it is now known that Gs can also affect K+ 
and Ca2+ ion channels and Gi can regulate K+ channels (see table 1.1; see Bimbaumer, 
1992; Conklin & Bourne, 1993; Reithmann et al., 1990). Indeed, several forms of each of 
these G-proteins have so far been identified. These include three isoforms of Gi, namely 
Gi-i, Gi-2 , and Gi.3, and four splice variants of Gs (see table 1.1 and figure 1.1; see 
Bimbaumer, 1992; Bimbaumer et al.f 1990; Reithmann et al., 1990; Conklin & Bourne, 
1993). The G-protein classes, G* and GSt can be distinguished from one another not only 
by their activity but also their interaction with cholera and pertussis toxins (from Vibrio 
cholera and Bordetalla pertussis, respectively; see Yamane & Fung, 1993). Gs proteins are 
affected by cholera toxin and Gi by pertussis toxin, although Gi can also be affected by 
cholera toxin in a receptor-dependent manner (see Reithmann et al.> 1990; Yamane & Fung, 
1993). Both toxins cause a NAD+-dependent ADP-ribosylation of the a-subunit. The 
pertussis toxin site on the a-subunit of Gi is at a cysteine four amino acids from the C- 
terminal of the protein whilst the cholera toxin site in a-G s is just before the guanine 
nucleotide binding domain (Argl87/188; see Yamane & Fung, 1993). ADP-ribosylation 
results in a persistent activation of the stimulatory a  subunit (as) and an inhibition of the 
effects of the inhibitory a  subunit (ai).
The mode of action of the Gs is clear in that the Os subunit directly interacts with 
and activates adenylyl cyclase (Gilman, 1987; Reithmann et al., 1990), although there is 
now evidence that some isoforms of adenylyl cyclase can also be activated by py-subunits 
(see section 1.2.3.1; Tang & Gilman, 1991; see Bimbaumer, 1992; Lefkowitz, 1992; 
Yamane & Fung, 1993; Choi et al., 1993). The mode of action of Gi is more complex. It 
is conceivable that the a* subunit interacts with adenylyl cyclase and hence prevents its 
activation (see Reithmann et al., 1990) or the release of py subunits from Gi may prevent 
the dissociation of Gs, and so modulate adenylyl cyclase activity (see Gilman, 1987; 
Reithmann et al.9 1990) and as different experimental systems produce different results it is 
possible that both mechanisms may play a role in the inhibition of adenylyl cyclase (see 
Reithmann et al., 1990).
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Early work suggested that the biological activity of the heterotrimeric G-proteins 
was associated only with the a-subunits but there is now evidence that the (3y subunits may 
also have a role in signal transduction such as activating phospholipase A2 (see section
1.2.3.2), phospholipase C (see section 1.2.3.2; Camps eta l., 1992; Smrcka & Stemweis, 
1993), adenylyl cyclase (see section 1.2.3.1; Tang & Gilman, 1991; see Bimbaumer, 1992; 
Lefkowitz, 1992; Yamane & Fung, 1993) and the stimulation of receptor phosphorylation 
(e.g. |3-AR kinase; Kameyama et al., 1993; Koch et al., 1993). Both the p and y-subunit 
families consist of four isoforms (see table 1.1) and with both families containing at least 
four subunits this gives a possible sixteen py subunits but recent evidence has suggested 
that not all the p and y isoforms may be able to combine to form functional py subunits 
(Schmidt et al., 1992).
In addition to a-Gs and a-Gi further members of the a-Gs and a-Gi families have 
been identified and another a-G-protein family has also been described, namely that of a-Gq 
(see table 1.1 and figure 1.1; see Bimbaumer, 1992). The a-Gs family contains four splice 
variants of a-Gs with an additional member identified as a-G 0if, which occurs in the 
olfactory epithelium. The a-Gi family contains the three a-Gi's, together with a-G0i and 
a-G02 (splice variants of a-G0), a-Gz, a-Ggust, a-Gtr and a-G^. The third a-G-protein 
family is a-Gq and contains a-Gq, a -G n f a-G i4t a-G i6, a-G i2 and a-G i3 (see table 1.1; 
and figure 1.1; see Bimbaumer, 1992; Stemweis & Smrcka, 1992; Bimbaumer, 1992; 
Conklin & Bourne, 1993).
G0 (ather G-protein) is found in the brain where it is associated with neurite 
growth cones and with growth associated protein (GAP-43, Strittmatter et al., 1990). G0 
inhibits the actions of Ca2+ channels and may be involved in the activation of phospholipase 
C (see section 1.2.3.3). Gz (or Gx), can inhibit adenylyl cyclase, is the only member of the 
Gi family that cannot be ADP-ribosylated by pertussis toxin (Fong et al., 1988; Matsuoka et 
al., 1988) and has been shown to have one of the slowest GTPase activity of any of the G- 
proteins. This has led to the suggestion that it may be involved in long term signal 
responses (Casey et al., 1990). GgUSt is found in the taste buds and activates a cAMP 
specific phosphodiesterase (see section 1.2.3.2). a-Gtr and a-Gtc, originally called a-Gt, 
are associated with the photoreceptors with a-Gtr being found in the rods and a-Gtc in the 
cones. Both are sensitive to cholera and pertussis toxin (Lerea et al., 1986) and are not 
activated by hormones or transmitters but by the action of light on rhodopsin. The at 
subunits can activate cyclic-GMP specific phosphodiesterase (Fung, Hurley & Stryer, 
1981; Kohnken, Eadie & McConnell, 1981) and phospholipase A2 (Jelsema & Axelrod, 
1987). The a-Gq family is ubiquitously expressed, not effected by pertussis or cholera 
toxins and except for a-Gi2 and a-Gi3, *s involved in the activation of PLCp (see table 1.1 
and figure 1.1; see Bimbaumer, 1992; Conklin & Bourne, 1993; Reithmann et al., 1990; 
Stemweis & Smrcka, 1992).
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1 .2 .3  Effector systems and secondary messenger generation
The activated G-protein, a  or py subunits, finally conveys the 'message' to its 
effector system. To date it has been shown that activated G-proteins can interact with at 
least three different effector systems, adenylyl cyclase (see section 1.2.3.1), resulting in the 
stimulation or inhibition of cAMP production; phospholipases (see section 1.2.3.2); or ion 
channels.
1 .2 .3 .1  Adenylyl Cyclase and cAMP production
The first report of agonist-induced stimulation of cAMP production, on which the 
whole concept of secondary messengers was developed, was in 1960 by Sutherland and 
Rail (see Sutherland & Rail, 1960).
cAMP is produced from ATP and the reaction is catalysed by the Mg2+- 
dependent enzyme adenylyl cyclase. Cell surface receptors can either stimulate or inhibit 
c AMP production and these effects are mediated by two different classes of G-proteins (see 
section 1.2 .2.2  and table 1.1) with the two signalling systems co-existing in the same cell 
type (see Reithmann et al., 1990).
The catalytic subunit of adenylyl cyclase was first purified from heart in 1985 and 
brain in 1986 and had molecular weights of 150 kDa and 120 kDa respectively (see 
Reithmann et al., 1990). To date at least six distinct families (types I - VI) have been 
reported which contain up to eight isoforms, and although the enzymes have similar 
structures there is evidence that they possess different regulatory properties and show 
different tissue distributions (see Glatt & Snyder, 1993; Hellevuo et al., 1993; Pleroni et 
al., 1993; Yoshimura & Cooper, 1993; Choi et al., 1993; Tang & Gilman, 1992).
Types I and in  are stimulated by Ca2+ in the presence of calmodulin, type VI is 
inhibited by Ca2+ and types n, V and IV are insensitive to Ca2+ (see Yoshimura & Cooper, 
1993; Choi et al., 1993). In addition, types II and IV are stimulated by G-protein py 
subunits, type I is inhibited, and types El, V and VI are insensitive (Choi et al., 1993). All 
six adenylyl cyclases catalytic subunits have a predicted molecular weight of 120 - 130 kDa 
and contain twelve transmembrane sequences and two large cytoplasmic domains (Choi et 
al., 1993; Tang & Gilman, 1992). It has been suggested that the hydrophilic domains 
contain the nucleotide binding domains and hence the catalytic site (see Reithmann et al.,
1990).
The cAMP system has four main components (Ross & Gilman, 1980): the 
receptors (see section 1.2.1), the G-proteins (see section 1.2.2; Rodbell et al., 1971), 
adenylyl cyclase, and phosphodiesterase. Control, or modification, of the system can be 
achieved at any of the four levels and by changes in the rate of cAMP leaving the cell.
Interaction of ligands with cell surface receptors results in the dissociation of the 
G-protein heterotrimer (see section 1.2.2) which in turn can activate, or inhibit, adenylyl 
cyclase. One ligand / receptor complex can interact with several G-proteins, which in turn
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can activate a number of adenylyl cyclase molecules, and each adenylyl cyclase molecule 
can produce many cAMP molecules. The resulting raised levels of intracellular cAMP 
causes the activation of cAMP dependent protein kinases (PKA, see section 1.2.4.1).
Adenylyl cyclase can be stimulated in cells by a naturally occurring diterpene, 
forskolin (isolated from Coleus forskohlii). Forskolin has also been demonstrated to inhibit 
the activity of a number of membrane transporter proteins, such as the glucose transporters, 
by a cAMP-independent mechanism (see Laurenza, McHugh Sutkowski & Seamon, 1989).
The effects of cAMP mediated cellular signalling can be modulated and finally 
deactivated by a group of enzymes that hydrolyse cAMP (see Beavo, 1990). These 
enzymes are called phosphodiesterases (PDE) and the cAMP specific PDEs are part of a 
family of enzymes that can also hydrolyse cGMP (see Beavo, 1990). The PDE family can 
be divided into five sub-groups, determined by the characteristics of the enzyme, with each 
subgroup being further divided (see Beavo, 1990). Group I contains the Ca2+ - calmodulin 
dependent PDEs; group II the cGMP - stimulated PDEs; group HI the cGMP - inhibited 
PDEs; group IV the cAMP - specific PDEs, and group V the cGMP - specific PDEs. The 
different isoforms of PDEs exhibit a range of molecular weights from 58 - 110 kDa (see 
Beavo, 1990), as well as different modes of activation, substrate specificities, tissue 
distributions and inhibition characteristics (see Beavo, 1990) but all can be inhibited by 
IBMX (3-isobutyl-1-methylxanthine; see Corda, Luini & Garattini, 1990).
Many reviews have appeared on G-protein structure and the function of the 
adenylyl cyclase signal transduction system which have been summarised above (see 
Baumgold, 1992; Choi et a l, 1993; Reithmann et al., 1990; Tang & Gilman, 1991; Tang & 
Gilman, 1992; Gilman, 1987; Levitzki, 1988; Neer & Clapham, 1988; Styer & Bourne, 
1986).
1 .2 .3 .2  Phospholipase and inositol phosphates
Over the past few years many excellent reviews have appeared on the generation 
of inositol phosphate (InsP) secondary messengers (see Abdel-Latif, 1986; Berridge, 
1987a, 1987b; Berridge, 1993; Berridge & Irvine, 1989; Osborne, Tobin & Ghazi, 1988; 
Rana & Hokin, 1990).
The first description of phospholipid turnover as a result of agonist stimulation 
was by Hokin and Hokin (Hokin & Hokin, 1955a, 1955b) but it was not until 1974 
(Hokin-Neaverson, 1974; Michell, 1975) that the components of the system were identified 
as phosphatidyl inositol and phosphatidic acid.
There are now recognised to be three families of phospholipases; phospholipases 
A2, C and D; with each family containing several isozymes. The phospholipases can act on 
different phospholipids to produce a range of secondary messengers and precursors for 
other signalling molecules.
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Phospholipases A2 (PLA2 ) catalyse the hydrolysis of many different 
phospholipids giving products which may serve as intracellular messengers or precursors 
for other messenger molecules (see Mayer & Marshall, 1993). The PLA2 family can be 
split into four subgroups (I - IV). Groups I, n, and ID are found in the extracellular fluids, 
will cleave most phospholipids, require Ca2+ for activation and have a molecular weight of 
14 kDa. These PLA2S are also referred to as the non-pancreatic or secretory. Group IV 
PLA2S are intracellular, will only cleave arachidonic acid containing phospholipids, also 
require Ca2+ for activation and have a molecular weight of 85 kDa (see Glaser et al., 1993; 
Mayer & Marshall, 1993).
The preferred substrate for phospholipase D (PLD) is phosphatidylcholine which 
it cleaves to produce phosphatidic acid and choline. Phosphatidic acid can then be further 
metabolised by phosphatidic phosphohydrolase to produce diacylglycerol. Again PLD, like 
PLC, can be found in cytosolic and membrane fractions and this is thought to reflect 
different isozyme distribution (see Billah, 1993).
Phospholipase C (PLC) produces two secondary messenger from 
phosphatidylinositol 4,5-bisphosphate (PIP2), namely diacylglycerol (DAG) which 
activates protein kinase C (PKC; see section 1.2.4.2; see Huang, 1989; May Jr et al., 1985; 
Nishizuka, 1984; Wolf et al., 1985; Cook & Wakelam, 1992) and D-myo-inositol 1,4,5- 
trisphosphate (Ins(l,4 ,5)P3) which mobilises Ca2+ from intracellular stores (see Berridge, 
1993; Berridge & Irvine, 1989). Two pathways have now been identified by which the 
enzyme can be activated and hydrolyse PIP2. One pathway does not require a mediator 
between the receptor but relies on tyrosine phosphorylation of the enzyme whilst the other is 
G-protein dependent (see Cockcroft & Thomas, 1992).
Early studies on PLC indicated that such an activity was predominantly associated 
with the cytosol which did not appear consistent with a role as an effector in the inositol 
phosphate signalling pathway (Fukui, Lutz & Lowenstein, 1988; Homma et al., 1988; 
Rebecchi & Rosen, 1987) although some activity was found associated with the membrane 
(Banno & Nozawa, 1987; Banno, Yada & Nozawa, 1988; Cockcroft, Baldwin & Allan, 
1984). It has also been shown that in permeabilised cells that the diffusion of PLC from the 
cytosol into the surrounding medium is very slow (Stutchfield & Cockcroft, 1988) and this 
suggests that the enzyme is not found exclusively in the cytoplasm.
To date three PLC isozymes have been identified based on sequence homology 
(p, y and 8) and four families based on enzyme purification data (a, y, 5 and e; see Cockcroft 
& Thomas, 1992; Guillon, Mouillac & Savage, 1992). The sequence data set can be further 
sub-divided to give p i, p2, p3, yl, y2, 51, 82, and 83. The phospholipases have been 
shown to have different tissue distributions and different modes of activation. PLC-p, pi 
and e have been shown to be regulated by Gq family of G-proteins (see table 1.1 and section
1.2.2.2) whilst PLC-yl and y2 have been shown to be activated by tyrosine kinase- 
mediated phosphorylation (see Cockcroft & Thomas, 1992). In addition there is now
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evidence that PLC may also be regulated by G-protein py subunits (Camps et al., 1992; 
Smrcka & Stemweis, 1993).
The substrate for PLC, namely PIP2, is produced from phosphatidyl inositol (PI) 
which is synthesised at the rough and smooth endoplasmic reticulum (Williamson & Morre, 
1976) before being transferred, by a carrier protein (Somerhaiju, Paridon & Wirtz, 1983), 
to the plasma membrane and further phosphorylated. The hydrolysis of PIP2, besides 
producing Ins(l,4 ,5)P3 and DAG, may also result in the production of a small quantity of 
D-myo-inositol (l:2-cyclic,4,5)-trisphosphate (see Hawkins etal., 1986; Ishii et al., 1986; 
Wilson et al., 1985).
The metabolic fate of Ins(l,4 ,5 )P3 is to be either phosphorylated to 
In s(l,3 ,4 ,5 )P4 or dephosphorylated to Ins(l,4 )P2 - These InsPs can then be further 
phosphorylated to produce a range of inositol polyphosphates (up to InsP6) or 
dephosphorylated to finally give inositol which can then be recycled to produce PIP2. The 
route for the metabolism of Ins(l,4 ,5 )P3 is dependent on cell type, and not all of the 
metabolites of Ins(l,4 ,5)P3 have been found in all cells studied.
The inositol phosphates can be divided into two groups; those whose levels rise 
as a result of agonist-induced stimulation and those which are agonist insensitive (e.g. 
Ins(l,3 ,4 ,5 ,6)P5 and InsP6). It has been suggested (see Berridge & Irvine, 1989) that only 
three of the agonist sensitive metabolites of PIP2 assert any function as secondary 
messengers (namely Ins(l,4 ,5 )P3, Ins(l,3 ,4 ,5 )P4 and DAG) and that the other agonist 
sensitive metabolites are breakdown products. The wide array of breakdown products may 
represent cellular control in preventing an increase in the levels of a biologically active InsP 
(e.g. Ins(l,4 ,5)P3) as a result of the breakdown of another InsP (e.g. dephosphorylation 
of Ins( 1,3,4,5)P4 not producing the biologically active Ins(l,4 ,5)P3 (see Berridge & Irvine, 
1989).
Ins(l,4 ,5 )P3 has been identified as mobilising Ca2+ from non-mitochondrial 
Ca2+ pools (see Berridge, 1993; Berridge & Irvine, 1989; Putney et al., 1989; Schulz, 
Thevenod & Dehlinger-Kremer, 1989; Streb et al., 1983). These stores are now known to 
contain three components: pumps for the recovery of released calcium, binding proteins 
such as calseqestrin and calreticulin to store the calcium and Ins(l,4 ,5)P3 receptor ( I P 3R )  or 
ryanodine receptors to control release into the cytoplasm. There are now known to be at 
least five IP3R (IP3Rla, IP3Rlb, IP3R2 , IP3R3, and IP3R4 ; [see Berridge, 1993]). The 
receptors contain four subunits with each subunit possessing a C-terminal membrane 
spanning region and a N-terminal Ins(l,4 ,5 )P3 binding domain. Although the receptors 
contains four Ins(l,4 ,5)P3 binding sites it is not known whether all four sites have to be 
occupied or if occupancy of one site is enough to evoke Ca2+ release (see Berridge, 1993). 
It is now thought that the receptors are located on specialised regions of the ER (see 
Berridge, 1993).
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Diacylglycerol is involved in the activation of protein kinase C (PKC; see section 
1.2.4.2; see Nishizuka, 1984) and cellular levels may only rise briefly as DAG can be 
readily metabolised to PIP2, via phosphatidic acid (see Berridge, 1987b), or converted to 
arachidonic acid (see O'Flahery, 1987) which can be used for the production of 
thromboxanes, prostaglandins, and leukotrienes which can have localised actions. DAG 
can also be produced by the agonist induced breakdown of phosphatidylcholine (Billah et 
al.y 1988; Pelech & Vance, 1989; see Exton, 1990) by phospholipase D, or from inositol 
containing glycolipids (Chan, Chao & Saltiel, 1989).
1 .2 .3 .3  Secondary messenger system crosstalk
Recent years have seen a growing body of evidence for the ’cross talk1 between 
receptors linked to different secondary messenger pathways (see Houslay, 1991a; Geny, 
Stutchfield & Cockcroft, 1989; Hill & Kendall, 1989; Sagi-Eisenberg, 1989). Briefly, the 
above authors have described 'cross talk’ as either an enhancement, or attenuation, of 
normal agonist induced secondary messenger levels by the action of another (or even the 
same) agonist on a different receptor which is linked to a different secondary messenger 
system. An example is the decrease in the accumulation of cAMP by a phosphodiesterase 
(see section 1.2.3.2) which is activated by Ca2+ released as a result of Ins(l,4 ,5)P3 
production by muscarinic receptor activation (see section 1.2.3.2). Phorbol esters have 
been shown to increase cAMP levels, in the presence of cAMP agonists, by the activation of 
protein kinase C (see section 1.2.4.2) which phosphorylates adenylyl cyclase (see section
1.2.3.2) or a G-protein (see section 1.2.2 and 3.1.1; Sagi-Eisenberg, 1989). The InsP 
pathway can be affected by the cAMP system but the method, or point, of control is 
unknown (Hill & Kendall, 1989) although the Ins(l,4 ,5)P3 receptor for Ca2+ release (see 
section 1.2.3.2) has been shown to be a substrate for the cAMP dependent protein kinase A 
(Ferris et al., 1989; Supattapone et ai> 1988).
1 .2 .4  Protein kinases and phosphatases
Many cellular systems have now been shown to be regulated by the 
phosphorylation of specific components within the system. The result of phosphorylation 
can be to cause either a stimulation, or enhancement of the system or an inhibition. As the 
phosphorylation state of a protein can affect its activity then the processes of phosphate 
addition and removal have to be tightly controlled.
To date well over 100 mammalian protein kinases have been identified (see 
Hunter, 1991). The kinases seem to consist of a modular structure with the segment 
responsible for the catalytic activity of the enzyme being highly conserved and the other 
modules introducing functional properties to the molecule (see Taylor, Buechler & 
Yonemoto, 1990). The kinases can be broadly divided into three categories based on their 
phosphorylations sites. One group of kinases (e.g. activated insulin receptor, see section
15
Chapter 1
1.4) phosphorylate on tyrosines, another group phosphorylate on serines and / or 
threonines (e.g. protein kinase A [see section 1.2.4.1] and protein kinase C [see section
1.2.4.2]) and the third, and least common, group have been reported to phosphorylate on 
histidine, lysine and arginine (see Hunter, 1991; Taylor et al., 1990).
The tyrosine and serine /  threonine kinases can be further subdivided depending 
upon their method of activation, although this kind of categorisation is flawed as the method 
of activation of some kinases is still not understood (see Hunter, 1991). This has lead to 
the subdivision of some of the members of the serine /  threonine kinases into families such 
as the cyclic nucleotide-regulated protein kinases (e.g. cAMP-dependent protein kinases 
[PKA]; see section 1.2.4.1); calmodulin-regulated protein kinases (e.g. the myosin light 
chain kinases) and a family of diacylglycerol-regulated protein kinases (e.g. PKC; see 
section 1.2.4.2; see Hunter, 1991; Taylor et al., 1990).
The removal of phosphates from proteins is carried out by a group of enzymes 
called phosphatases and these can be divided into two groups, the protein-serine / threonine 
phosphatases and the protein-tyrosine phosphatases, which can also be further sub-divided 
(see section 1.2.4.3).
1 .2 .4 .1  Protein kinase A
Protein kinase A is a cAMP dependent serine kinase which was first described in 
1968 (see Johnson & Barford, 1993). The kinase consists of four subunits, two of which 
are regulatory (R) and two catalytic (C; see D0skeland, Maronde & Gjertsen, 1993). The 
mechanism of activation of PKA is unusual in that cAMP binds to the regulatory subunit 
which causes the subunits to dissociate and release two active catalytic subunits (see 
Ddskeland et al., 1993; Johnson & Barford, 1993).
Three isoforms of the catalytic subunit have been identified (C a, Cp, Cy, see 
D0 skeland et al., 1993; Hanks & Quinn, 1991; Hunter, 1991) with alternative splice 
variants of C a  (C a l and Ca2) and Cp (C pl and Cp2) also being detected and four isoforms 
of the regulatory subunit (R Ia, R ip, R lla  and RHp; see Ddskeland et al., 1993; McKnight 
et al., 1988). The three isoforms C a, R Ia  and R lla  are expressed in most tissues and Cp, 
R ip  and RIIp are highly expressed in the central nervous system and at very low levels in 
other tissues (McKnight et al., 1988).
The regulatory subunits contain four functional domains, the so called N-terminal 
dimerisation domain, the auto-inhibitory or hinge region, and two cAMP binding sites (see 
Ddskeland et al., 1993; Taylor et al., 1990). The dimerisation domain is the region of the 
protein where greatest variation amongst regulatory subunit types is found and it is in this 
region that the interaction between two R-subunits occurs to form the R-R dimer. The auto- 
inhibitory, or hinge region, shows little variation between R-subunit types and it is this 
region that contains the pseudo-substrate motif (arginine-arginine-x-serine [where x is any 
amino acid]) to which the kinase domain of the C-subunit binds (see Ddskeland et al., 1993;
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Taylor et al., 1990). In addition, mutation studies of the catalytic site of the C-subunit and 
the hinge region of the R-subunit have shown that the R-subunit is still able to interact with 
the C-subunit. This demonstrates that there must also be another R-C-subunit interaction 
site (Orellana et a l, 1993; Wang et al., 1991). The two cAMP binding regions (A and B) 
consist of a conserved structure which gives the regions a three a-helix, eight stranded anti- 
parallel (3-barrel cAMP binding domain. The binding of cAMP to one of the sites, either A 
or B, causes an increase in the affinity of the empty site for cAMP. Once the second site is 
occupied this increases the probability of the dissociation of the R-C complex although 
occupation of all four sites is required for the release of the catalytic subunits (see 
D0skeland et al., 1993; Orellana et al., 1993; Taylor et al., 1990).
To date little is known about the functions of the different C-subunits or even 
why there are different R-subunits, although the R-subunits may provide differential cAMP 
control and cellular localisation of the C-subunits (Bregman, Bhattacharyya & Rubin, 1989; 
Bregman, Hirsch & Rubin, 1991; see D0skeland et al., 1993). It has been demonstrated 
that Ca and Cp have similar substrate specificities but Cy seems to prefer histone (see 
Dpskeland et al., 1993).
In addition to the R-subunit mediated inhibition of the activity C-subunit a second 
cellular control mechanism has been described which uses a 75 amino acid specific protein 
kinase inhibitor (PKI). Two isoforms of PKI have been identified and like the R-subunits 
they contain a pseudo-substrate motif and a second point of interaction with the C-subunit 
(Orellana et al., 1993).
A range of PKA inhibitors are becoming available for experimental use and one 
of these is HA1004 (N - (2'-guanidinoethyl) - 5 - isoquinoline - sulfonamide; available form 
LC Services Corporation) which, although at high concentrations is a non-specific protein 
kinase inhibitor (see section 1.2.4), can show specificity for PKA with a reported inhibitor 
potency of 2.3 |xM. For the other kinases it has been reported as 1.3 pM for PKG (cGMP 
activated protein kinase; Asano & Hidaka, 1984; Hidaka et al., 1984) and 40 pM for PKC 
(see section 1.2.4.2).
1 .2 .4 .2  Protein kinase C
The activation of cell surface receptors linked to the InsP pathway (see section
1.2.3.2) results in the production of two intracellular messengers, the cytosolic InsPs and 
membrane bound diacylglycerol (DAG). The intracellular rise of Ins(l,4 ,5)P3 and the 
subsequent rise of Ca2+ levels can last for many minutes but the increase in DAG is 
transient and it is rapidly recycled back into the InsP pathway or further metabolised (see 
section 1.2.3.2). In some cell types a second increase of DAG occurs which arises from 
agonist induced breakdown of phosphatidylcholine (Billah et al., 1988; Pelech & Vance, 
1989; see Exton, 1990) by phospholipase D (see section 1.2.3.3), or from inositol 
containing glycolipids (Chan et al., 1989). It has been shown that the membrane bound
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DAG, when complexed with phosphatidylserine and Ca2+, activates a specialised protein 
kinase, protein kinase C (PKC), and increases its affinity for Ca2+ (May Jr et al., 1985; 
Wolf et al., 1985; see Huang, 1989). The Ca2+ released by Ins(l,4 ,5)P3 may not be 
required by PKC for its activation as physiological levels of Ca2+ may be sufficient 
(Castagna, 1987), or the PKC isoform may not require Ca2+ (Ha & Exton, 1993). Upon 
activation, some isoforms of PKC can translocate from the cytosol to the membrane (see 
table 1.2; Harrison & Mobly, 1990; Hirota et al., 1985; Kraft & Anderson, 1983; Osborne 
et al., 1991; Tapley & Murray, 1984) with the correct orientation of PKC in the membrane 
being insured by the hydrophobic domain of DAG (see Huang, 1989).
PKC has a predicted molecular weight of 67 - 84 kDa (Huang et al., 1987; 
Huang & Huang, 1986; Stabel & Parker, 1993) and can be divided by proteolysis to give 
48 kDa and 38 kDa portions which represent the catalytic and regulatory sites of the enzyme 
(Huang & Huang, 1986). It has been shown that PKC is associated with many different 
tissues (Kikkawa et al.y 1988) and that it can be isolated in both membrane and cytosolic 
fractions. It has been shown that the enzyme can exist in multiple forms of closely related 
structure as a result of interaction of the same species of PKC with different cofactors 
(Huang, 1989).
Nine species of PKC have now been identified, a, p i, p ll, 5, e, y, q, £ and 0 
with a possible further two subspecies, e' and based on alternative mRNA splicing of e 
and £ respectively (see table 1.2; see Hug & Sarre, 1993; Stabel & Parker, 1993). The 
PKC species a , pi, pH, 8, e and £ show a heterogeneous tissue distribution, y is found 
exclusively in the central nervous system, q in the skin and lungs, and 0 in the muscle (see 
table 1.2; Hug & Sarre, 1993). The PKC isozymes can be divided into two groups, A and 
B or cPKC and nPKC, on the basis of the conservation of the protein sequence (Considine 
& Caro, 1993; Huang et al., 1987; Huang, 1989; Ono et al.y 1988) and Ca2+ sensitivity 
(see Hug & Sarre, 1993). Group A, consists of a, pi, p n  and y, are Ca2+ dependent, and 
contain five variable regions separated by four highly conserved regions. Group B (Ca2+ 
independent, 8, e, q, £ and 0) shows similarities to group A in two of the conserved regions 
but completely lacks one of the conserved sequence of group A PKCs (Ono et a i, 1988; see 
Hug & Sarre, 1993). The PKCs within one group display similar characteristics but PKCs 
from different groups exhibit different characteristics (see Huang, 1989). It has been 
shown that the PKC species exhibit a range of affinities for DAG (Huang et al., 1988b), 
hence DAG, and phorbol esters, may have different effects on different species of PKC or 
on the same species of PKC under altered cellular conditions (see table 1.2; Huang, 1989). 
In addition, PKC activated by phorbol esters or by DAG show different phosphorylation 
products (see Castagna, 1987).
A wide variety of substrates have been identified for PKC both in vivo and in 
vitro (see Nishizuka, 1986). It has been shown to phosphorylate both membrane bound 
proteins (e.g. receptors; see Nishizuka, 1986); G-proteins, (see Jakobs et al., 1985;
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Lounsbury era/., 1993; Morris era/., 1994; Sagi-Eisenberg, 1989; see section 3.1.1); 
adenylyl cyclase, (Olianas & Onali, 1986); and cytosolic proteins (e.g. intermediate 
filaments; vimentin, Huang, Devanney & Kennedy, 1988a).
Table 1.2: Isoforms of protein kinase C.
mily PKC Tissue MW SDS Ca2+ DAG/PE Auto Location Trans Down
A a Ubiquitous* 76.8 80-81 + + +S C Y Y
A PI Ubiquitous 76.8 79-80 + + +T C Y Y
A pH Ubiquitous 76.9 80 + + +ST c Y Y
A y Brain 78.4 77-84 + + +
B 5 Ubiquitous 77.5 74-79 - + + C/M - Y
B e Ubiquitous* 83.5 89-96 - + + C/M - Y/N
B (£-) -
B c Ubiquitous 67.7 76-80 - - +S C ? ?
B (C-) -
B T1 Skin/Lung 77.9 82-86 - + + NUC ND N
B e Muscle 81.6 79 ND ND + M ND
Nine isoforms have been identified, plus two subspecies based on alternative mRNA 
splicing (shown in parenthesis). "Family" indicates which family the different isoforms 
belong (A or B); tissue indicates their tissue distribution; MW = predicted molecular weight 
(kDa) based on cDNA clone; SDS = observed molecular weight (kDa) in SDS-PAGE; 
Ca2+, "+" indicates isoform requires Ca2+ for activation, "-" indicates that it does not; 
DAG/PE indicates whether the isoform is activated by diacylglycerol or phorbol esters; 
"Auto" = autophosphorylation, S if the site is serine, T for threonine; "Location" is the 
cellular distribution in unstimulated cells, C = cytosol, M = membrane, C/M = cytosol or 
membrane (i.e. dependent on cell type), NUC = nucleus; Trans, Y the isoform is 
translocated,indicates that it depends on cell type, ? unknown; Down, Y = the isoform 
is down regulated on chronic exposure to phorbol esters, Y/N, down regulation depends on 
cell type, ? data inconclusive; ND = not determined; * not in hepatocytes (see Azzi, 
Boscoboinik & Hensey, 1992; Hug & Sarre, 1993).
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An increasingly wide range of artificial activators and inhibitors of PKC are 
available. PKC can be activated by 4-amino pyridine and the tumour promoting phorbol 
esters. The phorbol esters interact with DAG binding site on the regulatory domain of PKC 
(see Blumberg et al., 1984; Sharkey, Leach & Blumberg, 1984). The inhibitors of PKC 
can be divided into two groups (Huang, 1989). One group interacts at the catalytic (kinase) 
site of the enzyme by competing with ATP or other substrates (e.g. H7, see Hidaka & 
Hagiwara, 1987; Nakadate, Jeng & Blumberg, 1988); or by binding directly to the catalytic 
site (e.g. staurosporine, Nakadate et al., 1988). The catalytic site inhibitors tend to show 
an inhibitory effect on other kinases due to interactions with the similar catalytic sites. The 
other group of inhibitors interacts with the regulatory site of PKC and so prevents the 
activation of the enzyme by competing with the activator for the binding site (e.g. 
Polymixin B; Huang, 1989). These inhibitors can be very specific for PKC if they interact 
with DAG or phorbol ester binding site, but interaction at the acid phospholipid binding site 
will tend to be make the inhibitor less specific (see Huang, 1989).
Phorbol esters possess structures similar to DAG and their mode of action of the 
phorbol esters is similar to that of DAG in that they can insert into the cell membrane, bind 
to the regulatory site of the enzyme, increase its affinity for Ca2+, and hence activate the 
enzyme (see Blumberg et al., 1984; Castagna, 1987). Unlike DAG, phorbol esters are long 
lived in biological systems and are not readily metabolised.
1 ,2 ,4 .3  Protein phosphatases
Protein phosphatases can be split into two main groups; one group removes 
phosphate groups from the amino acid tyrosine, whilst the other group is described as 
threonine /  serine specific phosphatases.
The first tyrosine phosphatase was purified in 1988 (PTPase IB; see Pot & 
Dixon, 1992) and so far some 42 PTPases have been identified. It was found that PTPase 
IB did not have any sequence similarities to the serine /  threonine phosphatases but it did 
possess sequence homology with lymphocyte cell surface protein called CD45 (see Pot & 
Dixon, 1992). CD45 is a 'receptor-like' molecule found on the surface of lymphocytes and 
it is an intracellular portion of the molecule which contains the region that is highly 
conserved between both CD45 and PTPase IB. This has led to the idea that the protein 
tyrosine phosphatase family can be divided into two groups, the so called receptor-like 
tyrosine phosphatases and the non-receptor-like. The receptor-like phosphatases, with the 
exception of PTPase-p and DPTP10D, contain two 200 amino acid cytosolic tyrosine 
phosphatase domains and a transmembrane spanning region whilst the non-receptor-like 
phosphatases contain only one 200  amino acid phosphatase domain and no trans-membrane 
spanning region (see Pot & Dixon, 1992).
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The serine /  threonine phosphatases can be divided into two main groups, type 1 
and type 2. Phosphatases were classed as type 1 (PP1) if they could dephosphorylate the p- 
subunit of phosphorylase kinase and were inhibited by nanomolar concentrations of two 
small inhibitory proteins called inhibitor 1 (1-1) and inhibitor 2 (1-2 ; also called modulator). 
Type 2 (PP2) phosphatases dephosphorylate the a-subunit of phosphorylase kinase and are 
insensitive to 1-1 and 1-2 (see Bollen & Stalmans, 1992; Cohen, 1991; Kemp & Pearson, 
1991). The type 2 phosphatases can be further sub-divided into three groups, PP2A, PP2B 
and PP2C, in a number of ways but the most simply based on divalent cation requirement. 
PP2A is partially active in the absence of cations, PP2B requires Ca2+ and PP2C requires 
Mg2+ (see Bollen & Stalmans, 1992; Cohen, 1991). The system of classification of the 
phosphatases has now been complicated by reports of phosphatases that may only fit one of 
the criteria to place them in a particular group (see Bollen & Stalmans, 1992). Examination 
of mammalian phosphatases has shown that both type 1 and type 2  phosphatases are widely 
distributed amongst different tissues, have a wide range of substrate specificities in vitro, 
and appear to be involved in the regulation of may cellular processes (see Cohen, 1991). 
By the use of cDNA cloning it has now been found that there are at least two isoforms of 
PP1, PP2A and PP2B present in mammalian tissues. These isoforms are distinguished in 
the literature by the inclusion of a  or (3 after the phosphatase type. In addition the 
phosphatases can also be described not only by their type but also by other proteins to 
which they are found complexed (e.g. in the muscle; glycogen [PPIgL myofibrillar [PPIm] 
or inactive [PPli]) or by elution from protein separation columns (see Bollen & Stalmans, 
1992; Cohen, 1991; Hubbard & Cohen, 1991).
The phosphatases can be inhibited by an increasing range of commercially 
available inhibitors. On such inhibitor is okadaic acid which is a polyether fatty acid 
secreted by dinoflagellates (Okadaic acid used in these studies was from Prorocentrum lima, 
although it was originally isolated from the marine sponge, Halichondria okadaii) and is a 
potent inhibitor of the PP1 and 2A, and has also been reported to inhibit phosphatase 2B at 
high concentrations. Okadaic acid has not been shown to inhibit protein tyrosine 
phosphatases or any of the kinases (see Cohen, 1991; Hardie, Haystead & Sim, 1991; 
Haystead et al.y 1989).
1 .3  Cellular signalling and disease
In has long been recognised that in many disease states the fault lies in some 
element of signal transduction. In some instances this may be as a result of the over 
production of hormones or neurotransmitters (e.g. possible over production of dopamine in 
schizophrenia) in which case the disease may be treated by the use of receptor specific 
antagonists or by inhibiting the transmitter production system; or it may be an under­
production of a transmitter (e.g. Pakinsons disease; type I diabetes [see section 1.3.1]) 
hence the transmitter levels may be increased (e.g. injections of insulin in type I diabetes) or
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by stimulating the production system (e.g. sulphonylureas stimulating insulin release from 
the pancreas; also see section 5.1.2).
Some disease states and illnesses may be the result of a post - receptor 
dysfunction of the signal transduction system (e.g. type II [insulin independent] diabetes; 
see section 1.3.1), and this has now become the target of research for drugs that may be 
able to interact specifically at that level and so correct the problem (see section 5.1.2).
1 .3 .1  Diabetes
Diabetes is a condition when the body is no longer able to maintain blood glucose 
levels between the normal physiological levels. The term diabetes mellitus is derived from 
the observation that the urine contains sugar and is therefore sweet (diabetes, Greek 
meaning siphon; mellitus is Latin for honeyed) and one of the earliest recorded descriptions 
of this complaint was in 15th century BC Egypt (see Bottazzo, 1993). The 'sweet-urine' 
(glycosuria) results from an increased blood glucose level above the kidney threshold and 
so excess glucose is excreted. Diabetes is diagnosed in non-pregnant adults if they are 
found to meet one of the following criteria: 1. Random plasma glucose >11.1 mM (plus 
symptoms such as polydipsia, polyuria, polyphagia and weight loss). 2. Fasting plasma 
glucose levels > 7.8 mM on more than two occasions. 3. Fasting glucose levels < 7.8 mM 
plus elevated plasma glucose levels (> 7.8 mM) during two or more oral glucose tolerance 
tests (If the plasma glucose level is > 7.8 mM at two hours, and at least one other sample 
between 0 and 2 hours, after the administration of 75 g of glucose then a lack of glucose 
tolerance is observed; see Ruoff, 1993; Tattersall & Gale, 1990).
The condition of diabetes can be divided into two forms, so called insulin- 
dependent diabetes mellitus (IDDM), early onset, juvenile or type I, and non-insulin- 
dependent diabetes mellitus (NIDDM), late onset, or type II. Type I diabetes is 
characterised by a failure of the p-cells of the pancreas to produce insulin in response to 
increased blood glucose levels. This form is usually treated with insulin therapy in the form 
of injections. Type I diabetes is an auto-immune disease and it is thought that it may be a 
modem disease that has only become prominent in the last two centuries (see Bottazzo, 
1993).
Type II diabetes represents a more intriguing dysfunction of the system. The 
disease state is characterised by both abnormalities in insulin secretion and in insulin 
resistance at the target tissues (i.e. liver, fat and muscles; see DeFronzo, 1992; Haring, 
1991). The insulin resistance can occur as a result of a change in insulin binding 
characteristics, changes in the tyrosine kinase activity of the receptor (see section 1.4), 
mutations in the receptor, or from a combination of the above (see Cocozza et al., 1992; 
Haring, 1991; O’Rahilly & Moller, 1992). Events such as mutations of the receptor are 
very rare and therefore do not explain all the cases of type II diabetes. It is still not known 
whether the altered rates of insulin production are the cause or a symptom of the disease
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because as the body becomes insulin resistant and blood glucose levels rise the pancreas 
compensates by increasing insulin production and such elevated levels of production may 
finally cause the pancreas to fail resulting in abnormal insulin production. The disease is 
characterised by a failure of insulin to reduce glycogen storage in the muscle and to 
suppress normal hepatic glucose output. Treatment of type II diabetes has tended to 
concentrate on modifications of diet, increased physical activity, oral hyperglycaemic agents 
and insulin (see Ruoff, 1993). Clearly a better understanding of the normal functioning of 
the insulin receptor (see section 1.4) and the post-insulin binding events (see section 1.4) 
would be useful in determining the selective malfunction that occurs and thus for the 
treatment of type II diabetes.
Both forms of diabetes can lead to long and short term health problems. In the 
short term poor control of blood glucose can result in hypoglycaemia if glucose levels fall 
below 2.5 mM or ketoacidosis (results from lack of insulin and hence reduced glucose 
uptake) if glucose levels rise above 15 mM (hyperglycemia) for long periods (see Watkins, 
Drury & Taylor, 1990). Both problems can eventually result in death if not treated 
promptly (see Watkins et al., 1990). Long term problems resulting from lack of control are 
nephropathy, neuropathy, retinopathy, coronary heart disease and stroke (see Ruoff, 1993; 
Nathan, 1993).
1 .4  The Insulin Receptor
Although recent years have seen a great increase in our knowledge and 
understanding of the function of the activated insulin receptor it is clear that the complete 
signal transduction system has not been fully described.
1 .4 .1  Insulin
Insulin is a fifty-one amino acid poly-peptide hormone which is secreted from the 
(3-cells of the pancreas. The secretion is regulated by the interaction of a variety of 
nutrients, hormones and neurotransmitters but glucose is the predominant trigger. The 
ability of the cells to secrete insulin depends on the metabolism of glucose and the 
generation of a range of intermediates which results in membrane depolarisation and Ca2+ 
entry (see Cook, Satin & Hopkins, 1991; Wang et al.t 1993). It is also a process in which 
G-proteins may play a role (see Robertson, Seaquist & Walseth, 1991). The biosynthetic 
precursor of insulin is proinsulin which is a single-chain poly peptide containing 81-86 
amino acids with a molecular weight of ~9 kDa. The precursor is kept in storage granules 
where it has a connecting peptide enzymatically removed to produce two polypeptide chains 
(A and B) linked by disulphide bridges (final molecular weight ~6  kDa; see Wang & Tsou,
1991) which is stored in crystallin hexatrimeric form complexed with zinc (see Brader & 
Dunn, 1991).
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1 .4 .2  Insulin Receptor Structure
In the 1950s it was thought that the receptors for insulin were part of a matrix 
surrounding the target cells and that insulin binding caused a disturbance which was 
propagated throughout the tissue (see Rodbell, 1992). It is now known that the insulin 
receptor is located in the plasma membrane of the target cells and that it consists of two 
subunits (a and p), and the full receptor complex has two a  and two p subunits (molecular 
weight 450 kDa). The subunits are the product of a single gene which has 22 exons and is 
located on chromosome 19 in humans. The precursor poly-peptide contains 1343 or 1355 
amino acids preceded by a 27 amino acid leader sequence which is cleaved during the 
processing of the receptor. During processing the precursor poly-peptide has oligo­
saccharide side chains added to specific glycosylation sites, two monomers associate to 
form a dimeric structure and a four amino acid sequence is removed ffom each monomer to 
yield a receptor that consists of two a  and two p subunits joined by disulphide bonds (see 
figure 1.3). This results in a modular protein that contains several functional domains and 
has a specific membrane orientation (see Hollenberg & Jacobs, 1990; Olefsky, 1990). The 
receptor is orientated such that the a  subunits of the receptor are located on the extra-cellular 
face of the plasma membrane with the p subunit providing the membrane spanning portion 
of the receptor.
1 .4 .2 .1  The a-subunit
The a  subunit (135 kDa [82 kDa before glycosylation]) contains the insulin 
binding site which consists of a cysteine rich site with at least two other regions of the a  
subunit contributing to the binding domain. Although each receptor contains two a  
subunits, and hence two insulin binding sites, the occupancy of one site inhibits the binding 
of insulin to the second. When both sites are unoccupied the a  subunits exerts a tonic 
inhibition on the biological activity of the p subunit. As stated above the polypeptide chain 
can have either 1343 or 1355 amino acids. The extra 12 amino acids can be found 
associated with the a  subunit where they have been shown to cause a decrease in the 
receptors affinity for insulin. The a  subunits are linked by disulphide bonds to each other 
and to the p subunit (see Haring, 1991; Olefsky, 1990; see figure 1.3).
1 .4 .2 .2  The p-subunit - structure and function
The p subunit has a molecular weight of 90 kDa (70 kDa before glycosylation) 
and consists of two globular domains joined by a single a  helix (see figure 1.3). The 
function of the extracellular domain, other than binding the a  subunit and transmitting the 
insulin signal, is unknown. The function of the a  helix, which joins the two globular 
domains, is to provide membrane anchorage for the receptor and to transmit the insulin 
signal between the domains. The result of insulin binding to the a-subunit is to produce a 
conformational change in the C-terminal of the p-subunit with any further conformational
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changes resulting from subsequent phosphorylation of the subunit (Baron et al., 1992; see 
section 1.4.3). The biological effects of insulin are produced by the intracellular portion of 
the p subunit. This region contains the tyrosine kinase domain, several phosphorylation 
sites (Tavar6 et al., 1988), which are both stimulatory and inhibitory on receptor function, 
and a C-terminal which has a number of insulin-receptor-specific sequences (see figure 1.3; 
Avurch et al., 1990; Begum, Olefsky & Draznin, 1993; Hollenberg & Jacobs, 1990; 
Houslay & Siddle, 1989; Olefsky, 1990). The tyrosine kinase domain becomes active as a 
result of the autophosphorylation, or transphosphorylation, of tyrosines 1146, 1150 and 
1151 in the regulatory region and tyrosine 960 in the juxtamembrane region of the p subunit 
(see Feener et al., 1993; Denton et al., 1992; Avurch et al., 1990; Haring, 1991; Tavare et 
al., 1988) with the phosphorylation event occurring asymmetrically with more phosphate 
being incorporated into the p-subunit that is not bound to the insulin bound a-subunit (Lee 
et al., 1993). In addition phosphorylation has also been reported on tyrosines 1316 and 
1322 (see Denton et al., 1992; Haring, 1991). It appears that some of the sites undergo an 
insulin independent phosphorylation and dephosphorylation whilst the other sites are insulin 
dependent (Argetssinger & Shafer, 1992). Recent reports have emerged in which type II 
diabetes (see section 1.3.1) has been observed in patients that have exhibited a point 
mutation near an autophosphorylation site of the receptor and although this does not effect 
insulin binding or insulin-independent kinase activity it does result in a receptor that is no 
longer able to phosphorylate its substrates (Formisano et al., 1993).
The p-subunit also possess serine (1293 and 1294) and threonine (1336) 
phosphorylation sites (see figure 1.3) which when phosphorylated attenuated the receptor's 
kinase activity (see Denton et al., 1992; Chin et al., 1993; Considine & Caro, 1993; 
Hollenberg & Jacobs, 1990; Haring, 1991). These phosphorylations appear to be carried 
out by PKC, PKA, and some additional kinases (see section 1.2.4; Ahn, Donner & Rosen, 
1993; Smith, King & Sale, 1988; see Grunberger, 1991). In addition there is evidence that 
the insulin signal transduction system can activate PKC and it is by this mechanism that 
insulin may produce some of its responses. This kinase has also been implicated in type II 
diabetes (see Chin et al., 1993; Considine & Caro, 1993).
1 .4 .3  Insulin signalling - the activated receptor
The interaction of insulin with its receptor is not easily understood. Firstly, the 
binding characteristics of insulin are confusing and complex; secondly, interaction of insulin 
with its receptor results in a diverse range of cellular responses which can occur over time- 
courses from milliseconds to tens of hours (see table 1.3; see Hollenberg & Jacobs, 1990; 
Houslay & Siddle, 1989).
The earliest effect of insulin binding with its receptor is seen in muscle where it 
produces a change in membrane potential within milliseconds. In general, the first response 
is an increase in receptor auto-phosphorylation at specific tyrosine residues on the (3 subunit
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Figure 1.3: Diagrammatic representation of the insulin receptor
Diagrammatic representation of the insulin receptor showing receptor orientation, 
phosphorylation sites (number indicating position in primary sequence; Tavar6 et al., 1988; 
Haring, 1991), and putative receptor - effector coupling site. The insulin receptor contains 
two sub-units (a  and p), and the full receptor complex has two a  and two p subunits linked 
by disulphide bonds. This results in a modular protein that contains several functional 
domains (see Olefsky, 1990) and has a specific membrane orientation. The receptor 
contains two insulin binding sites which when they are both unoccupied exerts a tonic 
inhibition on the biological activity of the p subunit. The p subunit the tyrosine kinase 
domain, several autophosphorylation sites (tyrosines 960, 1316, 1322, 1146, 1150, and 
1151) which stimulate receptor activity, and several serine /  threonine phosphorylation sites 
(serines 1293 and 1294, and threonine 1336) which are inhibitory on receptor function. 
The receptor also has a C-terminal which has a number of insulin-receptor-specific 
sequences (see Hollenberg & Jacobs, 1990; Houslay & Siddle, 1989; Olefsky, 1990).
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which results in an increase of its tyrosine kinase activity (see section 1.4.2.2; Avurch et 
al., 1990; Rothenberg et al., 1990). The activated receptor then forms microclusters before 
being endocytosed. After internalisation, insulin dissociates from the receptor as a result of 
the acidified environment of the endosome and is degraded. The receptor bearing 
endosomes can then either fuse with lysomes, which results in the receptors' being 
degraded, or the receptors can be recycled to the plasma membrane (see Carpentier, Gorden 
& Lew, 1992; Hollenberg & Jacobs, 1990). The initial internalisation of the insulin 
receptor is Ca2+ independent but the subsequent processing and recycling to the plasma 
membrane has been shown to be Ca2+ dependent (Carpentier et al., 1992). It is thought 
that the early responses to insulin binding are triggered as a result of the formation of the 
microclusters of activated receptors and that the prolonged actions are initiated after the 
receptors are internalised (see Hollenberg & Jacobs, 1990; Olefsky, 1990) although it has 
also been reported that internalisation of the receptor is not required for it to produce its 
responses (McClain, 1990). An alternative to the receptor recycling is that they are 
redistributed to internal membranes, but this has not been fully demonstrated (see 
Hollenberg & Jacobs, 1990; Olefsky, 1990).
Table 1.3: Cellular responses to insulin and their respective time courses.
Response Time Course
Regulation of ion flux (Na+, K+, Ca2+) 
Stimulation of receptor tyrosine kinase 
Stimulation of receptor-substrate phosphorylation 
Stimulation of glucose transport 
Stimulation of enzyme activity 
Glycogen synthase 
Pyruvate dehydrogenase 
Acetyl-CoA-carboxylase 
Stimulation of amino acid transport 
Stimulation of protein synthesis 
Regulation of gene transcription 
Stimulation of cell division
Milliseconds to seconds 
Seconds to minutes 
Minutes 
Minutes
Minutes
Minutes
Minutes
Tens of minutes 
Tens of minutes to hours 
Tens of minutes to hours 
Tens of hours
Taken from: Hollenberg, 1990
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1 .4 .3 .1  Insulin receptor tyrosine kinase activity and the insulin receptor
substrate
As outlined in table 1.3 the insulin receptor mediates a range of cellular 
responses, yet the method, or methods, by which all the effects are produced is unknown. 
One of the best characterised responses of the receptor is its tyrosine kinase activity. The 
kinase activity has been examined and several intracellular insulin-dependent- 
phosphoproteins identified (see Avurch et al., 1990; Dent et al., 1990; Denton, 1990; 
Haring, 1991; Hollenberg & Jacobs, 1990; Pillion et al., 1992). The most prominent 
insulin-dependent phosphotyrosine protein described, other than the p subunit of the 
receptor, has a molecular weight of 160-185 kDa and has now been called insulin receptor 
substrate 1 (IRS1; Avurch et al., 1990; Dent et al., 1990; Denton, 1990; Hollenberg & 
Jacobs, 1990; Keller & Lienhard, 1993; Rothenberg et al., 1990; see Myers & White, 
1993). It has also been found that this protein can be phosphorylated by insulin-like growth 
factor-I receptor (Giorgetti et al., 1993; Myers et al., 1993). Conversely it has been shown 
that the activated receptor can also cause the dephosphorylation of several cellular proteins. 
This has lead to the proposal that the receptor initiates a phosphorylation / 
dephosphorylation cascade (Avurch et al., 1990; Dent et al., 1990). In this cascade, which 
is involved in the metabolism of glycogen, several of the component enzymes have been 
identified (Dent et al., 1990). It has been shown that the cascade is dependent on the 
tyrosine kinase activity of the receptor and the link between the receptor and the first 
identified enzyme in the cascade may be via IRS1 (see figure 1.4; see Klarlund et al., 1993; 
Tobe et al., 1993).
IRS1 was first described in 1985 but it was not known if there were one or more 
of these proteins as the molecular weights reported ranged from 160 to 185 kDa. In 1991 
the protein was cloned and the situation was resolved to show only one protein which was 
subsequently named IRS1 (see figure 1.4; see Keller & Lienhard, 1993). The protein has 
now been cloned from several different tissues, and species, and although it does not have 
extended homology with any other know proteins its conservation between the species 
examined is greater than 90% (Keller et al., 1993). IRS1 has a predicted molecular weight 
of 131 kDa, is very hydrophilic and possesses numerable phosphorylation sites (see Keller 
& Lienhard, 1993). The protein is rich in sites for threonine and serine phosphorylations 
and contains twelve sites (out of thirty-four) that have good tyrosine kinase recognition 
motifs (Shoelson et al., 1992). Several of these tyrosines are also in sequences that makes 
them good src homology 2 (SH2) binding domain recognition sites and it is via these sites 
that IRS 1 binds to at least four SH2 domain containing proteins (see Keller & Lienhard, 
1993; Myers & White, 1993). It has been reported that the protein has phosphotyrosine 
phosphatase activity associated with it (Goren & Boland, 1991) and no tyrosine kinase
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Figure 1.4: Diagrammatic representation of the interaction of the activated insulin
receptor and the insulin receptor substrate
Diagrammatic representation of the interaction of the activated insulin receptor (see figure 
1.3) and the insulin receptor substrate (IRS 1; see Keller & Lienhard, 1993). (GAP, 
GTPase activating protein; MAPK, mitogen-activated protein kinase; MAPKK, mitogen- 
activated protein kinase Idnase; PI3K, phosphatidylinositol 3-kinase [p85 = regulatory 
domain, p i 10 = catalytic domain]; SH2 and SH3 are src homology domains binding 
domains 2 and 3; ?, unknown protein; Syp, tyrosine phosphatase; Nek, protein of unknown 
function although likely to be an adapter protein; Grb2, growth factor receptor-bound 
protein; Sos, Son of sevenless)
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activity (Goren, Boland & Fei, 1993). Increased phosphorylation of IRS1 has been 
detected in the insulin induced regeneration of hepatocytes indicating its role in transmitting 
the insulin signals to intracellular regulators of growth (Sasaki et al., 1993) but, in contrast, 
constant stimulation of the insulin signalling pathway causes an increase in the rate of 
degradation of IRS 1 (Rice, Tumbow & Gamer, 1993).
The four proteins that have so far been reported as binding to IRS1 are 
phosphatidylinositol 3-kinase (PI 3-kinase; Backer et al., 1993; Backer et al., 1992; Hadari 
et al,, 1992; Kelly & Ruderman, 1993; Okamoto et al., 1993; Myers & White, 1993); 
growth factor receptor-bound protein 2 (Grb2; Skolnik et al., 1993a, see Keller & 
Lienhard, 1993; Skolnik et al., 1993b; Tobe et al,, 1993; Myers & White, 1993); Nek (see 
Keller & Lienhard, 1993); and Syp (or SH PTP2; Kuhn6 et al,, 1993; see Myers & White, 
1993). It has been demonstrated that tyrosine phosphorylated IRS1 possesses more than 
one protein /  protein interaction site as it can bind one or more of these proteins at a time 
(see figure 1.4; Keller & Lienhard, 1993; Skolnik et al., 1993b; Tobe et al., 1993).
PI 3-kinase was shown to be associated with IRS1 as immunoprecipitates of 
IRS1 from insulin stimulated cells also contained PI 3-kinase activity (Folli et al., 1992; 
Kelly & Ruderman, 1993; Sung & Goldfine, 1992). PI 3-kinase consists of two subunits, 
a 85 kDa regulatory (p85) and a 100 kDa catalytic (pi 10) subunit and it is via the SH2 
domains in p85 that IRS1 and PI 3-kinase interact. The result of the interaction is an 
activation of the enzyme and an increase of PI 3,4-bisphosphate and PI 3,4,5-trisphosphate 
levels in the membrane (Lamphere et al., 1993). An alternative method of activation of PI 
3-kinase by insulin is by the direct tyrosine phosphorylation of the 85 kDa regulatory 
subunit by the insulin receptor (Hayashi et al., 1992; Hayashi et al., 1991; Hayashi et al., 
1993).
Grb2, also known as abundant sre homology (ASH), also co-immunoprecipitates 
with IRS1. The protein has a molecular weight of 23 kDa and contains one SH2 domain 
and two SH3 domains (see Keller & Lienhard, 1993). The presence of the SH domains 
indicates that it acts as an adapter protein with the SH2 domain binding to IRS1 and the 
SH3 domains interacting with other proteins. Biochemical evidence indicates that Grb2 is 
involved in the activation of ras (see section 1.2.2; Gale et al., 1993) through an additional 
protein. The link protein between Grb2 and the activation of ras is Sos (son of sevenless) 
which is a guanine nucleotide-releasing protein for ras (see Baltensperger et al., 1993; 
Keller & Lienhard, 1993; Li et al., 1993; Rozakis-Adcock et al., 1993; Skolnik et al., 
1993a; Skolnik et al., 1993b).
Nek is a 47 kDa protein that has been found associated with the tyrosine 
phosphorylated form of IRS1. The function of the protein is unknown but as it contains 
one SH2 domain and three SH3 domains it would appear that it may function as an adapter 
protein (see Keller & Lienhard, 1993).
32
Chapter 1
If the function of tyrosine phosphorylated IRS1 is to act as an initiator for some 
of the insulin receptor stimulated signalling pathways then a method for dephosphorylation, 
and hence deactivation, of the protein must exist. Failure to regulate the level of 
phosphorylation of IRS 1, and its rate of dephosphorylation, could lead to the development 
of diabetes. It has already been demonstrated that insulin activates a serine phosphatase, 
protein phosphatase 1 (PP-1), by means of a C-terminal domain on the receptor (Begum et 
al., 1993; see Bollen & Stalmans, 1992) but a method for dephosphorylation of the tyrosine 
residues of the receptor and IRS1 still has to be demonstrated. Insulin regulation of 
phosphotyrosine phosphatase activity has been reported (Meyerovitch et al., 1992) but the 
phosphatase was only shown to dephosphorylate the insulin receptor in vitro. Work by 
Mooney and Bordwell (Mooney & Bordwell, 1992) has shown that a rapid turnover of 
phosphate does occur on the insulin receptor and IRS1 upon activation of the receptor, and 
that IRS1 is the most sensitive to phosphatase action. In addition it has been shown that 
tissue specific changes in phosphatase activity do occur in diabetes which indicates the 
importance of phosphatase activity in the correct processing of the insulin signal (Begum, 
Sussman & Draznin, 1991; Goldstein, 1992; Goren & Boland, 1991; Hauguel et al., 
1993). Goren (Goren & Boland, 1991) has shown that ppl80 (IRS1) had, when 
immunoprecipitated, tyrosine phosphatase activity associated with it and it maybe that the 
phosphatase responsible for the termination of the IRS1 and insulin signals and ppl80 were 
co-immunoprecipitated. An alternative method for the dephosphorylation of the receptor 
that has been proposed is a phosphatase-independent dephosphorylation (Gruppuso et al.,
1992).
A candidate protein for the phosphatase involved in the deactivation of the insulin 
receptor and IRS1 is the fourth protein that has been identified as binding to IRS1, Syp. 
This is a ubiquitously expressed phosphotyrosine phosphatase that contains two SH2 
domains (Ahmad et al., 1993; Freeman, Plutzky & Neel, 1992). It has been shown that 
Syp will bind to, and be phosphorylated by, activated EGF and PDGF receptors (Feng, Hui 
& Pawson, 1993), but not the insulin receptor (Kuhn6 et al., 1993). The IRS1 / Syp 
complex was co-immunoprecipitated in insulin treated 3T3-L1 adipocytes (Kuhne et al.,
1993) and association of the two proteins was found to be dependent upon IRS1 being 
tyrosine phosphorylated. The formation of the complex may result in the activation of the 
phosphatase and ultimately in the dephosphorylation of IRS1 and the insulin receptor. The 
dephosphorylation of IRS1 by Syp has been demonstrated in vitro (G.E. Lienhard, 
personal communication).
1 .4 .3 .2  Secondary messenger production and the interaction o f  the insulin
receptor with G - proteins
An alternative method by which insulin may produce some of its intracellular 
signals is if the autophosphorylation of the receptor produces a conformational change such
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that it can interact with G-proteins, or directly with enzymes such as PLC and adenylyl 
cyclase (see Hollenberg & Jacobs, 1990; Houslay & Siddle, 1989; Olefsky, 1990).
As insulin is able to produce such a range of metabolic effects the production of 
'classical' secondary messengers by the receptor has been examined. A number of 
candidates have been put forward as secondary messengers of insulin, namely, cGMP, 
Ca2+ and inositol-glycans (see Romero, 1991); it has also been shown that the receptor can 
attenuate the production of cAMP (see Hollenberg & Jacobs, 1990; Houslay & Siddle, 
1989; Olefsky, 1990; Saltiel, Cuatrecasas & Jacobs, 1990).
The production of inositol-glycans is believed to be mediated by an isoform of 
PLC (see section 1.2.3.2; see Saltiel et al., 1990). It has been shown that insulin does not 
cause the production of inositol polyphosphates as a result of PLC activation but it has been 
demonstrated in adipose tissue that it can cause an increase in the rate of incorporation of 
inositol into PI 3,4-bisphosphate and PI 3,4,5-trisphosphate levels in the membrane by the 
activation of PI-3 kinase (Lamphere et al., 1993; see sections 1.4.3.1 and 1.2.3.2; see 
figure 1.4; see Hollenberg & Jacobs, 1990). As in the classic inositol phosphate cycle (see 
section 1.2.3.2; see Berridge, 1993; Berridge & Irvine, 1989), the production of inositol - 
glycans is coupled to the production of another secondary messenger DAG (see sections
1.2.3.2 and 1.2.4.2). There is no clear evidence as to whether the inositol-glycan is 
produced on the intra- or extracellular face of the plasma membrane. It has been suggested 
that the glycan regulates the activity of some of the enzymes which are known to be affected 
in some way by insulin (see Houslay & Siddle, 1989; Saltiel et al., 1990).
It has been shown that insulin can increase the concentration of DAG. This could 
arise either as a result of inositol-glycan production or from de novo synthesis (see Houslay 
& Siddle, 1989; Luttrell et al., 1990). DAG is known to be an activator of PKC (see 
section 1.2.4.2; see Huang, 1989; Nishizuka, 1984) and it may be it is by the activation of 
this enzyme that insulin mediates some of its effects.
The activated insulin receptor can only attenuate the production of cAMP if the 
cAMP system is being stimulated (see sections 1.2.2, and 1.2.3.1; see Hollenberg & 
Jacobs, 1990; Houslay & Siddle, 1989). There is no evidence that insulin can change the 
rate of release of cAMP from the cell (see Houslay & Siddle, 1989), but there are 
indications that the attenuation may be produced by modifications of the G-proteins (see 
section 1.2 .2 ), by the inhibition of adenylyl cyclase (see section 1.2.3.1) or by the 
stimulation of specific species of cAMP - PDE (see section 1.2.3.1; see Houslay, 1990). 
The insulin mediated change in PDE activity is a result of the activation of two specific 
species of PDE. The two species involved are the peripheral plasma membrane PDE (PPM- 
PDE) and the 'dense-vesicle' PDE (DV-PDE). The PPM-PDE is activated by 
phosphorylation (Kilgour, Anderson & Houslay, 1989) but the mode of activation of the 
DV-PDE is unknown (see Houslay, 1990).
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Inhibition of adenylyl cyclase by insulin has not been shown to be mediated by 
Gibut  caused either by the action of an unique G-protein or possibly by the 
phosphorylation of adenylyl cyclase itself. Alternatively the attenuation of the cAMP 
system may be achieved by the modification of G-proteins as a result of phosphorylation 
(see Haring, 1991). The direct involvement of Gi in the attenuation of adenylyl cyclase has 
been discounted in experiments which show that in diabetic animals, which exhibit Gi 
depleted hepatocyte plasma membranes and show a loss of cAMP attenuation, the 
attenuation can be restored by a drug, metformin, which does not effect Gi levels (see 
Houslay, 1990). This raises the possibility that as Gi levels are reduced in diabetes, and 
that they do not appear to be involved with adenylyl cyclase inhibition, that they may play 
some other role in the insulin signal transduction system such as glucose transport and 
metabolism (Moises & Heidenreich, 1990).
There have been reports of a 40 kDa GTP-binding site in adipocytes which is 
activated by the insulin receptor and is distinct from a-Gs (Kellerer et al., 1991; see Haring,
1991) and may (Jo et al., 1992) or may not (Kellerer et al., 1991) be a-Gi. There has also 
been a report of an insulin-dependent binding of GTP to a 66 kDa protein which has been 
partially purified from human placenta (G^; Srivastava & Singh, 1990). The interaction of 
GTPyS (non-hydrolysable analogue of GTP) with this protein inhibits the binding of insulin 
to its receptor (Srivastava & Singh, 1990) and it has also been shown that GTPyS can 
inhibit insulin receptor function via a novel G-protein that is not Gs, Gi or G0 (Davis & 
McDonald, 1990). In addition, a pertussis toxin sensitive 40 kDa G-protein (see section
1.2 .2 .2) in myocytes has been implicated in the insulin signal transduction system where it 
has been demonstrated that pertussis toxin treatment attenuates the insulin-dependent 
production of DAG (see section 1.2.3.2) and inositol-glycans, but not the phosphorylation 
of the receptor and IRS1, and in membrane preparations insulin also increases the GTPase 
activity and GTPyS binding (Luttrell et al., 1990). The 'small* G-protein, (see section
1.2 .2) p21ras, and some other membrane proteins have been implicated in the transduction 
of the insulin signal (see section 1.4.3.1; see figure 1.4; see Hollenberg & Jacobs, 1990; 
Houslay, 1990). How the activated insulin receptor interacts or activates the heterotrimeric 
G-proteins is not known but in vitro studies have shown that a-Gi and cc-G0 provide good 
substrates for insulin-promoted tyrosine-phosphorylation and a-G s and a-Gt do not 
(Krupinski et al., 1988) although the a-Gt data is contradicted by Zick et al. (1986).
Although it has not been conclusively shown that the insulin receptor is coupled 
to the second messenger systems by heterotrimeric G-proteins there is increasing evidence 
that the activated receptor can modify the action of some other G-protein coupled systems. 
For example, p21ras inhibits the autophosphorylation of the receptor and insulin can inhibit 
the ADP-ribosylation of Gi in preparations of hepatocyte membranes (Rothenberg & Kahn, 
1988; Rothenberg etal., 1990; see Haring, 1991; Morris, N.J. unpublished results).
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The possible sites of interaction between G-protein-coupled-receptors and G- 
proteins have been characterised (see Regoli & Nantel, 1990). The receptor G-protein- 
binding site shows a degree of sequence conservation, and in the sites that have been 
sequenced all have been shown to contain basic amino acids and to be in close proximity to 
the plasma membrane. This motif has been demonstrated in the insulin-like growth factor 
(IGF)-l receptor. Examination of the amino acid sequence of the p-subunit of the insulin 
receptor has revealed no direct correlation with this motif, but it does contain regions which 
may possess the necessary properties to interact with G-proteins.
1 .5  A im s
Activation of the insulin receptor is known to produce a wide array of responses 
in the target tissue with time periods varying from milliseconds to tens of hours. One of the 
earliest effects of receptor activation is the autophosphorylation of the receptor which results 
in the activation of its tyrosine kinase activity. It has been suggested that the 
phosphorylation may also result in a conformational change of the receptor such that it is 
able to interact with membrane proteins (e.g. phospholipase C, G-proteins) or that the 
activated receptor could modulate some of its effects via G-proteins. Possible interactions 
of the activated receptor with G-proteins have been demonstrated but no direct link between 
the receptors and G-proteins has been established. It is therefore proposed to further 
demonstrate whether any such interactions occur and to examine whether any changes occur 
in the signal transduction system as a result of diabetes.
The aim of the study was to examine the phosphorylation of the guanine 
nucleotide binding protein a-Gi-2, to identify the phosphorylation sites by peptide mapping, 
to investigate the effects of insulin on the phosphorylation events and to explore any 
changes in the phosphorylation characteristics in diabetic models. If any changes were 
observed in the models of type II diabetes it was proposed to use a development drug from 
SmithKline Beecham, which had been shown to be beneficial in treatment of animal 
models, to see if it had any effect on the phosphorylation event.
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Materials and Methods
2.1 Materials
2.1.1 A nim als
Animals were obtained from stocks kept either at the University of Glasgow or at 
SmithKline Beecham, Epsom, Surrey. They were kept in similar conditions (unless stated 
otherwise in the text) of day-light /  dark cycles with free access to food and water.
2.1.2 Chemicals
Inorganic [32p] phosphate was purchased from Amersham International, UK. 
Phorbol 12-myristate 13-acetate (PMA) was from Cambridge Bioscience, UK. Insulin and 
protein A-agarose were bought from Sigma, UK. Cellulose t.l.c. plates were from Eastman 
Kodak Company, Rochester, N.Y., USA. Tosylphenylalanylchloromethane (TPCK)- 
treated trypsin, a-chymotrypsin, collagenase and Staphylococcus aureus V8 were 
purchased from Lome Laboratories Ltd, Reading, Berks, UK. Okadaic acid from Mona 
Bioproducts, Hawaii, USA. Glucagon, Boerhringer Ltd, UK. and amylin from Bachem 
Ltd, UK. Peptides were produced by either Biomac, Department of Biochemistry, 
Glasgow University, Glasgow, Scotland or the Department of Virology, Glasgow 
University, Glasgow, Scotland. All other biochemicals were from Boerhringer Ltd, UK 
and other chemicals, unless stated otherwise, were of AR grade from BDH Ltd, UK or 
from Sigma, Poole, Dorset, England.
2.2 M ethods
2 .2 .1  Antibody Production
Peptide conjugates were prepared using a method based on Reichlin (Reichlin, 
1980). The peptides were coupled to hemocyanin (KLH; from Keyhole limpets, Megathura 
crenulata) using glutaraldehyde. 20 mg of KLH were dissolved in 2 ml of 0.1 M sodium 
phosphate buffer, pH7, and dialysed overnight. To the dialysed KLH 6 mg of peptide were 
added and dissolved. To the resulting solution 1.0 ml of 21 mM glutaraldehyde, dissolved 
in 0.1 M sodium phosphate buffer (pH7), was added drop-wise over an 8 hour period. The 
procedure was carried out at room temperature with constant stirring. The coupled peptide 
was stored in 100 pi aliquots at -80°C until required.
Conjugated peptides were prepared for injection by diluting one aliquot of 
conjugated peptide (100 pi, 0.2 mg of peptide) to 0.5 ml with phosphate buffered saline 
(PBS, see Appendix 1). This was then mixed with 0.5 ml Freunds adjuvant (complete 
Freunds for primary injections and incomplete for boosters) and placed in a sonicating water 
bath for two 15 second pulses. The solution was then mixed further by inversions of the
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tube until the adjuvant was completely dispersed. The rabbits were injected at five or six 
sites on the back.
Bleeds were taken from all animals before the primary injection and the serum 
collected. Animals were given a booster injection 30 days after the initial immunisation and 
a test bleed was taken 10 days later. A final booster was given 50 days after the initial 
injection and a final bleed collected 10 days later.
For the preparation of rabbit serum blood was collected in 25 ml glass bottles, 
allowed to coagulate overnight at 4°C and the blood clots spun down at 500 - 700 x g in a 
bench centrifuge. The supernatant was collected (serum) and 0.1% (w/v) sodium azide 
added. The serum was aliquoted and stored at -80°C until required.
2 .2 .2  Hepatocyte preparation
Hepatocytes were prepared from male Sprague-Dawley, Zucker or diabetic 
Sprague Dawley rats (see Appendix 2) by using a modification of the methods of Berry, 
Elliott and Heyworth (Berry & Friend, 1969; Elliott & Pogson, 1977; Heyworth & 
Houslay, 1983). Sprague-Dawley rats (220-250g) or Zucker rats were given an 
intraperitoneal injection of pentobarbitone (Sagatal, 60 mg/ml) at 0.4 ml per 250g rat. Once 
the animal had become fully unconscious, determined by loss of the blink reflex, a 
laparotomy was performed. The viscera were displaced from the abdominal cavity and the 
inferior vena cava cannulated with a 15 gauge needle filled with heparin (see Appendix 2), 
and the liver perfused, via the hepatic portal vein, with 100 ml of stock Krebs buffer plus 
EDTA (see Appendix 2) which was allowed to drain to waste. Whilst the blood was 
flushed from the tissue the superior vena cava was clamped. Next, the liver was perfused 
with 80 ml Krebs /  glucose buffer (see Appendix 2), which also drained to waste, before a 
final perfusion with 100 ml of recirculating Krebs / glucose buffer containing 0.5 -1.0 mg 
collagenase per ml. The liver was perfused for 30 minutes or until the tissue showed signs 
of digestion such as excessive 'leakiness'. The liver was removed into 30 ml of Krebs, 
roughly chopped with scissors, and filtered through gauze before being centrifuged in two 
pre-warmed 50 ml centrifuge tubes at 100 x g in a bench centrifuge for 2 minutes. The 
supernatant was aspirated and the pellets washed twice with Krebs buffer. Finally the cells 
were washed in Krebs / Ca2+ (see Appendix 2) and cells needed for phosphorylation 
studies resuspended in low phosphate Krebs (see Appendix 3). All perfusion and wash 
buffers were gassed with 95% O2 /  5% CO2 and at 37°C.
2 .2 .3  Phosphorylation o f a-Gi.2
The method followed was as outlined in Bushfield et al., 1990a and Bushfield et 
al., 1990b. Hepatocytes (see section 2.2.2) were diluted to 106-107 cells /  ml in low 
phosphate Krebs buffer (see Appendix 3). The cells were aliquoted 1 ml per 25 ml 
siliconised conical flasks (see Appendix 3) and pre-incubated, with continuous shaking, for
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65 min at 37°C in the presence of 0.2 mCi 32P / ml. The cells were gassed every 10 
minutes for 30 seconds with 0 2/C02 (19:1). Ligands were added for the last 5 -15  minutes
of the incubation before the reaction was stopped by transferring the cells to ice and adding 
10 ml of ice - cold low phosphate Krebs (see Appendix 3). The cells were harvested by 
centrifugation (100 x g; 2 minutes). The cells were then solubilised and the protein 
immunoprecipitated (see section 2.2.4).
2 .2 .4  Solubilisation o f cells and immunoprecipitation o f  a-Gi. 2
The method used for the immunoprecipitation of a-G i-2 is as outlined in 
Bushfield et al., 1990a and Bushfield et al., 1990b. To pelleted cells (see section 2.2.3) 1 
ml of ice cold solubilising buffer was added (see Appendix 4) and vortexed. The cells were 
left on ice for 60 minutes before the solution was transferred to eppendorfs and centrifuged 
at 14,000 x g for 10 minutes at 4#C. The supernatant was then transferred to clean 
eppendorfs and 50 pi of antiserum added. The tubes were then left overnight at 4°C.
The antibody was precipitated by adding 50 pi of protein A agarose and the tubes 
incubated at 4°C, with occasional inversions, for 90 - 120 minutes. The protein A agarose 
was then pelleted at low speed in a microfuge at 4°C and given two washes with 1 ml of 
Wash buffer + SDS and one wash with Wash buffer - SDS (wash buffers at 4°C; see 
Appendix 4). In all washes the pellet was resuspended by inversion and gentle shaking. 
After the final wash the pellet was resuspended in Laemmli buffer (Laemmli, 1970; see 
Appendix 5), boiled for 3 minutes and centrifuged at 14,000 x g for 5 minutes at room 
temperature before the proteins were separated by SDS-PAGE (see section 2.2.5).
2 .2 .5  SD S-PAG E
The discontinuous buffer method of Laemmli (1970) was used. Gels, 10% 
(w/v), were poured into dry, clean, glass plates separated with 1.5 mm spacers (see 
Appendix 5). The main gel was overlaid with a small quantity of water saturated isobutanol 
and the gel allowed to polymerise. Polymerisation usually took 20 - 30 minutes at room 
temperature. Polymerised gels were used immediately and, where possible, long term 
storage was avoided. Prior to the addition of the stacking gel and the insertion of the well 
former, the layer of water / isobutanol was removed. Once the stacking gel had 
polymerised the well former was removed and the gel apparatus reservoirs filled with 
Running buffer (see Appendix 5). The samples (as prepared in section 2.2.4) were loaded 
(with care to avoid any protein A agarose pellet) and the gels run at 50 mA per gel (with 
cooling, run time 3 - 4  hours), or 7 mA per gel overnight, until the dye front had just run 
off the end of the gel. Gels were either used for Western blotting (see section 2.2.15) or 
dried, without fixing, at 65°C using a Biorad gel dryer. Dried gels were stapled to pre­
flashed X-ray film (Fuji RX, see Appendix 6) and put down for autoradiography at -80°C 
(immunoprecipitates of phosphorylated a-Gi-2 only required overnight exposure using one
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intensifying screen). The autoradiography was either quantified using a Shimadzu CS-9000 
densitometer or by removal of the identified bands from the gel and radioactivity determined 
by Cerenkov counting.
2 .2 .6  Elution o f 32P-labelled a - G ^  from  polyacrylamide gels
The method of Boyle, van der Geer & Hunter, 1991 was used. Poly-acrylamide 
gel chips, from unfixed gels, containing the samples were rehydrated in 500 pi of freshly 
prepared 50 mM ammonium bicarbonate (see Appendix 7) for 5 minutes at room 
temperature before being Cerenkov counted. The gel chips were then homogenised using 
disposable plastic pestles and homogenisation was judged to be complete when the sample 
was small enough to pass through the tip of a 50 - 200 p.1 pipette. The homogenate was 
then transferred to a clean screw top microfuge tube and the pestle, and its accompanying 
tube, given two washes with 250 p.1 of buffer. The final volume of homogenate was 1 ml 
and to this 50 p.1 of 2(3 - mercaptoethanol and 10 p.1 of 10% (w/v) SDS solution was added 
before the sample was mixed and boiled for 5 minutes. The samples were then incubated 
for 90 minutes at 37°C with constant shaking to elute the protein.
After incubation the samples were centrifuged at low speed in a microcentrifuge at 
room temperature to pellet the gel pieces. The supernatant was transferred to clean tubes 
and a second volume of ammonium bicarbonate, plus 2p - mercaptoethanol and SDS, was 
added to the gel pieces so that a final total volume of 1.2 ml of supernatant could be 
collected. The samples were mixed and boiled for 5 minutes before a second elution at 
37°C for 60 minutes. A second volume of eluate was collected and pooled with the first and 
the total eluate (~1.2 ml) was clarified by centrifugation for 10 minutes at 14,000 x g. The 
samples were then Cerenkov counted. From a typical elution procedure 80 - 90% of the 
counts in the original gel chip could be recovered in the eluate, if the figure was found to be 
less than 80% the elution procedure was repeated. Gloves were worn throughout the 
elution procedure and subsequent protein handling steps to avoid contamination with ’skin 
proteases'. Eluted proteins were either immediately precipitated and oxidized (see section 
2.2.7) or stored overnight at -80°C. Only one gel chip was processed per tube and if 
samples required pooling for analysis this was done after the desalting in section 2.2 .8.
2 .2 .7  Precipitation and oxidation o f eluted proteins
To ice cold protein elutes 20 |Xg/ml carrier protein (BSA) and TCA (final 
concentration 20% (w/v)) were added. The samples were then left on ice for 1 hour to 
allow the protein to precipitate and the protein collected by centrifugation at 14,000 x g for 
10 minutes at 4°C. The supernatant was aspirated and the samples briefly centrifuged and 
any remaining supernatant removed. The pellet was given one wash with ice cold acetone, 
the protein pelleted and the supernatant removed. All collected supernatants were kept.
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The pellet was allowed to air dry at room temperature before being Cerenkov 
counted. The recovery from precipitation and acetone wash should be at least 70% of the 
original counts. If the counts were less than 70% the TCA precipitate and acetone wash 
supernatants were examined for radioactivity. If the radioactivity was found still to be in the 
supernatants the solutions were reprocessed to recover the maximum counts.
The air dried protein pellet was placed on ice and then oxidised for 60 minutes by 
dissolving it in 50 p.1 of ice-cold performic acid (performic acid was prepared by mixing 
nine parts of 98% formic acid with one part 30% hydrogen peroxide and incubating for 1 
hour at room temperature). Oxidation was stopped by the addition of 400 p.1 of ice cold 
water and the samples lyophilised. At no stage of the oxidation was the sample allowed to 
warm as this would result in the occurrence of side reactions and so prevent good separation 
of the peptides by thin layer chromatography. Lyophilised samples were stored at -80°C 
before being digested as outlined in section 2 .2 .8 .
2 .2 .8  Proteolytic cleavage and desalting
The lyophilised samples were resuspended in 50 pi of 50 mM ammonium 
bicarbonate (pH 8 [ammonium bicarbonate solution prepared the day before should have 
drifted to this pH]; see Appendix 7), vortexed and briefly centrifuged to return the liquid to 
the bottom of the tube. To each tube 10 pi of the appropriate enzyme was added and the 
tubes typically incubated at 37*C for 5 hours. The tubes were then vortexed for 40 seconds 
and centrifuged to collect the liquid in the bottom of the tube. A further 10 pi of enzyme 
was added and the samples incubated for another 5 hours. The reaction was stopped by the 
addition of 400 pi of water and the sample lyophilised. The samples were then repeatedly 
resuspended in 300 pi of water and relyophilised until the salt content had been reduced to a 
minimum which would normally take three to four rounds of freeze drying. After the 
penultimate lyophilisation the samples were dissolved in 300 pi of water, centrifuged at
14,000 x g for 2 minutes at room temperature and the supernatant transferred to a new 
tube. The sample was then lyophilised and stored at -80°C until required for analysis. The 
enzymes that were used for digestion were TPCK-trypsin, a-chymotrypsin and 
Staphylococcus aureus V8 . Stock solutions of 1 mg/ml were made up at the start of 
digestion and stored at -20°C until required. Trypsin was made up in 0.1 mM HC1 and a  - 
chymotrypsin and V8 in water (see Carrey, 1989). Occasionally longer periods of digestion 
were used and any variations are indicated in the results.
2 .2 .9  Separation o f  32P-labelled enzymatic cleavage products
Digested samples were Cerenkov counted, resuspended in 10 pi of pH1.9 
electrophoresis buffer (see Appendix 7) and vortexed for 1 minute. A 20 x 20 cm cellulose 
t.l.c. plate was overlaid on a template constructed to the measurements shown in figure 2.1 
and sample and marker dye application positions marked with a soft lead pencil. The
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Figure 2.1: Diagrammatic representation of t.l.c. plate template used for two dimensional
chromatography analysis of phospho - peptides
Diagrammatic representation of t.l.c. plate template used for two dimensional 
chromatography analysis of phospho - peptides. (+) and (-) indicate the orientation of the 
electric field in the first dimension.
Di
rec
tio
n 
of 
sec
on
d 
di
m
en
sio
n
2cm^ r"”5cm """ I *
\ Dye ongin mark 
(first dimension)
(+) (-) 20 cm
✓Marker dye (second dimension)
/  .✓Sample origin mark
*r + *
3 cm I
I 5 cm i
TH  ►»___________________________________  T
20 cm
Direction of first dimension
Chapter 2
samples were then applied at the sample origin in 0.5 -1.0 ill aliquots, with cold air drying 
between applications (see figure 2.1). After the last application the tube was re-counted and 
if more than 10% of the counts remained, the sample was re-dissolved and the procedure 
repeated. To the dye origin mark (first dimension) 5 |xl of marker dyes (see Appendix 7) 
were applied in 0.5 pi aliquots. The marker dye contained e - dinitrophenyl (DNP) lysine 
(yellow, positively charged at pH1.9); DNP-DL-glutamic acid (yellow, neutral charge at 
pH1.9); xylene cyanol FF (blue, negatively charged at pH1.9).
Before electrophoresis the plates were made damp with pH 1.9 electrophoresis 
buffer. This was achieved by using a plate blotter which consisted of a 25 cm x 25 cm 
sheet of 3MM filter paper with two 8 -1 0  mm diameter holes cut in it so that when it was 
laid on a t.l.c. plate the holes were directly over the sample and dye origins. The blotter 
was laid over the t.l.c. plate and, using a shaving brush dampened with pH 1.9 buffer, the 
holes were circled to encourage a flow of buffer towards the centre of the hole thus 
concentrating the sample. The rest of the filter paper was then brushed to dampen the plate. 
Correctly dampened plates had a dull grey appearance with no obvious shiny patches of 
excess buffer. If areas of excess buffer existed these were carefully removed using dry 
3MM filter paper. The t.l.c. plates were run for 2 hours at 400 v in pH 1.9 electrophoresis 
buffer (see Appendix 7) in a flat bed electrophoresis tank with the electric field orientated as 
shown in figure 2.1. After running the plates were air dried and 5 p.1 of marker dye (see 
Appendix 7) applied to the marker dye (second dimension) origin. The second dimension, 
ascending chromatography was then carried out in a 3MM filter paper lined chromatography 
tank containing phospho-chromatography buffer (see Appendix 7) with the buffer deep 
enough to cover only the bottom 0.5 - 1.0 cm of the plate. The plates were run until the 
solvent front was about 3 -4  cm from the top of the plate which would normally take 3 -4  
hours. The labelled peptides were identified by autoradiography on pre-flashed film at 
-80°C (see Appendix 6) with exposure times of 6  -10 days.
2 .2 .1 0  Recovery o f peptides and secondary digests
Where secondary digests of peptides were required the samples would be scraped 
from t.l.c. plates and pooled. The resulting powder was Cerenkov counted, resuspended in 
300 p.1 of distilled water and vortexed for 1 minute. The samples were then centrifuged at
14,000 x g for two minutes at room temperature. The supernatant was collected and the 
pellet resuspended in 200 p.1 of distilled water, vortexed and centrifuged. The supernatant 
was collected and pooled with the first. Total volume recovered was approximately 400 pi 
which normally contained more than 80% of the counts in the original powder. If the 
counts recovered were lower than 80% the procedure was repeated.
The solution was freeze dried, resuspended in ammonium bicarbonate buffer (see 
Appendix 7) and the digestion and desalting carried out as described in section 2.2.8 and the 
digestion products separated as outlined in 2.2.9.
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2 .2 .1 1  Phosphoamino acid analysis
The method used for phosphoamino acid analysis was as outlined in Boyle et a l , 
1991 with the following changes. Samples were collected from t.l.c. plates as described in 
section 2.2.10 and freeze dried. The samples were dissolved in 500 |il of 6 N HC1, sealed 
under vacuum and heated to 105°C for 90 minutes. The resulting solution was allowed to 
cool, collected and lyophilised using a freeze drier fitted with a NaOH trap. The samples 
were dissolved in pH 1.9 electrophoresis buffer and applied to a 20 x 20 cm t.l.c. plate 
which had sample application origins marked using the dimensions shown in figure 2 .2 . 
The plates were dampened with pH 1.9 buffer (see section 2.2.9; Appendix 7) and run at 
400 v for 30 minutes at pH1.9 (see Appendix 7) in the first dimension with the electric field 
orientated as shown in figure 2.2 and air dried. The plate was rotated through 90° and 
carefully made damp with pH3.5 electrophoresis buffer (see Appendix 7) with care taken to 
avoid the samples which were now 'streaked' out from the application points. The plate 
was run at 400 v for 30 minutes at pH3.5 (see Appendix 7) in the second dimension with 
the electric field orientated as shown in figure 2.2. Markers of phosphoserine, 
phosphothreonine and phosphotyrosine were included with the samples and these were 
visualised by staining with 0.25% (w/v) ninhydrine in acetone. Plates were put down on 
pre-flashed film (see Appendix 6) at -80#C for 10 -14 days.
2 .2 .1 2  Prediction o f enzyme cleavage products and mass charge ratios
The prediction of peptide fragments produced by enzymatic cleavage and
estimations of their mass-charge ratios was based on the methods outlined in Offord, 1966 
and Boyle et al., 1991 (see Chapter 3, section 3.1.4). The peptides produced by the 
enzymes can be predicted and the mass-charge ratio calculated from:
mr = keM ^
Where mr = mass-charge ratio, k = constant, e = charge on the peptide, and M = 
molecular weight of the peptide (plus any added phosphate groups). The charge of the 
peptide can be calculated from the sum of the charges at pH1.9 of its constituents where the 
N-terminal and the amino acids arginine, histidine and lysine had a charge of +1, cysteine a 
charge of approximately -1 and phospho-serine a charge of -1. Mass charge ratios were 
calculated using a macro written for Excel (see Appendix 8).
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Figure 2.2: Template for the layout of t.l.c. plates used for phospho-amino acid analysis
Template for the layout of t.l.c. plates used for phospho-amino acid analysis. The template 
shows the dimensions for marking out the plate for the application of four samples and the 
orientation of the electric fields. Spots marked Pi, P-Ser, P-Thr and P-Tyr show the final 
position of inorganic phosphate, phospho-serine, phospho-threonine and phospho-tyrosine, 
respectively, from a sample applied to position 3.
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2 .2 .1 3  Preparation o f plasma membranes from  rat hepatocytes
A plasma membrane containing fraction was prepared from hepatocytes (see 
section 2 .2 .2) using the following method.
The hepatocytes were collected by centrifugation (100 x g, 2 minutes room 
temperature) and resuspended in 3 volumes (approx. 20 ml) of ice cold Buffer A (see 
Appendix 9). The cells were homogenised by thirty strokes of a hand-held homogeniser at 
4°C and the resulting homogenate was centrifuged for 10 minutes at 4°C and 1000 x g. The 
supernatant was collected and centrifuged at 4°C for 65 minutes at 100,000 x g. The 
supernatant was discarded and the pellet resuspended in Buffer A (approximately 5 ml) and 
snap freezed in 100 pi aliquots. The samples were assayed for protein content (see section 
2.2.14) and stored at -80°C.
2 .2 .1 4  Protein Determination
A standard protein assay procedure based on Bradford was used (Bradford, 
1976). In brief, a standard curve (0 - 20 pg BSA per tube) was prepared and standards and 
samples diluted to 800 pi with distilled water. To each tube 200 pi of Biorad protein reagent 
(Biorad) was added and the tubes vortexed. Samples were read at 595 nm.
2 .2 .1 5  Western blotting
Gels were prepared and run as described in section 2.2.5 and the Western 
blotting method of Towbin (Towbin, Staehelin & Gordon, 1979) used. In brief, the 
stacking gel was discarded and the main gel equilibrated in Blot Electrode buffer (BEB, see 
Appendix 10) for 5 minutes. Prior to use, nitro-cellulose sheets were washed for 5 minutes 
in distilled water. The gel was sandwiched, with the nitro-cellulose, between two 3MM 
filter pads and two 'Scotch-Brite' pads. The sandwich was assembled whilst submerged in 
BEB and firmly clamped before being transferred to the blotting tank. Blotting was carried 
out overnight by the application of a constant current of 10 mA (electrodes 10 cm apart) 
with cooling.
2 .2 .1 5 .1  Immuno-staining o f Western Blots
The method of Birkett et al., (1985) was used with the following modifications. 
Blotting sandwiches were dismantled and the nitro-cellulose sheets removed. The blots 
were briefly stained with Ponceau S (see Appendix 10), and the required lanes cut out. The 
stain was removed with several washes in BEB (see Appendix 10). After destaining the 
blots were given two 5 minute washes with Tris-buffered saline Tween (TBS-T, see 
Appendix 10) and then incubated, with constant shaking, for 90 - 120 minutes with the 
appropriate primary antibody diluted in TBS-T. After incubation the primary antibody 
solution was removed and the blots were given two 5 minute washes with TBS-T, followed 
by one five minute wash with High-salt Tris-buffered saline (HST, see Appendix 10). This
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was followed by a further two 5 minute washes with TBS-T. The blots were then 
incubated for 90 minutes with the appropriate secondary antibody labelled with horseradish- 
peroxidase (HRP) diluted in HST. After incubation the blots were given three 5 minute 
washes with TBS-T, followed by a 10 minute wash with HST, and three more 5 minute 
washes with TBS-T. After the final wash the blots were incubated with the Developing 
solution (See Appendix 10) to visualise the labelled bands. Development was stopped by 
repeated washes with distilled water. The blots were dried before being scanned by 
reflectance using a Shimadzu CS-9000 densitometer. Protein bands were visualised by 
staining with Ponceau S (see Appendix 10).
2 .2 .1 6  Enzyme linked immuno - assay (ELISA)
The method used for ELIS As is essentially as outlined in section 2.2.15 for 
Western blots with the following changes. Samples were diluted in sodium carbonate 
buffer (see Appendix 11) to 4 pg/ml. 100 pi aliquots were placed in each well of the plate 
and left overnight at room temperature in a humidified container. The plates were then 
given two washes with TBS-T (see Appendix 10) and left incubating in TBS-T for 1 hour.
Primary antibodies were diluted in TBS-T and aliquoted at 100 pi per well. 
Antibodies were left on the plate for 90 minutes before the plate was subjected to a wash 
and secondary antibody regime as outlined in section 2.2.15.
After incubation with the secondary antibody, and the subsequent washes, the 
plates were developed for 20  minutes by incubating with substrate solution (100 pi per well; 
see Appendix 11) and the reaction then stopped by the addition of 50 pi of 4 N H2SO4. 
Plates were read at 492 nm on Titeiek Multiskan.
2 .2 .1 7  Statistical analysis
Statistical significance was determined using the Student t-test available on Excel 
(Microsoft Corporation), or Statworks on the Macintosh, or by a Mann-Witney test (Mann 
& Witney, 1947) using a macro written for Excel (see Appendix 8). A value of p < 0.05 
was taken as significantly different. Where appropriate any curves were fitted using the 
regression function of Cricket Graph (Cricket Software).
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Multiple phosphorylation sites of a-G i. 2
3 .1  Introduction
Many cell-surface receptors control the activity of their effector systems through 
specific members of a family of guanine nucleotide-binding regulatory proteins (G-proteins; 
see section 1.2; see Gilman, 1989; Gilman, 1987; Milligan et al., 1990; Neer & Clapham,
1988). The receptor-dependent production of cAMP is effected by adenylyl cyclases (see 
section 1.2.3.1) whose activities are regulated by two distinct heterotrimeric G-proteins 
termed Gs (stimulatory) and Gi (inhibitory; see section 1.2.2). These G-proteins are 
characterised by unique a-subunits which are the products of different genes (see section
1.2.2.2). The Gi family comprises of eight related proteins but only the pertussis toxin- 
sensitive G-proteins a-Gi-i, a-Gi-2 anti a-Gi-3 are involved in the inhibition of adenylyl 
cyclase (see section 1.2.2.2; table 1.1). Whilst the specificity of these Gi proteins is not yet 
fully characterised, a number of groups have provided evidence that a-Gi-2 can act as an 
inhibitory G-protein controlling adenylyl cyclase activity (Bushfield etal., 1990b; Senogles 
et al., 1990; Simmonds et al., 1989; Pyne et al., 1989b).
3 .1 .1  Phosphorylation o f  G-proteins
In various cell types the activation of PKC (see section 1.2.4.2) has been shown 
to result in the alterations of the regulation of adenylyl cyclase activity (see section 1.2.3.3; 
see Houslay, 1991a). In some instances this has enhanced basal and agonist-stimulated 
action but in others cases a loss of receptor-mediated stimulation has been reported and the 
process has believed to involve the phosphorylation of the receptor (see Geny et al., 1989; 
Hill & Kendall, 1989; Jakobs et al., 1985; Sagi-Eisenberg, 1989). Further evidence from a 
number of studies has indicated that the inhibitory regulation of adenylate cyclase through 
a-Gi can be prevented by activation of PKC (see section 1.2.4.2; Bushfield, Lavan & 
Houslay, 1991; Bushfield et al., 1990b; Daniel-Issakani, Spiegel & Strulovici, 1989; 
Katada et al., 1985; Pyne et al., 1989a; Pyne et al., 1989b). Indeed, it has been shown that 
the activation of this enzyme in hepatocytes, either by phorbol esters or by hormones which 
stimulate phosphoinositide metabolism, can lead to the phosphorylation of a-Gi-2 and to the 
loss of GTP-elicited Gi functioning (Bushfield et al., 1991; Bushfield et al., 1990b; Pyne et 
al., 1989b). A loss of GTPase activity of a -G i-2 as a result of PKC mediated 
phosphorylation has also been demonstrated in vitro (Sauvage, Rumigny & Maitre, 1991) 
and PKC mediated phosphorylation of a-Gj-i or a-Gi-2 has been demonstrated in platelets 
where it was shown to inhibit Ca2+ mobilisation (Yatomi et al., 1992) and to abolish Gi 
inhibition of adenylyl cyclase (Katada et al., 1985). Interestingly Carlson (Carlson, Brass
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& Manning, 1989) and Lounsbury (Lounsbury et al., 1991) showed that neither a-Gi-i or 
a-Gi_2 were phosphorylated by PKC in platelets.
Treatment of intact cells with phorbol esters and in vitro studies have 
demonstrated that other G-proteins can also be phosphorylated by PKC or other kinases. In 
human platelets treatment with thrombin or phorbol esters leads to the phosphorylation of a- 
Gz or a similar protein (Carlson et al., 1989; Lounsbury et al., 1991; Lounsbury et al., 
1993). a-Gs has been shown to be phosphorylated by PKC (Pyne, Freissmuth & Palmer, 
1992; Sauvage et al., 1991) and PKA (Sauvage et al., 1991) in vitro whilst PKA has be 
shown not to phosphorylate a-Gi in vitro (Lincoln, 1991) although cAMP dependent 
phosphorylation of a-Gi_2 in Dictyostelium has been reported but it was not demonstrated to 
be PKA dependent (Gundersen & Devreotes, 1990).
Incubation of intact hepatocytes with a range of ligands capable of activating 
PKC, including PMA (phorbol ester), vasopressin, angiotensin II, and those capable of 
activating cAMP-dependent protein kinase (PKA, see section 1.2.4.1), such as glucagon 
and 8-bromo-cyclic-AMP, resulted in the selective serine-specific phosphorylation of 
a-Gi-2, but did not affect either a-Gi.3 or a-Gs (Bushfield et al., 1990b). Indeed, exposure 
of hepatocytes to the phosphoprotein phosphatase (1 and 2A) inhibitor okadaic acid (see 
section 1.2.4.3), also caused the phosphorylation of Gj_2 (Bushfield et al., 1991). It has 
been suggested (Bushfield et al., 1991) that the activity of this guanine nucleotide 
regulatory protein may be controlled, in hepatocytes, by a phosphorylation / 
dephosphorylation cycle. These events may be cell-type dependent as the challenge of 
platelets and human kidney 293 cells with phorbol esters also results in the phosphorylation 
of a G-protein, a -G z , but did not affect a-G i (Lounsbury et al., 1993), with the 
phosphorylation of a-Gz occurring on serine 27.
It has been suggested that a-Gi-2 may be phosphorylated at one site by ligands 
which cause activation of PKC and at a separate site which is dependent upon the activation 
of PKA but may not be phosphorylated directly by the kinase (Bushfield et al., 1990b).
3 .1 .2  Kinase motifs
To date over 100 mammalian protein kinases have been described (see section 
1.2.4; see Hunter, 1991). These kinases not only have different modes of activation (see 
section 1.2.4) but also have different substrates which possess different kinase recognition 
motifs (e.g. see table 3.1; Azzi et al., 1992; Hug & Sarre, 1993; Kennelly & Krebs, 1991; 
Pearson & Kemp, 1991).
The work described in this chapter is associated primarily with the activation of 
two protein kinases, PKA (see section 1.2.4.1) and PKC (see section 1.2.4.2). Both these 
kinases are classed as serine / threonine kinases (see Hunter, 1991) and the possible 
recognition motifs, and their occurrence in a-Gi-2, are shown in table 3.1.
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Table 3.1
The occurrence of protein kinase recognition motifs in a-Gi-2.
PICA = protein kinase A; PKC = protein kinase C; CDPKII = Calmodulin-dependent 
protein kinase II; CKI = Casein kinase I; CKII = Casein kinase II; PKG = cGMP dependent 
protein kinase; GSKm = Glycogen synthase kinase HI; GHK = Growth associated histone 
HI kinase (MPF, cdc2+/CDC28 protein kinase); S = serine, K = lysine, R = arginine, V = 
valine, S(P) = phospho-serine, D = aspartic acid, E = glutamic acid, P = proline, x = any 
amino acid; Ratios refers to the number of phosphorylation sites that fit the motif out of all 
sites identified to date (Pearson & Kemp, 1991); references: 1 = Pearson & Kemp, 1991; 2 
= Kennelly & Krebs, 1991; 3 = Hug & Sane, 1993; 4 = Azzi et al., 1992
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Kinase Site(s) Ratio Serine Ref
PKA RxS 21/46 None 1
PKA RRxS 12/46 None 1
PKA RxxS 11/46 None 1
PKA KRxxS 2/46 None 1
PKA a) RR/KxxS None 2
PKA b) RxxS None 2
PKA c) RxS None 2
PKA RS 16 144 207 2
(a>b>c)
PKC RxxSxR None 3
PKC SxK/R 44 207 247 4
PKC K/RxxS None 4
PKC K/RxxSxK/R None 4
PKC K/RxS None 4
PKC K/RxSxK/R None 4
PKC SxK/R 20/37 44 207 247 1
PKC K/RxxS 13/37 None 1
PKC K/RxxS xxK/R 7/37 None 1
PKC K/RxS 10/37 None 1
PKC K/RxSxK/R 6/37 None 1
PKC a) R/Kl-3x2-oSx2-oR/Ki_3 16 144 207 2
PKC b) Sx2^)R/Ki.3 16 44 144 207 306 2
PKC c) R/Ki-3x2-0S 16 47 144 207 2
(a>b>c)
CDPKII xRxxS 13/20 None 1
CDPKH xRxxSV 6/20 None 1
CDPKII RxxS None 2
CKI S(P)xxS 5/9 47 1
CKI a) S(P)xi.3S 47 306 2
CKI b) (D/E2-4,X2-o)xS 47 62 125 264 302 2
a»b
CKII SxxE 23/30 62 306 1
CKII SxxD 3/20 6 229 1
CKII S (D/E/S (P) i-3»x2-0) 6 62 229 306 2
PKG R/KxS 9/10 None 1
PKG R/KxxS 8/10 None 1
PKG R/KR/KxS 7/10 None 1
PKG R/KxxxS 5/10 166 247 1
PKG SxR/K 2/10 44 207 247 1
PKG R/K2.3XS 166 247 2
GSKIII SxxxS(P) 6/12 302 1
GSKIII Sx3S(P) 302 2
GHK SPxK/R 6/15 None 1
GHK K/RSP 5/15 None 1
GHK SPK/R 4/15 None 1
GHK SPxK/R None 2
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3 .1 .3  Protein structure
Proteins consist of twenty different amino acids which are used to form a poly­
peptide chain referred to as the primary structure of the protein. This poly-peptide chain can 
then undergo spontaneous folding to produce a secondary structure and finally a tertiary 
structure. The folded protein may also form a subunit in some larger protein giving a final 
protein that is described as possessing quaternary structure (see Argos, 1989; Chou & 
Fasman, 1978; Chothia & Finkelstein, 1990).
The folding of the poly-peptide to form the secondary structure only takes into 
account the poly-peptide backbone of the protein and not the side-chain configurations. The 
secondary structures typically consists of a-helixes, p-sheets and p-tums (see section
3.1.3.2). The tertiary folding of the protein takes into consideration the arrangement of the 
atoms, the occurrence of disulphide bridges and the interaction of the side chains (see 
Argos, 1989; Chou & Fasman, 1978).
3 .1 .3 .1  Primary sequence o f a-Gi-2
The primary sequence of rat a-Gi-2 was determined by Itoh et al. in 1986 and 
Jones and Reed in 1987 (Itoh et al., 1986; Jones & Reed, 1987). The primary sequence is 
shown in figure 3.1 and in Appendix 12. The primary sequence consists of 355 amino 
acids and has a predicted molecular weight of 40,503.
3 .1 .3 .2  Secondary structure o f  a-Gi-2
A protein can possess four classes of secondary structure and these structures can 
be predicted, albeit with a certain degree of uncertainty, using a range of methods (see 
Argos, 1989). The four classes of structure are typical protein structures (a-helices, p- 
sheets, turns; see Argos, 1989; Chou & Fasman, 1978; Gamier, Osguthorpe & Robson, 
1978), trans-membrane helices, signal and target structures and antigenic sites (see Argos,
1989). The methods used to carry out such predictions can be divided into three groups, 
probabilistic (or statistical), physico-chemical, and information theory.
Probabilistic methods rely on the analysis of proteins whose secondary structure 
is known and the analysis of the amino acid sequence in the secondary structures. From 
such an analysis the amino acids are assigned a value and these values are then used to 
predict whether that type of secondary structure is likely to occur in another protein. The 
analysis of the secondary structure of a new protein is carried out by assigning the amino 
acid values for the structure of interest (e.g. a-helix) and then averaging the values of the 
amino acids over a four to eight amino acid stretch. If the mean value for the amino acids is 
greater than some pre-determined threshold value then the region of protein is reported as
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Figure 3.1: The primary sequence of rat a-Gi-2
The primary sequence of rat a-Gi-2 (Itoh et a l 1986).
1,0 20 3,0 40 5,0
1 ■ 1 ■ i I ■ ■ ■ 1 I ■ ■ ■ « I ■ ■ ■ * I 1 * » ■ I ■ ■ 1 ■ I » ■ 1 » I ■ » ■ ■ I 1 ■ ■ ■ I » » 1 1 I___________
M G C T V S A E D K A A A E R S K M I D K N L R E D G E K A A R E V K L L L L G A G E S G K S T I Y  5 0
K Q M K 1 1 H E D G Y S E E E C R Q Y R R V V Y S N T I Q S I M P I I V K f l M G N L Q I D F f l D P Q R  1 0 0
A D D A R Q L F A L S C A A E E Q G M L P E D L S G Y I R R L V A D H G V Q A C F G R S R E Y Q L N  1 5 0
D S A A Y Y L N D L E R I A Q S D Y I P T Q Q D V L R T R Y K T T G I V E T H F T F K D L H F K N F  2 0 0
D V G G Q R S E R K K W I H C F E G V T A I I F C V A L S A Y D L V L A E D E E r i N R I I H E S I I K L  2 5 0
F D S I C N N K V F T D T S I I L F L N K K D L F E E K I T Q S P L T I C F P E Y T G A N K Y D E A  3 0 0
A S Y I Q S K F E D L N K R K D T K E I Y T H F T C A T D T K N V Q F V F D A V T D Y I I K N N L K  3 5 0
D C G L F  3 5 5
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having a high probability for the occurrence of that type of secondary structure (see Argos, 
1989; Chou & Fasman, 1978; Gamier et al., 1978). Examples of this type of method are 
those of Chou / Fasman (see Chou & Fasman, 1978) and Gamier / Robson (see Gamier et 
al., 1978) and these methods are used for the prediction of secondary structures such as a- 
helices, p-sheets and p-turns (see Argos, 1989; Chou & Fasman, 1978; Gamier et al., 
1978).
Physico-chemical methods rely on examining the primary sequence of a protein 
for the occurrence of defined patterns in the distribution of polar and non-polar amino acids. 
An example of this is if a spatial construction of an a-helix is formed then one side will 
contain hydrophilic amino acids and the other hydrophobic, therefore examining a primary 
sequence for regions where such arrangements are possible will give a prediction for the 
occurrence of a-helices. If the primary sequence is examined and regions are found where 
alternating polar and non-polar amino acids occur then this may indicate the presence of p- 
strands (see Argos, 1989).
The information theory approach is similar to the probabilistic approach in that it 
examines known secondary structures and then analyses their amino acid composition. The 
information derived from this approach is then used to predict secondary structures in other 
proteins. The approach can be viewed as examining a known secondary structure and then 
looking for sequence homology in the new protein that corresponds to that sequence (see 
Argos, 1989).
The accuracy of the above prediction methods for a-helices, p-sheets and p-tums 
lies between 50 and 60% (see Argos, 1989) with accuracy approaching 90% (see Chou & 
Fasman, 1978) with some of the more refined methods available or when a combination of 
methods is used (see Argos, 1989; Chou & Fasman, 1978). These levels of accuracy 
compare favourably with the random prediction of the three structures which would only 
give 33%. A combination of methods maybe used when it is known that one tends to over 
predict the occurrence of certain structures whilst another under-predicts (see Chou & 
Fasman, 1978).
The prediction of the occurrence of secondary structures, and a final tertiary 
structure (see section 3.1.3.3) of a-Gi-2 has been carried out by Bourne's group (Berlot & 
Bourne, 1992; Conklin & Bourne, 1993; Masters, Stroud & Bourne, 1986). An 
information theory approach has been taken where the known sequence and established 
structure of EF-Tu and p21ras, determined by x-ray crystallography, has been exploited in 
the prediction of the protein structure of the a-subunit of the heterotrimeric G-proteins. As 
EF-Tu and p21ras have a shorter primary sequence than a-Gi-2 then secondary structure 
prediction methods have been used for the insert and extension regions. By using a 
combination of the methods of Chou / Fasman (see Chou & Fasman, 1978) and Gamier / 
Robson (see Gamier et al., 1978) the secondary structures of a-Gi-2 was predicted and only 
regions of the protein that possessed the same structure in both prediction methods were
57
Chapter 3
considered as possessing that structure. The results are shown in figures 3.2 and 3.18 and 
discussed in sections 3.3.5. and 3.4.
3 .1 .3 .3  Tertiary structure o f a-Gi.2
The prediction of the tertiary structure of a protein is complicated and usually 
relies on the comparison of the sequence of known tertiary structures of proteins with those 
of the new protein; this process is described as knowledge based modelling (see Sali et al., 
1990; Baron, Norman & Campbell, 1991). By the use of this approach it has been possible 
to model the tertiary structure of a-Gi_2 (Conklin & Bourne, 1993; Masters et a l , 1986).
The structure is based on the known configuration of the GTP binding domain of 
the proteins EF-Tu (bacterial elongation factor) and p21ras (see section 1.2.2; see figure 3.2; 
Conklin & Bourne, 1993; Masters et al., 1986). Both EF-Tu and p21ras are considerably 
shorter polypeptides than any of the a-subunits but it is possible to align the proteins and 
therefore infer the structure of the G-protein a-subunit (see Berlot & Bourne, 1992; Conklin 
& Bourne, 1993; Masters et al., 1986). Using this approach EF-Tu and p21ras have been 
aligned with the G-protein a-subunits and the secondary and tertiary structures predicted. 
As EF-Tu and p21ras are shorter poly-peptides than the a-subunits this leaves six regions 
that do not occur in EF-Tu or p21ras. The regions of unknown structure occur at the N and 
C terminals and also comprise of four insertions within the protein (see figures 3.18 and 
3.2; see Berlot & Bourne, 1992; Conklin & Bourne, 1993; Masters et al., 1986). Using 
these strategies (see Berlot & Bourne, 1992; Conklin & Bourne, 1993; Masters et al., 1986) 
an approximation for the structure of the heterotrimeric G-protein a-subunit has been 
proposed. The protein is believed to be arranged with the GTP-binding domain facing the 
cytoplasm of the cell with the a-subunit anchored to the membrane via the N-terminal. 
From the N-terminal extension, the peptide chain leads into the first p-sheet which forms 
part of the GTP-binding domain (see figures 3.2 and 3.18). The protein is then arranged 
with the first (il) and third (i3) inserts facing the cytoplasm and inserts two (i2) and four 
(i4), and the C-terminal extension facing the membrane (see figures 3.18 and 3.2; see Berlot 
& Bourne, 1992; Conklin & Bourne, 1993; Masters et al., 1986).
The regions of the protein involved in GTP binding been have predicted from 
both the studies of the structure of EF-Tu and p21ras. The use of antibodies, mutations, 
chemical cross linking and peptide competition studies has led to the suggestion for the 
location of some of the other functional domains of the protein (see figures 3.18 and 3.2; 
Conklin & Bourne, 1993; Masters et al., 1986). Thus it has been found that the receptor 
interacts with a portion of the N-terminal extension, the C-terminal extension and sections 
of the tenth turn and sixth p-sheet; the py-subunit binds to part of the N-terminal extension, 
the second a-helix and a region at the start of the first insertion; and the effector interacts 
with the second and fourth insertions and part of the second a-helix (see figures 3.2 and 
3.18; see Conklin & Bourne, 1993).
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Figure 3.2: Tertiary structure of a-Gi_2
. Tertiary structure of a-Gi-2 (Berlot & Bourne, 1992; Conklin & Bourne, 1993; Masters et 
al., 1986). Barrels represent regions of a-helix, arrows p-sheets of EF-Tu and p21ras, and 
dashed lines extensions and insertions.
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3 .1 .4  Enzymatic cleavage, prediction o f  peptides and their movement in
two-dimensional chromatography
The prediction of peptide fragments produced by enzymatic cleavage and 
estimations of their mass-charge ratios was based on the methods outlined in Boyle et al. 
(1991). Although it is possible to predict the peptides produced by the enzymes, the tertiary 
and secondary structures of the protein may mask the cleavage sites and the amino acid 
sequence at the cleavage site may effect the efficiency of the enzyme. Peptides were 
predicted by following the information as outlines in sections 3.1.4.1, 3.1.4.2 and 3.I.4.3.
If the peptides produced by the enzymes can be predicted then the movement of 
the peptide in two-dimensional chromatography can be estimated based on the mass-charge 
ratio of the peptide in the first electrophoretic dimension and its Rf value in the second 
ascending chromatography dimension. The mass-charge ratio can be calculated from the 
equation:
mr = keM ^
Where mr = mass-charge ratio, k = constant, e = charge on the peptide, and M = 
molecular weight of the peptide plus the additional phosphate groups (Offord, 1966; see 
Boyle et al> 1991). The charge of the peptide can be calculated from the sum of the charges 
at pH1.9 of its constituents where the N-terminal and the amino acids arginine, histidine and 
lysine have a charge of +1, cysteine a charge of approximately -1 and phospho-serine a 
charge of -1 (see Boyle et al., 1991). Mass-charge ratios were calculated using a macro 
written for Excel on the Macintosh (see Appendix 12).
The Rf value of the peptide can be calculated by using the known Rf values of the 
individual amino acids (see Boyle et al., 1991) and by calculating the sum of the Rf values 
of the individual amino acids in the peptide and dividing by the number of amino acids 
present (see Boyle et al., 1991). This method of prediction is not very accurate as the Rf 
values of the individual amino acids do not take into consideration the loss of charge on the 
NH2 and COOH groups when the peptide is formed. As a consequence of this the resulting 
predicted Rf values for the peptides tends to be lower and closer together than the actual 
values (see Boyle et al., 1991).
Furthermore, additional information concerning the phosphopeptides can be 
derived from the final pattern of spots on the autoradiography. Thus, two spots of similar 
mass-charge ratio that are only separated by ascending chromatography may indicate a 
peptide that contains more than one phosphorylation site of which only one is 
phosphorylated at a given time. Such peptides would have the same mass charge ratios and 
may have different Rf values. Another indication of the identity of the peptide is if the 
pattern of spots is seen to lie on a diagonal. In such instances, if the diagonal slopes 
towards the anode then this indicates that the peptide contains multiple phosphorylation sites
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with each spot representing a change in the number of phosphate groups and where the 
peptide furthest from the application origin contains the least number of phosphorylated 
residues. If the diagonal slopes toward the cathode this indicates that the peptides are partial 
cleavage products and are related by the addition of a single basic residue (lysine [K], 
arginine [R] or histidine [H]; see Boyle et al., 1991).
3 .1 .4 .1  Prediction o f tryptic cleavage products o f a-G i.2
Trypsin catalyses the hydrolysis of the peptide bonds between the COOH of 
arginine (R) or lysine (K) residues and the NH2 group of the next amino and the efficiency 
of the enzyme can be affected by the surrounding amino acids. Trypsin will not cleave at 
either arginine - proline or lysine - proline and will cleave more slowly if the basic residue 
(R or K) is adjacent to an acidic residue (aspartic acid [D] or glutamic acid [E]) or cysteine 
(C). Cleavage can also be affected by the occurrence of multiple arginine or lysine residues, 
or when arginine or lysine occurs in the following sequence, Arg/Lys - x - P-Ser/P-Thr 
where P-Ser, P-Thr and x are phospho-serine, phospho-threonine and any amino acid, 
respectively. Interestingly the occurrence of the phosphorylation site next to the cleavage 
point does not always affect the hydrolysis (see Boyle et al., 1991; Carrey, 1989; Smyth, 
1967).
3 .1 .4 .2  Prediction o f  V8 cleavage products
V8 is a glutamic acid (E) and aspartic acid (D) specific protease produced by 
Staphylococcus aureus, which under certain incubation conditions has been reported to be 
specific only for glutamic acid (see Boyle et al., 1991; Carrey, 1989; Drapeau, 1977). The 
incubation conditions required for glutamic acid specificity are the inclusion of ammonium 
bicarbonate in the reaction buffer (see Boyle et al., 1991; Carrey, 1989; Drapeau, 1977) but 
it has been shown that the bicarbonate only inhibits the rate of cleavage at aspartic acid and 
under prolonged incubation conditions or high enzyme concentration, cleavage at aspartic 
acid will still occur (S0rensen, Sdrensen & Breddam, 1991).
The activity of the enzyme is also affected by modifications near the cleavage site 
in the protein such as carboxylmethylation (Sellinger & Wolfson, 1991) and also shows 
reduced rates of cleavage at glutamic acid when it occurs in the following sequences; proline 
- x - glutamic acid; glutamic acid - aspartic acid; glutamic acid - proline; and glutamic acid - 
x - proline (where x is any amino acid; Breddam & Meldal, 1992).
3 .1 .4 .3  Prediction o f  a-chymotrypsin cleavage products
oc-chymotrypsin is a protease that cleaves at tyrosine (Y), phenylalanine (F) and
tryptophan (W; see Boyle et al., 1991; Carrey, 1989; Smyth, 1967) although it has also 
been reported to cleave at leucine (L), methionine (M) and alanine (A; see Carrey, 1989; 
Smyth, 1967). Cleavage at the additional sites seems to be dependent on the adjoining
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amino acids to the cleavage site and unless incubations conditions are carefully controlled 
the enzyme can exhibit a broad range of specificities (see Smyth, 1967).
3 .2  A im s
The phosphorylation of the a-subunits of G-proteins has been reported both in 
vitro and in vivo (see section 3.1.1; Carlson et al., 1989; Lounsbury et al., 1991; 
Lounsbury et al., 1993; Lincoln, 1991) and in rat hepatocytes the phosphorylation of 
a-Gi-2, but not a-Gs or a-Gi.3, has been demonstrated (Bushfield et al., 1991; Bushfield et 
a l , 1990b).
The only G-protein that has had the site of phosphorylation identified is a-Gz and 
this has been found to be serine 27 which is not found in any of the other G-proteins 
(Lounsbury e ta l , 1993).
The aim of the work described in this chapter was to identify the phosphorylation 
sites in rat hepatocyte a-Gi-2. This was achieved by raising antisera which would 
specifically immunoprecipitate a-Gi-2, and using the antisera to obtain 32P labelled a-Gi-2 
from rat hepatocytes which had been incubated with various agents to activate the different 
cellular signalling systems. The recovered phosphorylated a-Gi-2 was then digested with 
TPCK-trypsin, V8 or a-chymotrypsin and the peptides separated by two-dimensional 
chromatography. The peptides were recovered and either further digested or subjected to 
phosphoamino acid analysis. In addition, theoretical studies of possible enzyme cleavage 
products were carried out and the mass-charge ratio of the peptides determined. This 
information was then used to predict the phosphorylation sites in rat hepatocyte a-Gi-2 and 
to examine their relationship to known or predicted structures and functions of the protein.
3 .3  R esu lts
3 .3 .1  Production and characterisation o f  polyclonal rabbit anti-a - G i.j
antisera
Antibodies were raised in adult New Zealand white rabbits as described in section 
2.2.1. All antisera was subjected to Western blotting (see section 2.2.15) and examined for 
the ability to immunoprecipitate phosphorylated a-Gi-2 from rat hepatocytes (see sections
2.2.2 to 2.2.5).
During the course of the study ten different animals were injected with conjugated 
peptides that would produce anti-a-Gi-i+2 antibodies, except rabbit 1605 which received a 
peptide unique to a-Gi-2 (see table 3.2). The a-Gi-2 peptide used were KNNLKDCGLF 
which is the C-terminal decapeptide and CLERIAQSDYI which is from an internal sequence 
unique to a-Gi-2 (peptides from Biomac, Department of Biochemistry, Glasgow University 
except the peptide for rabbit 1607 which was produced on a poly-L-lysine backbone by the 
Department of Virology, Glasgow University). Antisera 1430 and 1432 were raised and 
characterised by Dr. Mark Bushfield; antisera 1520 to 1607 were raised and characterised
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by myself under the supervision of Dr. Mark Bushfield; antisera 1867 and 1868 were raised 
and characterised by myself; and antiserum 2394 was produced from peptide samples sent 
to Eastacres Biologicals, USA with characterisation carried out by myself.
All the pre-immune sera were tested and they all failed to show protein binding. 
It was found that antisera from immunised rabbits 1430,1432,1520,1867,1868 and 2394 
were able to recognise a-Gi-2 in Western blots of samples from rat hepatocytes and that 
antibody binding could be successfully competed out by the inclusion of a small quantity of 
the peptide used to raise them. Antisera 1521, 1605, 1606 and 1607 all showed poor or 
non-specific results in Western blotting (results not shown, see table 3.2).
Antisera which showed good Western blotting characteristics were tested for their 
ability to immunoprecipitate 32P labelled a-Gi-2. Of the antisera tested (1430,1432,1520, 
1867, 1868 and 2394) only 1867 and 1432 showed good immunoprecipitation 
characteristics; 1520 and 2394 showed moderate to poor characteristics; and 1430 and 1868 
did not immunoprecipitate detectable levels of the phosphorylated protein (see figure 3.3). 
Titration experiments with antiserum 1867 showed that 50 pi of serum gave a maximum 
immunoprecipitation (see figure 3.3).
Table 3.2: Antibodies raised for the detection and immunoprecipitation of a-Gi-2 from
rat hepatocytes.
Number Peptide G-protein Coupling Blotting Precipitation
1430 KNNLKDCGLF a i i+ 2 Glutaraldehyde /  KLH 1:500 -
1432 KNNLKDCGLF Ctil+2 Sulfo MBS / KLH 1:500 ++
1520 KNNLKDCGLF Ctil+2 Glutaraldehyde / KLH 1:500 +
1521 KNNLKDCGLF « i l+ 2 Glutaraldehyde / KLH NSB NT
1605 CLERIAQSDYI « i2 Sulfo MBS/KLH NSB NT
1606 KNNLKDCGLF Ctil+2 Glutaraldehyde /  KLH Poor +
1607 KNNLKDCGLF Ctil+2 Poly-lysine backbone NSB NT
1867 KNNLKDCGLF Ctil+2 Glutaraldehyde / KLH 1:5000 +++
1868 KNNLKDCGLF Ctil+2 Glutaraldehyde / KLH 1:500 -
2394 KNNLKDCGLF Ctil+2 Glutaraldehyde /  KLH 1:500 +
Number represents the identification number of the antiserum; peptide shows the 
decapeptide sequence used; G-protein indicates in which a-subunits the sequence occurs; 
coupling, the coupling procedure used; blotting, the maximum dilution used in Western 
blotting; and precipitation indicates whether the antiserum were a very strong (+++), strong 
(++), weak (+), or very poor (-) immunoprecipitator of phosphorylated a-Gi-2; NT 
indicates that the antisera was not tested
64
Figure 3.3: Immunoprecipitation of 32P labelled a-Gi-2 with antisera 1867,1868,2394
and 1432
Immunoprecipitation of 32P labelled a-Gi-2 with antisera 1867 (lanes 1 [100 pi], 2 [50 pi] 
and 3 [10 pi]), 1868 (lanes 4 [100 pi], 5 [50 pi] and 6  [10 pi]), and 2394 (lanes 7 [100 pi], 
8 [50 pi] and 9 [10 pi]). Lane 10 shows a control lane in which 100 pi of antiserum 1432, 
which had been characterised as a-Gi-2 specific by Dr. Mark Bushfield, was used to 
immunoprecipitate the phospho-protein from rat hepatocytes. As can be seen 1867 is a 
strong immunoprecipitater with 50 pi giving a maximum response (lane 2); 1868 does not 
immunoprecipitate 32P-a-Gi-2J and 2394 gives a poor immunoprecipitate and all 
immunoprecipitation antisera produced a protein of the same molecular weight (-40 kDa).
1 2 3  4 5 6 7 8 9  10
—  110 
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The specificity of the immunoprecipitation of antisera 1432 was tested by Dr. 
Mark Bushfield and it was found that the antibody specifically immunoprecipitated a-Gi-2 
(results not shown). The specificity of 1867 was characterised by comparing the molecular 
weight of the precipitated protein to that of the protein immunoprecipitated by 1432 and it 
was found that both antisera immunoprecipitated a protein of approximately 40 kDa which 
is the correct weight for a-Gi-2 (see figure 3.3). Peptide competition studies on antiserum 
1867 showed that immunoprecipitation of the protein could be inhibited by incubating the 
antisera overnight with the a-Gi-2 peptide KNNLKDCGLF but incubation with the 
equivalent peptide from a-Gi-3 (KNNLKECGLF) did not effect immunoprecipitation (see 
figure 3.4). Although the immunoprecipitation experiments also showed that other 
phospho-proteins were precipitated, notably one at approximately 50 kDa (see figures 3.3 
and 3.4), the results shown in figure 3.4 (peptide competition studies) demonstrate that the 
precipitation of the main band at 40 kDa is a-Gi-2 antibody specific (see figure 3.4, lanes 2 
and 3). The antiserum 1867 can therefore be considered to be a-Gi-2 specific because it 
immunoprecipitates a protein of the correct molecular weight and the precipitation can be 
inhibited by a specific a-Gi-2 peptides. The antiserum cannot be immunoprecipitating 
a-Gi.3 as the equivalent peptide did not inhibit immunoprecipitation (lane 4). Furthermore, 
it can not be immunoprecipitating a-Gi_i, which has the same C-terminal peptide sequence 
as a-Gi-2, as it has been demonstrated that rat hepatocytes do not contain a-Gi_i (Griffiths, 
Knowler & Houslay, 1990; Bushfield et al., 1990b).
3 .3 ,2  Two-dimensional thin layer analysis o f  phosphopeptides derived
from  a-Gi.2
In order to assess whether a-Gi-2 was subjected to multiple-site phosphorylation, 
and to determine the phosphorylation site(s), [32p]-iabelled a-Gi-2 was digested using the 
enzymes trypsin (see section 3.1.4.1), a-chymotrypsin (see section 3.1.4.3) and V8 (see 
section 3.1.4.2) and separated by two-dimensional phosphopeptide mapping analysis (see 
section 2.2.2 to 2.2.9; see Boyle et al., 1991). This was performed using phosphorylated 
a-Gi-2 immunoprecipitated from control cells (basal state) and from cells that had been pre­
treated with various agents in order to activate PKC (phorbol ester PMA) or PKA (8- 
bromo-cAMP, non-hydrolysable analogue of cAMP).
3 .3 .2 .1  Trypsin digestion products
Two dimensional analysis of the phosphopeptides resulting from trypsin 
digestion of a-Gi-2 from control cells identified three major phosphopeptides (labelled Cl, 
C2 and C3; see figures 3.5 and 3.16) all of which were positively charged. Peptides Cl, 
C2 and C3 were resolved by chromatography but only C3 was resolved by electrophoresis 
at pH1.9 (see figures 3.5, 3.6 and 3.16). These three peptides were consistently identified 
using cell preparations from twelve different animals.
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Figure 3.4 Specificity of the immunoprecipitation of a-Gi-2 by antisera 1867
Hepatocytes were labelled with 32p for 65 minutes and then subjected to detergent 
extraction, immunoprecipitation with antiserum 1867, SDS-PAGE and autoradiography 
(see sections 2.2.2 - 2.2.5) Lane 1 show control (1867 only), lanes 2 and 3 antiserum 
1867 in the presence of two different concentrations of a-Gi-2 peptide and lane 4 antiserum 
1867 pre-incubated with an equivalent a-Gi.3 peptide. As can be seen only the a-Gi-2 
peptide competes out a-Gi-2 immunoprecipitation therefore demonstrating the antiserum 
only precipitates a-Gi-2. The molecular weight of the immunoprecipitated phospho-protein 
was approximately 40 kDa. The results shown are from a typical experiment which was 
performed three times with similar results.
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Figure 3.5: Phosphopeptide map of a-G i-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle solution. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH 1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where vehicle produced spots Cl, C2, and C3. Diagrammatic representation of 
the results is shown in figure 3.16. The experiment was performed at least three times with 
similar results.
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Figure 3.6: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with PMA and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
PMA (100 ng/ml) for 15 minutes. The hepatocytes were harvested and a-G i-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiments where PMA produced spots C l, C2, and C3. 
Diagrammatic representation of the results is shown in figure 3.16. The experiment was 
performed at least three times with similar results.
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Digestion of a-Gi-2 phosphoprotein from hepatocytes that had been treated with 
PMA also produced a similar spot pattern to that of control (see figure 3.6 and 3.16) with all 
three tryptic peptides (Cl, C2, and C3) present. Due to the method used to produce the 
peptide maps it was not possible to establish if PMA treatment caused an increase in the 
level of phosphorylation of any of the peptides.
The digestion and separation of a-Gi-2 phosphopeptides from hepatocytes that 
had been incubated with 8-bromo-cAMP again showed the presence of the phosphopeptides 
Cl, C2 and C3 but also revealed the presence of another phosphopeptide (AN; see figures 
3.7 and 3.16). This novel peptide had a greater mass-charge ratio (see section 3.1.4) than 
Cl, C2 or C3 and also exhibited a lower mobility in the second dimension.
Work carried out by Dr. Mark Bushfield (see Morris et al., 1994) showed that 
trypsin digestion of a-Gi-2 from control hepatocytes only produced two peptides Cl and 
C2. Careful examination of Dr. Bushfield's autoradiography also revealed the presence of a 
very faint spot which was equivalent to C3. Experiments in which reduced digestion times 
(five hours instead of ten; see section 2 .2 .8) and lower concentrations of the enzyme were 
used (half standard concentrations; see section 2 .2 .8) produced autoradiographs that did not 
contain the peptide C3 thus confirming the work of Dr. Bushfield (see figure 3.8).
3 .3 .2 .2  V8 digestion o f  the tryptic peptides
Further digestion of the peptides Cl, C2 and C3, pooled from several plates, by 
V8 showed that all three peptides were susceptible to cleavage (see figures 3.9 and 3.16). 
Individual cleavage of spots Cl, C2 and C3 confirmed that Cl gave C21 (see figures 3.10 
and 3.16); C2 produced C2' and C2" (see figures 3.11 and 3.14); C3 gave C3' (see figures 
3.12 and 3.16); and AN gave AN' (see figures 3.13 and 3.16). All of these peptides were 
positively charged at pH1.9 and all the V8 peptides, except AN', had greater mass-charge 
ratios than their parent tryptic peptides and also exhibited a decrease in Rf values (see 
figures 3.9 and 3.16; see section 3.1.4).
Samples of the phosphopeptides Cl, C2, C3 and AN when digested with V8 
produced peptides C2', C2", C3' and AN' (see figures 3.14 and 3.16). The rate of 
cleavage of AN to produce AN' was very slow using the standard method (see section
2.2.8) and early experiments only showed small amounts of AN' being produced. If the 
standard digestion times and enzyme concentrations were doubled then a stronger signal for 
AN' could be achieved but again not all of AN was digested (see figure 3.14). Peptide AN' 
had a mass-charge ratio between that of C3 and C2 and had similar Rf values to C3 and C2 
(see figures 3.14 and 3.16).
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Figure 3.7: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with 8-bromo-cAMP and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
300 pM 8-bromo-cAMP for 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH 1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from typical experiments where 8-bromo-cAMP produced spots Cl, C2, C3 and AN. 
Diagrammatic representation of the results is shown in figure 3.16. The experiment was 
performed at least three times with similar results.
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Figure 3.8: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and then digested with trypsin: shortened
digestion period
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle solution. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin with an incubation time reduced to 5 hours at 
37°C. 32P-labelled tryptic phosphopeptides were then separated on thin-layer cellulose 
plates by electrophoresis at pH 1.9 and ascending chromatography. The final position of 
DNP-lysine is marked on each plate, SF represents the position of the solvent front, origin 
is the point of application of the sample, (+) and (-) indicate the orientation of the electric 
field, and the bar at the top of the plate indicates the separation of the negative, neutral and 
positive markers. The autoradiograph shows the result from a typical experiment where 
vehicle produced spots Cl and C2. Diagrammatic representation of the results is shown in 
figure 3.16. The experiment was performed at least three times with similar results.
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Figure 3.9: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and then first digested with trypsin followed 
by V8
Hepatocytes were labelled with 32P (See sections 2.2.2 and 2.2.3) and then challenged with 
vehicle. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-treated trypsin (see figure 3.5), the peptides collected (see section
2.2.4 - 2.2.10) and then digested with V8 as described in Chapter 2 (see sections 2.2.8 -
2.2.9). 32P-labelled tryptic /  V8 phosphopeptides were separated on thin-layer cellulose 
plates by electrophoresis at pH 1.9 and ascending chromatography. The final position of 
DNP-lysine is marked on each plate, SF represents the position of the solvent front, origin 
is the point of application of the sample, (+) and (-) indicate the orientation of the electric 
field, and the bar at the top of the plate indicates the separation of the negative, neutral and 
positive markers. Each condition was performed at least three times with similar results and 
the autoradiograph shows the result from a typical experiment where vehicle produced spots 
C2', C2" and C3' on V8 digestion. Diagrammatic representation in figure 3.16 shows the 
digestion of a-Gi_2 by trypsin and V8.
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Figure 3.10: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and digested with trypsin: Digestion of
tryptic peptide Cl with V8 to give C2*
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-trypsin as described in chapter 2 (see sections 2.2.4 - 2.2.9). 32p_ 
labelled tryptic phosphopeptides were then separated on thin-layer cellulose plates by 
electrophoresis at pH 1.9 and ascending chromatography. The final position of DNP-lysine 
is marked on each plate, SF represents the position of the solvent front, origin is the point 
of application of the sample, (+) and (-) indicate the orientation of the electric field, and the 
bar at the top of the plate indicates the separation of the negative, neutral and positive 
markers. The autoradiographs showed the typical tryptic peptide pattern (see figure 3.5) 
and the peptide from spot Cl was recovered (see section 2.2.10), subjected to V8 digestion 
and analysed by two-dimensional chromatography as described above (see sections 2 .2.8  -
2.2.9). The autoradiographs shows the results from a typical experiment where the spot Cl 
produced spots C2\ Diagrammatic representation in figure 3.16 shows the digestion of a- 
Gi-2 by V8. Each condition was performed at least three times with similar results.
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Figure 3.11: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and digested with trypsin: Digestion of
tryptic peptide C2 with V8 to give C21 and C2"
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-trypsin as described in chapter 2 (see sections 2.2.4 - 2.2.9). 32P- 
labelled tryptic phosphopeptides were then separated on thin-layer cellulose plates by 
electrophoresis at pH 1.9 and ascending chromatography. The final position of DNP-lysine 
is marked on each plate, SF represents the position of the solvent front, origin is the point 
of application of the sample, (+) and (-) indicate the orientation of the electric field, and the 
bar at the top of the plate indicates the separation of the negative, neutral and positive 
markers. The autoradiographs showed the typical tryptic peptide pattern (see figure 3.5) 
and the peptide from spot C2 was recovered (see section 2.2.10), subjected to V8 digestion 
and analysed by two-dimensional chromatography as described above (see sections 2 .2.8 -
2.2.9). The autoradiographs shows the results from a typical experiment where the spot C2 
produced spots C2' and C2". Diagrammatic representation in figure 3.16 shows the 
digestion of a-Gi_2 by V8 . Each condition was performed at least three times with similar 
results.
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Figure 3.12: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and digested with trypsin: Digestion of
tryptic peptide C3 with V8 to give C3'
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-trypsin as described in chapter 2 (see sections 2.2.4 - 2.2.9). 32P- 
labelled tryptic phosphopeptides were then separated on thin-layer cellulose plates by 
electrophoresis at pH 1.9 and ascending chromatography. The final position of DNP-lysine 
is marked on each plate, SF represents the position of the solvent front, origin is the point 
of application of the sample, (+) and (-) indicate the orientation of the electric field, and the 
bar at the top of the plate indicates the separation of the negative, neutral and positive 
markers. The autoradiographs showed the typical tryptic peptide pattern (see figure 3.5) 
and the peptide from spot C3 was recovered (see section 2.2.10), subjected to V8 digestion 
and analysed by two-dimensional chromatography as described above (see sections 2 .2.8  -
2.2.9). The autoradiographs shows the results from a typical experiment where the spot C3 
produced spot C3\ Diagrammatic representation in figure 3.16 shows the digestion of a- 
Gi-2 by V8. Each condition was performed at least three times with similar results.
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Figure 3.13: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with 8-bromo-cAMP and digested with trypsin: Digestion of
tryptic peptide AN with V8 to give AN1
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
300 |iM 8-bromo-cAMP. The hepatocytes were harvested and a-Gi-2 immunoprecipitated 
with antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered 
from the gel and digested with TPCK-trypsin as described in Chapter 2 (see sections 2.2.4 -
2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin-layer cellulose 
plates by electrophoresis at pH 1.9 and ascending chromatography. The final position of 
DNP-lysine is marked on each plate, SF represents the position of the solvent front, origin 
is the point of application of the sample, (+) and (-) indicate the orientation of the electric 
field, and the bar at the top of the plate indicates the separation of the negative, neutral and 
positive markers. The autoradiographs showed the typical tryptic peptide pattern (see figure 
3.5) and the peptide from spot AN was recovered (see section 2.2.10), subjected to V8 
digestion and analysed by two-dimensional chromatography as described above (see 
sections 2.2.8 - 2.2.9). The autoradiographs shows the results from a typical experiment 
where the spot AN produced spot AN’. Diagrammatic representation in figure 3.16 shows 
the digestion of a-Gi-2 by V8 . Each condition was performed at least three times with 
similar results.
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Figure 3.14: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with 8-bromo-cAMP and digested with trypsin followed by V8
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
300 pM 8-bromo-cAMP for 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin (see figure 3.5), 
the peptides collected (see section 2.2.4 - 2.2.10) and then digested with V8 as described in 
chapter 2 (see sections 2.2.8 - 2.2.9). 32P-labelled tryptic /  V8 phosphopeptides were 
separated on thin-layer cellulose plates by electrophoresis at pH 1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. Each condition was performed at 
least three times with similar results and the autoradiograph shows the result from a typical 
experiment where 8-bromo-cAMP produced spots C2', C2", C3' and AN' on V8 
digestion. Diagrammatic representation in figure 3.16 shows the digestion of a-Gi-2 by 
trypsin and V8 .
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3 .3 .2 .3  V8 digestion
Phosphorylated a-Gi-2 from hepatocytes that had been incubated with control 
(vehicle), PMA and 8-bromo-cAMP were digested with the enzyme V8 using the method 
outlined in section 2 .2 .8.
From experiments carried out on at least six separate occasions it was found that 
only a-Gi-2 from control or PMA treated hepatocytes could be digested by the enzyme (see 
figures 3.15 and 3.16) and that samples from cells that had been incubated with 8-bromo- 
c AMP could not be cleaved.
The phosphopeptides that were produced by V8 cleavage of the protein had the 
same mass-charge ratios and Rf values as the peptides C2\ C2" and C3' and it was 
therefore concluded that the peptides were C2', C2" and C3' (see figures 3.15 and 3.16).
3 .3 .2 .4  a-chymotrypsin digestion
Attempts to produce two-dimensional phospho-peptide maps from a- 
chymotrypsin cleaved samples of a-Gi-2 from control, PMA or 8-bromo-cAMP treated 
hepatocytes were unsuccessful. On the five occasions that this was attempted the resulting 
autoradiography either contained no discernible phosphopeptides or a series of poorly 
defined smudges (results not shown).
3 .3 .3  Phosphoamino acid analysis o f peptides C l, C2, C3 and AN
Phosphoamino acid analysis was carried out as outlined in section 2.2.11 with 
the samples from the acid digestion of phosphopeptides Cl, C2, C3 and AN being applied 
to four separate locations on the t.l.c. plate.
Analysis of the samples showed that all four peptides contained phospho-serine 
and no other phosphoamino acids were detected (see figure 3.17).
3 .3 .4  Prediction o f  enzymatic digestion products o f  phosphorylated
a-Gi.2  and associated mass-charge ratios
From the results outlined in section 3.3.3 then it is clear that the phosphorylation 
of a-Gi-2 only occurs on serine residues and that the phosphoprotein can be digested by 
both trypsin and V8 . Using this information, along with the digestion characteristics of the 
enzymes outlined in section 3.1.4.1 and 3.1.4.2, a range of possible peptides were
predicted and these are shown in Appendix 12.
3 .3 .5  Prediction o f the secondary structure o f a-Gi.2
As discussed in section 3.1.3 and 3.1.3.2, the secondary structure of proteins
can be predicted by using a range of methods.
Although the secondary and tertiary structures of heterotrimeric G-protein a- 
subunits has not been determined, predictions have been made about these based upon the
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Figure 3.15: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with vehicle solution and digested with V8
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with V8 as described in chapter 2 (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic 
phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis at 
pH 1.9 and ascending chromatography. The final position of DNP-lysine is marked on each 
plate, SF represents the position of the solvent front, origin is the point of application of the 
sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top of the 
plate indicates the separation of the negative, neutral and positive markers. The 
autoradiographs show the results from a typical experiments where vehicle produced spots 
C2', C2" and C3'. Diagrammatic representation in figure 3.16 shows the digestion of a- 
Gi-2 by V8 . Each condition was performed at least three times with similar results.
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Figure 3.16: Diagrammatic representation of the peptide distribution after two-
dimensional chromatography
Diagrammatic representation of the peptide distribution after two-dimensional 
chromatography. Black spots represent peptides present under the conditions stated, clear 
spots indicate peptides that have been digested by the second enzyme.
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Figure 3.17: Phosphoamino acid analysis of tryptic peptides Cl, C2, C3 and AN
Peptides Cl, C2, C3 and AN were recovered from t.l.c. plates and subjected to phospho­
amino acid analysis as outlined in sections 2.2.10 and 2.2.11). Peptide Cl was applied to 
position 1, C2 to position 2, C3 to position 3 and AN to position 4. The plate was run at 
pH1.9 in the first dimension and rotated 90* anti-clockwise before being run in the second 
dimension. Pi represents phosphate liberated from the peptide as a result of hydrolysis. 
P-Ser, P-Thr, and P-Tyr represent the final position of the applied standards 
phosphoserine, phosphothreonine and phosphotyrosine (see section 2.2.11 and figure 2.2). 
As can be seen all the peptides produced phosphoserine therefore confirming that the 
phosphorylation sites are serines.
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known structures of EF-Tu and p21ras (see section 3.1.3.3). As EF-Tu and p21^  are 
considerably smaller than any of the heterotrimeric G-protein a-subunits, then novel regions 
of the heterotrimeric G-proteins, namely inserts 1 to 4 and the N and C-terminal extension, 
have to be predicted de novo (see section 3.1.3.3; see Conklin & Bourne, 1993; Masters et 
al., 1986). Here this has been attempted using established methods for the prediction of a- 
helices, (3-sheets and turn regions (see section 3.3.1.2; see Argos, 1989; Chou & Fasman, 
1978; Gamier et al., 1978); flexible regions (see Karplus & Schulz, 1987; Karplus & 
Schulz, 1989); and surface probability plot (see Emini et al., 1985) using the computer 
program DNASTAR (DNASTAR Ltd,. UK). In the prediction of a-helices, p-sheets and 
turn regions, the methods of Chou-Fasman and Gamier-Robson were combined and only 
regions that were predicted by both methods to contain such secondary structure were taken 
(see figure 3.18). It is interesting to note that if the probabilistic prediction methods (see 
section 3.1.3.2) and the information theory method (see sections 3.1.3.2 and 3.1.3.3) 
based on p21ras and EF-Tu are compared then a degree of correlation is found (see figure
3.18).
3 ,4  D iscussion
The data presented in section 3.3.1 showed that antiserum 1867 can be 
considered to be a-Gi-2 specific because it immunoprecipitates a protein of the correct 
molecular weight and the precipitation can be inhibited by a specific a-Gi-2 peptides. The 
antiserum did not immunoprecipitate a-Gi-3 as the equivalent decapeptide does not inhibit 
immunoprecipitation and it can not be immunoprecipitating a-Gi-i, which has the same C- 
terminal peptide sequence as a-Gi-2, as it has been demonstrated that rat hepatocytes do not 
contain a-Gi-i (Griffiths etal., 1990; Bushfield et al., 1990b).
In order to gauge whether a-Gi-2 was subjected to multiple-site phosphorylation 
phosphopeptides of the protein were produced by enzymatic cleavage with trypsin, a- 
chymotrypsin and V8 and the peptides separated by two-dimensional phosphopeptide 
mapping. This was performed using phosphorylated a-Gi-2 immunoprecipitated from 
control hepatocytes (basal state) and from hepatocytes that had been pre-treated with various 
agents in order to activate PKC and/or PKA. Two dimensional analysis of the 
phosphopeptides resulting from trypsin digestion of a-Gi-2 from control cells identified 
three major phosphopeptides (labelled C l, C2 and C3) all of which were positively 
charged. Peptides C l, C2 and C3 were resolved by chromatography but only C3 was 
resolved by electrophoresis at pH1.9 (see figures 3.5 and 3.16). These three peptides were 
consistently identified using cell preparations from twelve different animals.
Previous work by Dr. Mark Bushfield (see Morris et al., 1994) only produced 
the two peptides Cl and C2, upon trypsin digestion of phosphorylated a-Gi-2- The
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Figure 3.18: The location of the seven proposed sites of serine phosphorylation shown in
conjunction with predicted secondary structure and protein features of a-Gi-2
The location of the seven proposed sites (based on mass charge ratio data) of serine 
phosphorylation are shown in conjunction with predicted secondary structure and protein 
features of a-Gi-2. Serines 125, 207, 264, 302 and 306 are shown in italic print as they 
have been eliminated as potential sites based on kinase motifs and change of mass charge 
ratio upon further digestion (see Discussion section 3.4). Serines 47 and 144 are shown in 
bold type as these are the most likely candidates for PKC phosphorylation sites. Alpha, 
beta and turn structure predictions were based on the regions of agreement between the 
prediction methods of Chou /  Fasman (see Chou & Fasman, 1978) and Gamier /  Robson 
(see Gamier et al., 1978). Flexible region predictions were by using the method of Karplus 
/  Schulz (see Karplus & Schulz, 1987; Karplus & Schulz, 1989) and the surface probability 
plot was derived using the method of Emini (see Emini et al., 1985). Structural predictions 
were performed using the program DNASTAR. Protein features were derived from the 
information in Masters et al., 1986, Jones & Reed, 1987, Berlot & Bourne, 1992 and 
Conklin & Bourne, 1993. (R = receptor; E = effector; n = N-terminal extension; c = C- 
terminal extension; il - i4 = inserts 1 to 4)
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increased digestion times of the protein used in this study caused the production of the third 
peptide C3 from either Cl or C2 (see figure 3.8; see section 3.3.2.1). This showed that the 
peptide C3 must contain the same phosphorylation site and be a shorter peptide than either 
Cl or C2.
Further digestion of the peptides Cl, C2 and C3 by V8 showed that all three 
peptides were susceptible to cleavage (see figures 3.9 to 3.12 and 3.16) and individual 
cleavage of spots C l, C2 and C3 confirmed that Cl gave C2f, C2 produced C2' and C2", 
C3 gave C3\ and AN gave AN’ (see figures 3.10 to 3.13) which again were all positively 
charged. These results showed that the peptides Cl and C2 must contain the same 
phosphorylation site as both peptides are able to produce a common peptide, C2\ upon 
cleavage with V8. As it has already been determined that peptide C3 is produced from 
increased digestion of Cl and C2, and hence contains the same phosphorylation site as 
either Cl or C2, then it would appear that peptides Cl, C2 and C3 all contain the same 
phosphorylation site and are just different products of partial digestions.
Examination of the V8 cleavage data of peptides Cl, C2 and C3 revealed that as 
Cl only gave the peptide C2’ and C2 gave C2’ and C2" then it would seem likely that Cl is 
the shorter of the two peptides. The peptide C3, which is a trypsin cleavage product of Cl 
and C2, gave the V8 peptide C3\ If Cl and C2 are the parent peptides of C3 then they 
should also produce the peptide C3' on V8 cleavage. Whilst no clear evidence was obtained 
to this end, it may be explained in terms of a failure of V8 to digest the peptides Cl and C2 
to their smallest components as a result of secondary structure masking of the cleavage site 
or as a requirement for longer digestion periods. However, secondary digestion of trypsin 
cleavage products often proved difficult due to the small amounts of labelled material 
recovered from the t.l.c. plates after the first analysis and so the identification of C3' from 
C2 or Cl may not have been possible due to the low levels of radioactivity. More strenuous 
efforts to address this problem were not possible due to the considerable amounts of 
radioactivity (2 mCi) already used in the experiments.
Digestion of phosphorylated control a-G i-2 with V8 produced peptides 
corresponding to the peptides C2\ C2" and C3' (see figure 3.15). This demonstrates that 
the peptides Cl, C2 and C3 must therefore contain two V8 cleavage points on either side of 
the phosphorylation site.
Treatment of hepatocytes with the protein kinase C activator PMA resulted in 
increased labelling of the protein (see Chapter 4; section 4.3.2) with no evidence for the 
appearance of any other phosphopeptides (see figure 3.6). This demonstrates that as a-Gi-2 
is known to be phosphorylated by PKC in vitro (Sauvage et al., 1991) and that 
phosphorylation in vivo does not give additional sites then some of the pool of a-Gi-2 must 
undergo PKC mediated phosphorylation in resting / unstimulated cells.
The idea that peptides Cl, C2 and C3 are related is further supported by previous 
stoichiometry data obtained in the laboratory (Bushfield et al., 1990b; see Morris et al.,
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1994) which showed that PMA incubation of hepatocytes gave a stoichiometry of ~1 mol 
32P / mol a-Gi-2.
In contrast, treatment of hepatocytes with 8-bromo-cAMP resulted in the 
appearance of a novel labelled phosphopeptide (labelled AN; see figures 3.7 and 3.16). 
This indicated that the activation of PKA in intact hepatocytes results in the phosphorylation 
of a-Gi-2 at a site within the peptide AN which was not normally phosphorylated under 
basal conditions. Again this peptide was sensitive to V8 treatment, producing peptide AN1 
(see figure 3.14), although increased incubation times were required. Attempts to cleave 
peptide AN with V8, unlike peptides Cl, C2 or C3 (see figures 3.10 to 3.12), also required 
increased enzyme concentrations and incubation times. As it has already been established 
that peptides C l, C2 and C3 produce the peptides C2', C2" and C3’ then the new peptide 
produced in figure 3.14 by V8 cleavage of 8-bromo-cAMP samples must be AN'. It is 
interesting to note that V8 cleavage of AN1 required increased digestion times and that even 
then not all of the AN peptide was digested (see figure 3.14). As peptides AN and AN’ 
were not produced from a-Gi-2 *n either control or PMA-treated hepatocytes then this 
demonstrates that a-Gi-2 does undergo multi-site phosphorylation. As a-Gi-2 has been 
phosphorylated by PKC but not PKA in vitro (Lincoln, 1991; Sauvage et al., 1991) then it 
appears that the protein undergoes multi-site phosphorylation by at least two kinases, one of 
which is PKC and the other is unknown.
Examination of the autoradiography does not show the presence of any diagonal 
spot patterns that may give an indication to the peptides structure (see figure 3.16; see 
section 3.1.4; see Boyle et al., 1991). The similar mass-charge ratios of Cl and C2 indicate 
that it may be the same peptide that contains two different phosphorylation sites though this 
idea does not fit the data for the generation of peptide C3 as longer digestions should 
produce two additional phospho-peptides and just not the one.
The amino acid sequence of rat a-Gi-2 is known (Itoh et al., 1986) and hence it is 
possible to predict, using the information on enzyme digestion characteristics presented in 
sections 3.1.4.1 and 3.1.4.2, the peptides that might be produced as a result of enzyme 
cleavage (see Boyle et al., 1991; Carrey, 1989; Smyth, 1967). In an ideal experiment 
trypsin cleaves at arginine (R) and lysine (K), but it can also produce partial digestion 
products as a result of the occurrence of multiple cleavage sites, modifications such as 
phosphorylations near to the point of cleavage and where the cleavage site is next to 
glutamic acid or proline (see section 3.1.4.1; see Boyle et al., 1991; Carrey, 1989; Smyth, 
1967). Such features can therefore lead to the production of further peptides due to partial 
digestion. Cleavage of a protein by V8 occurs mainly at glutamic acid (E) but it can also 
cleave at aspartic acid (D; see section 3.1.4.2; see Boyle et al., 1991; Carrey, 1989; 
Drapeau, 1977; S0rensen et al., 1991; Sellinger & Wolfson, 1991; Breddam & Meldal,
1992). The primary sequence of a-G i-2 contains 20 serines, 21 threonines and 12 
tyrosines, as well as multiple trypsin and V8 cleavage sites, some of which possess
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characteristics that may make them less susceptible to cleavage, thus the prediction of the 
peptides that are produced is, to say the least, somewhat complicated.
To aid the analysis the following deductive approach was made:- It was found 
that the phospho acceptor was serine (see section 3.3.3 and figure 3.17) and that both under 
basal conditions, and when PKC was activated, three peptides were produced (Cl, C2 and 
C3; see section 3.3.2.1) that were related and that all contained phospho-serine in a 
sequence that had a V8 cleavage site on either side. As the phosphorylation was PKC- 
mediated, the primary sequence of a-Gi-2 was examined for the occurrence of PKC 
recognition motifs (see table 3.1; see section 3.1.2 see Azzi et al., 1992; Hug & Sarre, 
1993; Kennelly & Krebs, 1991; Pearson & Kemp, 1991). In this respect serines 16, 44, 
47, 144, 207, 247, and 306 all occurred in regions that formed a possible PKC recognition 
motif (see table 3.1). These serines and their associated sequences were then used for the 
prediction of tryptic peptides (see Appendix 12).
The mass-charge ratios of the predicted tryptic peptides were calculated and as it 
was known that peptides C l, C2 and C3 had positive mass-charge ratios (see section
3.3.2.1) then any peptides which gave a negative or zero mass-charge ratio were eliminated. 
The peptides Cl, C2 and C3 could produce peptides C2', C2" and C3' on V8 cleavage and 
these peptides could also be produced by the cleavage of a-Gi-2 by V8. This indicated that 
the phospho-serine must have a V8 cleavage site on either side. The sequence of the 
remaining peptides were then examined to see which peptides possessed such a sequence 
and any that did not were again eliminated. Using the remaining peptides, the 
corresponding V8 peptides were predicted and their mass-charge ratios calculated. From 
the results obtained in section 3.3.2.2 it is known that the V8 peptides C2', C2" and C3* 
have a positive mass-charge ratio. This means that any predicted V8 peptide that has zero or 
negative mass-charge ratio cannot be the peptides C21, C2" and C3’. This enabled the 
elimination of some of the predicted V8 peptides and also their parent tryptic peptides.
By the above approach it was possible to reduce the number of possible serine 
phosphorylation sites from seven to four. The remaining sites are serines 47,144,207 and 
306 (see Appendix 12). The results in section 3.3.2.1 show that the trypsin digestion of a- 
Gi-2 produces three peptides Cl, C2, and C3. If serines 47, 144, 207 and 306 were to 
produce the tryptic peptides, and as it is predicted that Cl, C2 and C3 represent the same 
phosphorylation site, then each serine should produce at least three predicted tryptic 
peptides. Serine 47 produced three such peptides and also a range of predicted V8 peptides 
that could fit the tryptic and V8 digestion patterns. Serine 144 produced at least five tryptic 
peptides and an associated range of V8 peptides which could also accommodate the 
experimental data. However serine 207 only produced two tryptic and V8 peptides, 
enabling this to be eliminated from consideration as the phosphorylation site as also with 
serine 306 which produced insufficient potential tryptic peptides.
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The tertiary structure of a-G i_2 has been predicted based on the structural 
similarities with EF-Tu and p21ras (see section 3.1.3.3; Conklin & Bourne, 1993; Masters 
et al., 1986). From examination of the predicted structures it was found that serine 47 
occurred in a highly conserved region of the G-protein families, the GTP binding domain, 
and at the start of an a-helix (see figures 3.2 and 3.18; see Conklin & Bourne, 1993; 
Masters et al., 1986). Although the location of the serine in the GTP binding domain 
indicated that a phosphorylation at that site could have the potential to affect GTP binding, 
the location in such a site, coupled with the prediction from a surface probability plot (Emini 
et al., 1985) that it would not occur on the surface of the protein, indicates that it may not be 
readily available to interact with protein kinases (see figure 3.18). Serine 144 is found two- 
thirds of the way through the first insert (see figure 3.18; see Conklin & Bourne, 1993; 
Masters et al., 1986). This is a region of no known secondary structure or attributable 
function (see figure 3.18; see Conklin & Bourne, 1993; Masters et al.y 1986), although it is 
thought to occur next to the GTP binding pocket and to be exposed facing into the 
cytoplasm (see Conklin & Bourne, 1993). Predictions of the secondary structure of this 
insert suggest that serine 144 has a good probability of being on the surface of the molecule, 
close to a region turn and in a region of flexibility (see figure 3.18). This makes serine 144 
a good potential candidate for kinase action and in a region of the protein where a 
phosphorylation may have conformational effects. Indeed, serine 144 is only found in a- 
Gs and members of the a-Gi family, except a-Ggust and the rod and cone a-subunits. 
Interestingly a-GguSt and the rod and cone a-subunits belong to a different 'branch' of the 
G-protein phylogenetic tree from the other members of the ai family (see figure 1.1; see 
Bimbaumer, 1992).
In order to try to clarify further whether serine 47 or 144 is the most likely target 
for PKC-mediated phosphorylation an alternative approach to determine the 
phosphorylation sites was taken. This involved working through from predicted tryptic and 
V8 peptides to secondary structure and finally applying kinase motif recognition data. From 
the predicted peptides resulting from trypsin cleavage all that do not contain serine can be 
eliminated as it is known that the phosphorylation sites are serine (see section 3.3.3 and 
figure 3.17). The mass-charge ratio of the remaining tryptic peptides can be calculated and 
all zero or negatively charged peptides discounted as the peptides that are produced are 
positively charged (see figure 3.5 and 3.6). As peptides C2', C2" and C3' could be 
produced from basal /  PKC phosphorylated a-Gi_2 by either trypsin followed by V8, or just 
by V8, then the peptides Cl, C2 and C3 must contain a serine surrounded by two V8 
sensitive sites and hence all peptides that do not contain such an arrangement can also be 
eliminated. Finally, if the tryptic peptide produces a zero or negatively charged V8 peptide 
then these peptides, and their parent tryptic peptides, can also be discounted as all the V8 
peptides produced are positive. By carrying out this process of elimination there are six
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potential candidate sites which fit the criteria and these are serines 125,144,207,264, 302 
and 306.
Serine 125 is an unlikely phosphorylation site as it does not fit any of the 
recognised motifs for phosphorylation (see table 3.1; see Azzi et al., 1992; Hug & Sarre, 
1993; Kennelly & Krebs, 1991; Pearson & Kemp, 1991), interestingly, is not found in Gs, 
Gi_i or Gi_3 (see table 3.3). In addition it is in the first insert (see figure 3.18) and appears 
to be at the end of an a  helix and just before the start of a (3 sheet, but is not likely to be a 
surface amino acid based on surface probability plots (see figure 3.18).
Serine 144 is a good candidate site as it has a positive charge cluster associated 
with arginines although the glutamic acid does add a degree of negative charge just after the 
arginine (see table 3.3). A serine surrounded by two positively charged arginines is typical 
of PKC and PKA sites (K/RX(o-2)SX(o-2)K/R or SX(o_2)K/R for PKC and K/RX(o-2)S for 
PKA; see Azzi et al., 1992; Hug & Sarre, 1993; Kennedy & Krebs, 1991; Pearson & 
Kemp, 1991; see table 3.1). Out of twenty serines in a-Gi_2 only seven fit the PKC and 
three fit the PKA motif (see table 3.1; PKA sites are also PKC sites). Serine 144 is found 
in a-Gs, a-Gj.i, a-Gi-3 and G0 but in ad cases there is a slight difference in the motif (see 
table 3.3). Based on the mass charge ratio data, that is the change in mass charge of the 
tryptic peptide following V8 cleavage serine 144 is the most likely site for PKC mediated 
phosphorylation. The surrounding amino acids of serine 144 give it a high probability of 
being on the surface of the protein, in a region of flexibility and of turn, and is also 
hydrophilic (see figure 3.18). With its location on the surface, good kinase motif and in 
region that could alter the shape and hence the function of the protein, it makes the site a 
very good point for kinase interaction.
Serine 207 again displays the characteristics of PKC and PKA sites (see table 
3.1; see Azzi eta l., 1992; Hug & Sarre, 1993; Kennedy & Krebs, 1991; Pearson & Kemp, 
1991). It is in a region of the Gi family that is perfectly conserved in the rat for ten amino 
acids on the N-terminal side and twenty two amino acids on the C-terminal side of the 
serine. The region also shows a 80% homology with a-Gs but out of only seven amino 
acids that are different one is the serine. Again using the data derived from the change in the 
mass charge ratios it indicates that this serine is the PKA site as cleavage of the tryptic 
peptide by V8 causes a decrease in the mass-charge ratio and the only peptide that decreases 
is AN. The location characteristics of serine 207 place it just at the start of an a-helix, close 
to an effector and (3y binding site, and near the GTP binding site. Again this makes it a 
likely site for kinase interaction. Serine 207 is found just at the end of the GTP binding 
region which is an equivalent region to the site of cholera toxin catalysed ADP-ribosylation 
in a-Gs which has the effect of permanently activating the enzyme (see Bimbaumer etal., 
1990; Conklin & Bourne, 1993; Masters et al., 1986). It would therefore seem possible 
that a phosphorylation at this site may have some effect on the GTPase activity of the 
protein or on the rate of GDP / GTP exchange. It could be speculated that as this is most
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likely the AN site, that such a phosphorylation could cause a decrease in GTPase activity, 
and hence prolonged activation so suppressing further cAMP production, or it could cause 
an increase in GTPase activity and so remove the inhibitory effects of the protein on cAMP 
production, or interfere with GTP binding. Serine 207 can be discounted as a potential 
PKC site as all the peptides produced under conditions that would activate PKC produce 
tryptic peptides (Cl, C2 and C3) whose mass-charge ratio increases or changes very little 
upon V8 cleavage (C2\ C2" and C3'). Predictions for tryptic peptides that contain serine 
207 and undergo V8 cleavage show a decrease for mass-charge ratio. Although this fits the 
characteristics of peptide AN to AN' the serine at 207 has to be discounted as a potential 
phosphorylation site as the method used for predicting the six sites does not work for cAMP 
mediated phosphorylations as the resulting protein is resistant to V8 cleavage (see section
3.3.2.3).
Serine 264 again is an unlikely phosphorylation site as it does not fit any of the 
PKC recognition motifs for phosphorylation but it does fit a motif for casein kinase I (see
Table 3.3: Summary of the seven potential phosphorylation sites, associated kinase
motifs and occurrence in other G-proteins.
Kinase
Serine PKA PKC CKII GSKIII cc-Gs a-Gi-i p 1 a i a-G0
ESGK47STIVKQ - + - Yes Yes Yes Yes
PEDL125SGVIRR - - - No No No No
FGR144SREYQLN + + - Y /N Y /N Y /N Y /N
GGQR207SERKKW + + - No Yes Yes Yes
FDTDT^SHLFL - - - Y /N Yes Yes Yes
A302SYIQ306SKFED + (306) +(306) + (302) No No No No
The serines are shown with the surrounding amino acids that would contribute to the kinase 
recognition site. All known kinase motifs were examined (see table 3.1; Azzi et al., 1992; 
Hug & Sarre, 1993; Kennelly & Krebs, 1991; Pearson & Kemp, 1991). The serines were 
examined for their occurrence in a-Gs (Itoh et al., 1986,) a-Gi-i (Jones & Reed, 1987), a- 
Gi-3 (Jones & Reed, 1987; Itoh et al., 1988) or a-G0 (Itoh et al., 1986). 'No1 indicates that 
the serine is not present, 'Y / N' indicates the presence of the serine but there is some 
change in the surrounding amino acids, 'Yes' shows that the serine is present and the motif 
is conserved.
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table 3.1; see Azzi et al., 1992; Hug & Sarre, 1993; Kennelly & Krebs, 1991; Pearson & 
Kemp, 1991). The site is found in a-Gi.i and a-Gi.3 ^ d  has a certain degree of homology 
with the equivalent site in a-Gs. Serine 264 appears to be at the start of a p sheet and at the 
end of a region of turn (see figure 3.18). The surface plot predicts that it is not likely to be 
associated with the surface of the molecule and hence inaccessible to kinases (see figure
3.18). Serine 264 is found at the start of the GTP binding region and the end of an effector 
binding region (see figure 3.18; see Bimbaumer et al., 1990; Conklin & Bourne, 1993; 
Masters et al., 1986). Although this would make it an ideal location for effecting some 
change in the characteristics of the protein it is in such a position that may not be readily 
accessible to the kinases.
The final two serines are 302 and 306. Unfortunately these serines are not 
separated by digestion by either trypsin or V8 but from the mass-charge ratio data it is 
indicated that only one of the sites can be phosphorylated at any time, but no indication is 
given as to which site. Neither of the serines fit the PICA motif but 302 does fit the motifs 
for glycogen synthase kinase III and casein kinase I (GSKIII, SX3S(phos); and CKI, 
(D/E2-4 ,X2-o)xS; see Pearson & Kemp, 1991; Woodgett, 1991; see tables 3.1 and 3.3) 
although the motif for GSKIII requires the phosphorylation of serine 306 and the motif for 
CKI is not very good (see Kennelly & Krebs, 1991; see tables 3.1 and 3.2). Serines 306 
fits the motifs for PKC, and casein kinases I and II (CKII; SX2E/D; see Azzi et al., 1992; 
Hug & Sarre, 1993; Kennelly & Krebs, 1991; Pearson & Kemp, 1991; see tables 3.1 and
3.3). Serine 302 represents the only potential glycogen synthase kinase ID site in a-Gi_2 
and one of four casein kinase II sites. Neither of these serines are found in any of the 
G-protein a-subunits with the exception of transducin (a-Gt; see section 1.2.2.2) which 
contains an equivalent to serine 306 (see table 3.3). Phosphorylation of serine 302 by 
GSKIII would require the phosphorylation of serine 306 which possess the motif for CKII 
and these two kinase have already been reported as acting together in the phosphorylation of 
proteins (see Woodgett, 1991). The phosphorylation of serine 302 would seem unlikely as 
it also requires the phosphorylation of serine 306 and the data from mass-charge ratio 
analysis indicates that only one of the serines can be phosphorylated. Serine 306 occurs in 
an a-helix and just before an effector interaction region (see Conklin & Bourne, 1993; 
Masters et al.y 1986; see figure 3.18). Serine 306 can be discounted as a site of 
phosphorylation because as like serine 207 the predicted mass charge ratio decreases when 
the tryptic peptide is digested with V8.
From the two approaches taken to predict which serine is contained in the tryptic 
peptides Cl, C2 and C3 both methods indicated that the most likely candidate is serine 144 
with the first method also predicting serine 47. As stated above serine 144 occurs in the 
first insert and serine 47 in the GTP binding pocket (see figure 3.18). This indicates that 
serine 47 is less likely to be accessible to protein kinases than serine 144. In addition, 
serine 47 occurs in all the known G-protein a-subunits whereas serine 144 is only found in
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a-Gs and some members of the oq family (see table 3.3). Reports on the phosphorylation 
of G-proteins are confused with different groups finding different phosphorylation events in 
different cell-types (see section 3.1.1) and the only reported identification of a 
phosphorylation site is in a-G z where it occurs on serine 27 which is unique to that 
a-subunit (Carlson et al., 1989; Lounsbury et al., 1991; Lounsbury et al., 1993) thus, 
again, favouring serine 144.
The identification of the 8-bromo-cAMP site found within the peptides AN is 
more complicated than the identification of the serine in peptides Cl, C2 and C3. The 
phosphorylated form of a-Gi-2 from hepatocytes that have been incubated with 8-bromo- 
cAMP is more resistant to V8 cleavage than the PKC phosphorylated a-Gi-2. This was 
shown in experiments where V8 either failed to digest the whole protein or where increased 
incubation times were required to get digestion of the tryptic peptides (see sections 3.3.3.2 
and 3.3.3.3; figure 3.14). What the result do show is that when hepatocytes are treated 
with 8-bromo-cAMP the resulting phosphorylated form of oc-Gi-2 has undergone some 
degree of conformational change that now makes it V8 resistant. This indicates the 
importance of this phosphorylation event in the regulation of the protein as it causes such a 
change.
From the data presented here the unequivocal identification of the AN site is not 
possible. The only data available to aid the identification of the site is that the tryptic peptide 
has a mass-charge ratio greater than those of Cl, C2 and C3; that the AN peptide is poorly 
digested by V8, which results in a decrease in mass-charge ratio; the phosphorylation site in 
peptide AN is a serine; and phosphorylated a-Gi-2 from hepatocytes treated with 8-bromo- 
cAMP is not susceptible to V8 cleavage. In addition, although it is known that 8-bromo- 
cAMP will activate PKA, the phosphorylation of a-Gi-2 by this kinase in vitro, unlike for 
PKC, has not been demonstrated (see section 3.1.1). This means that, unlike the analysis 
of the PKC phosphorylation site that produces peptides Cl, C2, and C3, no assumption 
about the kinase responsible for the phosphorylation of the site in the peptide AN can be 
made and hence no assumption about which serines may be potential phosphorylation sites 
based on kinase motifs. Without any information on the possible kinase responsible for the 
phosphorylation then all twenty serines in a-Gi-2 have to be considered. This produces a 
table of possible tryptic peptides that is larger than that in Appendix 12. Using the 
information that the peptide is positively charged at pH1.9 and contains at least one V8 
cleavage site some of the tryptic peptides can be eliminated. The mass-charge ratios of the 
V8 peptides that would be produced from the remaining tryptic peptides can be calculated 
and any V8 peptides and their parent tryptic peptides which have zero, negative or show an 
increased mass-charge ratio when compared to the parent peptide, can be eliminated. By 
carrying out this procedure a large number of potential peptides for AN and AN' still remain 
and so no prediction could be made as to which of the serines in a -G i-2 were 
phosphorylated in response to the incubation of hepatocytes with 8-bromo-cAMP.
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In an attempt to overcome some of these problems a-Gi-2 from hepatocytes 
treated with 8-bromo-cAMP was digested with a-chymotrypsin. These experiments also 
proved unsuccessful as even the PKC phosphorylated form of the protein seemed to have a 
chymotrypsin resistant 'core' which was not susceptible to cleavage. The use of a- 
chymotrypsin as a secondary digestion enzyme did not aid identification as the final levels 
of peptide recovered were too low for analysis.
The inhibitory G-protein a-Gi-2 appears to play a pivotal role in controlling the 
functioning of adenylyl cyclase. The GTP-elicited inhibitory action of a-Gi-2 which is 
responsible, due to the high intracellular concentrations of GTP, for tonic inhibition of 
adenylyl cyclase is lost upon phosphorylation by PKC (Bushfield et al., 1990b; Pyne et al., 
1989b). Thus, the phosphorylation-dephosphorylation cycle acting at this site may serve to 
regulate and/or 'fine-tune' the control of adenylyl cyclase functioning through this G- 
protein.
By use of two dimensional peptide map it has been possible to show that under 
basal (resting) conditions that the protein can produce three phosphorylated peptides (Cl, 
C2 and C3) and that challenging the cells with 8-bromo-cAMP produces a second site 
(AN). By analysis of the data, the prediction of the peptides produced by the enzymes and 
the calculation of their mass-charge ratios, it has been possible to propose one potential 
phosphorylation site in the protein under basal conditions from a possible twenty sites. 
This site is serine 144 and has been shown to occur in predicted secondary structure regions 
of the protein that may have a potential to affect its function. Ideally the site should be 
confirmed by the use synthesised peptides, in vitro mutagenesis or by automated 
sequencing (see Boyle et al., 1991). The use of synthesised peptides is not possible as the 
sequence surrounding serine 144 seems to be able to produce a wide range of peptides and 
hence it has not been possible to assign any one theoretical peptide to the spots Cl, C2 or 
C3; an approach using site directed mutagenesis in vivo, as used by Lounsbury et al. 
(Lounsbury et al., 1993) in the determination of the phosphorylation site in a-Gz, is not 
possible as all cell types seem to express a-Gi-2 and the lack of material in the experiments 
(approximately 20 amole per plate after processing, therefore 6 amole per peptide; see 
Appendix 13) means that the 10 - 100 pmole required for analysis are not available (see 
Boyle etal., 1991).
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Phosphorylation of a-Gi-2 in hepatocytes from Sprague Dawley
rats:
Effects of insulin, amylin and streptozotocin-induced diabetes
4 .1  Introduction
As discussed in Chapter 3, a-Gi-2 from rat hepatocytes undergoes multi-site 
phosphorylation by at least two different kinases. One of the kinases was PKC (see section
1.2.4.2) and the other was activated in a cAMP-dependent manner but appears not to be 
PKA itself (see sections 1.2.4.1 and 3.1.1).
The phosphorylation of a-Gi-2 in rat hepatocytes has been investigated and it was 
found that various agents such as vasopressin, angiotensin n, glucagon, PMA, 8-bromo- 
c AMP and okadaic acid, caused an increase in the phosphorylation of the protein (Bushfield 
et al., 1990a; Bushfield et al., 1991; Bushfield et al., 1990b; Bushfield, Pyne & Houslay, 
1990c; Pyne et al., 1989b). Furthermore, streptozotocin-induced diabetes in rats (see 
section 4.1.1) caused both a decrease in the expression of a-Gi-2 and also effectively 
abolished the angiotensin II-, vasopressin- and PMA-mediated phosphorylation of a-Gi-2 
due to the remaining a-Gi-2 already being phosphorylated (Bushfield et al., 1990a; Gawler 
e ta l ,  1987).
One effect of the phosphorylation of a-Gi-2 in hepatocytes is to cause a loss of 
the Gi-mediated inhibition of adenylyl cyclase (see section 1.2.2.2; Bushfield et a l, 1990a; 
Bushfield et al., 1991; Bushfield et a l, 1990b; Bushfield et al., 1990c; Pyne et al., 1989b). 
If the phosphorylation of a-Gi-2 is of physiological significance in the control of the signal 
transduction system then a method for dephosphorylation must also exist. Indeed, 
Bushfield suggested that a-Gi-2 might be at the centre of a futile cycle of phosphorylation 
and dephosphorylation (Bushfield et al., 1991) and hence the loss of control of such a 
system in hepatocytes, and also the loss of a-Gi-2 in streptozotocin-induced diabetes, could 
have profound effects on the insulin signalling system.
4 .1 .1  Streptozotocin induced diabetes - type I  model
Treatment of rats with streptozotocin causes the destruction of the p-cells in the 
pancreas resulting in a loss of insulin production in the animal hence producing a model of 
type I diabetes (see section 1.3.1). Such administrations of streptozotocin cause a range of 
effects in the animal. It has been found, for example, that the treated animals exhibit a 
degree of insulin resistance; reduced levels of glucose transporters in the muscle and 
adipose tissues, which is connected to reduced glucose uptake and also increased insulin 
binding in the muscle, fat, kidneys and liver but not the brain (Sechi et a l, 1992).
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The increase in insulin binding is accompanied by an increase in insulin receptor numbers 
but effects such as insulin suppression of hepatic glucose production show no change (see 
Giorgino, Chen & Smith, 1992; Nishimura et al., 1989; Burant, Treutelaar & Buse, 1986; 
Kadowaki et al., 1984). The above effects tend to occur when the animals are examined at 
least one week after the treatment with streptozotocin (Nishimura et al., 1989).
The insulin resistance that was observed in streptozotocin treated rats may be 
explained by a loss of auto-phosphorylation of the receptor, and hence a loss of tyrosine 
kinase activity (Giorgino et al., 1992; Kadowaki et al., 1984; Burant et al., 1986). 
However, as an increased level in the phosphorylation of IRS1 was observed this suggests 
either an increase in receptor tyrosine kinase activity or a decrease in phosphatase activity 
(Giorgino et al., 1992; see section 1.4.3.1). Clearly the increased levels of IRS1 
phosphorylation and the decrease in insulin receptor activity are contradictory unless 
phosphatase activity has been reduced. The animals also show an altered form of the 
insulin receptor p-subunit which exhibits decreased migration rate in SDS-PAGE and this 
again may explain why even with the increased number of insulin receptor that some 
insulin-mediated effects may not change (Burant et al., 1986).
Rats that have been treated with streptozotocin and then examined two weeks later 
have also been shown to have increased levels of PKC (see section 1.2.4.2) activity in the 
retina, hearts and hepatocytes (Inoguchi et al., 1992; Tang et al., 1993). When the rat 
hepatocytes were examined for PKC expression it was found that only a, pH, e, and £ 
isoforms were detected, whilst pi, y, S, and r| were not, and that the levels of pH, a  and e 
isoforms increased upon the induction of diabetes with translocation of pH and a  from the 
cytosol to the membrane occurring (Tang et al., 1993). In the rat heart it was found that 
there was an increased expression of the a  and pH isoforms of PKC (e was not examined) 
and increased levels of diacylglycerol (see section 1.2.3.2; Inoguchi et al., 1992).
Another reported effect of streptozotocin-induced diabetes was a decreased 
expression of a-Gi-2 i*1 hepatocytes accompanied by an increased level of phosphorylation 
of the remaining pool of a-Gi_2. The hepatocytes also exhibited a decreased level of ligand 
induced 32P phosphorylation of a-Gi-2 and this has been explained as a consequence of the 
increased level of cold-phosphorylation of the a-Gi-2 pool. This idea was further supported 
by the observation that the rate of turnover of the phosphate groups on a-Gi-2 the diabetic 
animals was not as high as in the non-diabetic animals (Bushfield et al., 1990a). An 
explanation for the increased levels of phosphorylation seen in the diabetic animals may be 
the increased levels of PKC expression and its activator, DAG, reported by Inoguchi and 
Tang (Inoguchi et al., 1992; Tang et al., 1993).
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4 .1 .2  Glucagon and amylin
As discussed in Chapter 1 (sections 1.3.1 and 1.4) insulin plays an important role 
in glucose homeostasis in the body. Other hormones that is involved in the regulation are 
glucagon and a recently discovered poly-peptide hormone, called amylin.
Glucagon is a pancreatic polypeptide hormone which consists of a single chain of 
29 amino acids. The hormone is produced in response to a decrease in blood glucose levels 
and stimulates the hydrolysis of glycogen and lipids. The challenge of hepatocytes with 
glucagon causes a rapid rise in cAMP concentrations which is only transient as the hormone 
also activates a specific high-affinity cAMP-specific phosphodiesterase (see section
1.2.3.1). It has also been shown that the hormone can cause a weak stimulation of inositol 
phosphate metabolism, a strong stimulation of phosphatidyl choline metabolism and hence 
is capable of generating DAG (see section 1.2.3.2). Indeed, it is this generation of DAG 
that may be responsible for the glucagon-mediated activation of PKC reported by Tang and 
Houslay (see section 1.2.4.2; see Tang & Houslay, 1992).
Amylin is a 37 amino acid poly-peptide which is co-secreted with insulin from the 
p-cells of the pancreas and is nearly 50% identical to calcitonin gene-related peptide 
(CGRP). Amylin was initially isolated, purified and characterised as a major component of 
the amyloid deposits in the pancreatic islets of non-insulin dependent diabetics (type II; see 
section 1.3.1). The ratio of amylin and insulin secreted from the (3-cells is variable and may 
reflect different control systems for the gene expression and translation of amylin and 
insulin. The first reported effect of amylin was a reduction in the insulin-stimulated 
incorporation of glucose into glycogen in the muscle and it also appears to exert some 
control on glycogen synthesis in the liver. Indeed, experiments with streptozotocin-treated 
rats (see section 4.1.1) have shown that to return liver glycogen storage levels to normal, 
both insulin and amylin treatments are required. This in turn has led to the suggestion that 
amylin may be of use for the treatment of type I diabetics (see section 1.3.1) in that both 
insulin and amylin should be administered. In type II patients (see section 1.3.1), where 
increased levels of insulin production may occur, some of the symptoms observed may be 
caused by increased levels of amylin (see Westermark et al., 1992; Rink et al., 1993). In 
fact amylin appears to act as a non-competitive or functional antagonist for insulin in the 
muscle but there is no evidence that it interferes with the binding of insulin to its receptor or 
with the subsequent activation of the tyrosine kinase. In addition, it has been reported that 
amylin inhibits insulin secretion from the p-cells (see Westermark et al., 1992; Rink et al., 
1993) and it appears that amylin may produce some of its effects by the activation of 
adenylyl cyclase resulting in a rise in intracellular cAMP (see Bushfield et al., 1993; Rink et 
al., 1993). However, to date, no distinct receptor for amylin has been identified and it is 
thought to act via a shared amylin / CGRP receptor (see Bushfield et al., 1993; Rink et al.,
1993).
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4 .2  A im s
It has been established that in rat hepatocytes a-G i_2 undergoes multi-site 
phosphorylation and that certain ligands can cause an increase in the levels of 
phosphorylation (Bushfield eta l., 1990a; Bushfield et al., 1991; Bushfield et al., 1990b; 
Bushfield et al., 1990c; Pyne et al., 1989b).
The phosphorylation events were examined further with particular emphasis on 
the effects of insulin and amylin on the levels of phosphorylation and any other associated 
effects on ligand-induced phosphorylation. To this end, the dose-response and time- 
courses relationships for insulin and amylin were established, and the effects of 
streptozotocin-induced diabetes on a-Gi-2 phosphorylation examined.
4 .3  R esu lts
4 .3 .1  Effects o f insulin on a-Gi.2  phosphorylation - time course and dose
response
Hepatocytes were labelled to isotopic equilibrium with 32P and challenged with 
insulin. The methods used for hepatocyte preparation and a-Gi-2 isolation are as detailed in 
sections 2.2.2 to 2.2.5.
Figure 4.1 shows a typical autoradiograph of a gel from a time course experiment 
where the cells were exposed to insulin (10 jiM) for 0, 2 ,5 ,10  and 15 minutes. As can be 
seen there was phosphorylation of a-Gi-2 at 0 minutes (control, basal labelling) and that 
insulin caused a time-dependent decrease in the 32P labelling of the protein with a maximum 
effect at around 5 minutes (see table 4.1 and figure 4.2), where upon a new steady state of 
labelling of a-Gi-2 was achieved. This state then persisted for a further ten minutes.
Examination of the dose response of insulin induced inhibition of a-G i-2 
phosphorylation using a concentration range of 10“12 M to 10'5 M showed that after 15 
minutes incubation that concentrations from 10'9 M to 10'5 M significantly inhibited the 
phosphorylation of a-Gi-2, when compared to control (0%), with a maximum inhibition 
occurring at 10-8 M (see table 4.2 and figures 4.3 and 4.4).
In all subsequent experiments insulin was used at a concentration of 10'5 M and 
with a 15 minute incubation.
4 .3 .2  Examination o f ligand mediated phosphorylation o f rat hepatocyte
a-Gi.2  and the effect o f insulin
Isolated Sprague Dawley rat hepatocytes were incubated with a range of 
compounds that stimulated or inhibited different aspects of the secondary messenger 
systems (see section 1.1).
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Table 4.1: Time course of percentage insulin (10 p.M) induced phosphorylation of
a-Gi-2 in Sprague Dawley rat hepatocytes.
Time (min) Mean SEM n= P= Sig. Diff.
0 0 0 4 N
2 -12 2 4 0.016 Y
5 -21 2 4 0.004 Y
10 -18 4 4 0.032 Y
15 -23 5 4 0.031 Y
Control, 0 minutes, was taken as 0 % phosphorylation; SEM = standard error of mean; n = 
number of observations; p = significance value returned by single sample Student's r-test; 
Sig. Diff. = Significantly different from control (0%) by single sample Student's r-test, Y = 
significantly different (p<0.05), N = not significantly differently different (p>0.05).
Table 4.2: Induced levels of a-Gi-2 phosphorylation by insulin in Sprague Dawley rat
hepatocytes.
Log Ins Cone (M) Mean SEM n= P= Sig. Diff.
-12 -0 4 4 0.972 N
-11 -3 4 4 0.601 N
-10 -4 2 4 0.235 N
-9 -12 4 3 0.050 Y
-8 -14 6 3 0.049 Y
-7 -12 5 4 0.044 Y
-6 -17 6 3 0.032 Y
-5 -17 3 18 0.007 Y
Control, no insulin, was taken as 0 %; Log Ins Cone (M) = logarithm of the concentration 
of insulin; SEM = Standard error of mean; n = number of observations; p = significance 
value returned by single sample Student's r-test; Sig. Diff. = significant difference by one 
sample Student's r-test, Y = significantly different (p<0.05), N = not significantly different 
(p>0.05)
To stimulate cAMP-dependent phosphorylation of a-Gi-2 both 8-bromo-cAMP 
(300 pM), forskolin (100 |xM; see section 1.2.3.1) and glucagon (10 nM; see section 4.1.2) 
were used. It was found that all the compounds caused a significant increase in the 32P 
labelling of a-Gi-2, when compared to control (0%; see figures 4.6 and 4.8; see table 4.3).
PKC (see section 1.2.4.2) mediated phosphorylation of a-Gi-2 was stimulated by 
the phorbol ester PMA (100 ng/ml; see section 1.2.4.2) and again a significantly increase in 
the incorporation of 32P into a-Gi-2 was observed (see figure 4.6 and table 4.3).
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Figure 4.1: Typical insulin time course auto-radiograph
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
insulin (10 (iM) for 0 ,2 ,5 ,10  and 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The figure shows a typical auto-radiograph from one of four separate 
experiments. Lanes 1 and 2 are the control (0 minutes) sample; lanes 3 and 4, 2 minutes; 
lanes 5 and 6,5 minutes; lane 7,10 minutes and lane 8,15 minutes.
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The inclusion of insulin with 8-bromo-cAMP and PMA no longer produced a 
phosphorylation of a-G i-2 that was significantly different from control (0%) although 
inclusion of glucagon did (see figure 4.6 and table 4.3). Comparison of ligand and ligand 
plus insulin data, where the ligand-only data were taken as the control, showed insulin only 
significantly affected glucagon mediated phosphorylation, where it caused an enhancement 
of the level of phosphorylation (see figure 4.7 and table 4.4).
To examine further cAMP-dependent phosphorylation of a-Gi-2 hepatocytes were 
incubated with different combinations of forskolin (see section 1.2.3.1), IB MX (see section
1.2.3.1), and insulin (10 jxM). It was found that the inclusion of forskolin or IBMX in the 
incubation caused a significant increase in the phosphorylation of rat hepatocyte a-Gi-2 (see 
figure 4.8 and table 4.3); the addition of both forskolin and IBMX again caused an increase 
in the level of phosphorylation but, although it was significantly different from control 
(0%), it was not significantly different from either the forskolin or IBMX-only stimulations 
(see figures 4.8 and 4.9, and tables 4.3 and 4.4). The addition of insulin and forskolin or 
IBMX to the hepatocytes caused an inhibition of the phosphorylation of a-Gi-2 which was 
significantly different from the ligand-only values (see figure 4.9 and table 4.4), and the 
data also showed that insulin had no effect when both forskolin and IBMX stimulated the 
phosphorylation of a-Gi-2 (see figure 4.9 and table 4.4).
As the agents 8-bromo-cAMP and forskolin both stimulated the phosphorylation 
of a-G i-2  this suggested that the process maybe either mediated by PKA (see section
1.2.4.1) or by some undefined cAMP-dependent mechanism. In addition, the inhibitory 
effects of insulin, both on stimulated and basal phosphorylations, indicated that it may be 
acting by either inhibiting a kinase or stimulating a phosphatase (see section 1.2.4). To 
examine these effects experiments were carried out using a compound called H A 1004 (see 
section 1.2.4.1) which is known to inhibit PKA. Incubation of 32P labelled hepatocytes 
with HA1004 (1 pM) showed that HA1004 could significantly inhibit basal phosphorylation 
of a-Gi-2 but did not significantly affect forskolin stimulated phosphorylation of a-Gi-2 (see 
figures 4.10 and 4.11, and tables 4.3 and 4.4). Incubation of hepatocytes with both insulin 
and HA1004 did not produce an additive effect and left the phosphorylation at basal levels 
(see figures 4.10 and 4.11, and tables 4.3 and 4.4).
To examine whether insulin inhibition of a-Gi-2 phosphorylation was by the 
inhibition of a kinase or the activation of a phosphatase, okadaic acid (1 pM; see section
1.2.4.3), which is an inhibitor of phosphatases 1 and 2A, was used. It was found that the 
inclusion o f okadaic acid in the incubation caused a significant increase in the 
phosphorylation of a-Gi-2 (see figure 4.12 and table 4.3) and that the inclusion of insulin 
had no effect on this (see figures 4.12 and 4.13; tables 4.3 and 4 .4).
The ability of okadaic acid to inhibit phosphatase activity was also used to 
examine the phorbol ester mediated phosphorylation of rat hepatocyte a-Gi-2 - PMA (see 
section 1.2.4.2) and okadaic acid have already been shown to stimulate the phosphorylation
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Table 4.3: Percentage stimulation of the phosphorylation of a-Gi-2 in Sprague Dawley
rat hepatocytes.
Mean SEM n= P= Sig Diff
Forskolin (100 pM) 42 9 5 0.010 Y
Insulin (Ins; 10 pM) -17 3 18 0.000 Y
IBMX (100 pM) 46 12 4 0.035 Y
Forskolin (100 pM) + Insulin (10 pM) 2 20 5 0.930 N
Forskolin (100 pM) + IBMX (100 pM) 34 12 4 0.049 Y
Insulin (10 pM) + IBMX (100 pM) 10 5 4 0.210 N
For (100 pM)+Ins (10 pM)+IBMX (100 pM) 39 10 3 0.048 Y
HA1004 (1 pM) -16 2 4 0.004 Y
Forskolin (100 pM) + HA1004 (1 pM) -8 22 4 0.772 N
Insulin (10 pM) + HA1004 (1 pM) -42 27 3 0.267 N
PMA (100 ng/ml) 23 4 12 0.000 Y
Okadaic acid (OA; 1 pM) 112 33 5 0.028 Y
PMA (100 ng/ml) + Insulin (10 pM) 12 7 10 0.145 N
PMA (100 ng/ml) + Okadaic acid (1 pM) 85 18 4 0.020 Y
PMA (100 ng/ml) + Ins (10 pM)+ OA (1 pM) 97 29 4 0.046 Y
8-bromo-cAMP (8BrcAMP; 300 pM) 93 12 10 0.000 Y
8BrcAMP (300 pM) + Insulin (10 pM) 28 9 3 0.086 N
Okadaic acid (1 pM) + Insulin (10 pM) 111 15 4 0.005 Y
Glucagon (Glue; 10 nM) 37 13 6 0.038 Y
Glucagon (10 nM) + Insulin (10 pM) 33 3 5 0.001 Y
Amylin (Amy; 1 pM) 17 4 5 0.011 Y
Amylin (1 pM) + PMA (100 ng/ml) 29 4 4 0.007 Y
Amylin (1 pM) + Glucagon (10 nM) 19 8 5 0.090 N
Insulin (10 pM) + Amylin (1 pM) 26 5 5 0.007 Y
Amy (1 pM)+Ins (10 mM)+Gluc (10 nM) 6 16 6 0.709 N
Control was taken as 0 % phosphorylation; SEM = Standard error of mean; n = number of 
observations; p = significance value returned by single sample Student's r-test; Sig Diff = 
Significantly different by single sample Student's r-test from control (0%), Y = significantly 
different (p<0.05), N = not significantly different (p>0.05); IBMX = 3-isobutyl-1- 
methylxanthine; For = Forskolin; HA1004 = N - (2'-guanidinoethyl) - 5 - isoquinoline - 
sulfonamide; Ins = Insulin; PMA = Phorbol 12-myristate 13-acetate; OA = Okadaic acid; 
8BrcAMP = 8-bromo-cAMP; Glue = Glucagon; Amy = Amylin
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Figure 4.2: Time course of insulin induced phosphorylation of a-Gi-2
Time course of insulin induced phosphorylation of a-Gi-2 from Sprague Dawley rat 
hepatocytes labelled with 32p (see sections 2.2.2 and 2.2.3) and then challenged with 
10 pM insulin for 0, 2, 5,10 and 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2. The results are expressed as 
mean ± SEM (n = 4; see table 4.2). All points are significantly different (p<0.05, single 
sample Student's r-test) from control (0 minutes, 0%) although points at 2, 5, 10 and 15 
minutes are not significantly different from each other.
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Figure 4.3: Typical insulin dose response curve auto-radiograph
A typical insulin dose response curve auto-radiograph. Sprague Dawley rat hepatocytes 
were labelled with 32P (see sections 2.2.2 and 2.2.3) and were challenged with insulin 
(10-12 to 10'5 M) for 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). Lane 1 contains the control sample (no insulin); lane 2, insulin 
10'12 M; lane 3, insulin 10"11 M; lane 4, insulin 10"10 M; lane 5, insulin 10’9 M; lane 6, 
insulin 10'8 M; lane 7, insulin 10'7 M; lane 8, insulin 10'6 M; lane 9, insulin 10-5 M; and 
lane 10, another control (no insulin).

Figure 4.4: Dose response curve for the insulin induced phosphorylation of a-Gi-2 in
Sprague Dawley rat hepatocytes
Dose response curve for the insulin induced phosphorylation of a-Gi-2 in Sprague Dawley 
rat hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
insulin (10-12 to 10'5 M) for 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2. The data are expressed as mean
± SEM (n > 4; see table 4.2) where * indicates that the data are significantly different 
(p<0.05) from control (0%) with data tested using a single sample Student’s f-test.
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Figure 4.5: A typical auto-radiograph of 32P phosphorylated a-Gi-2 from Sprague
Dawley rat hepatocytes that have been challenged with vehicle solution, 
8-bromo-cAMP, PMA, glucagon, insulin, 8-bromo-cAMP and insulin, 
glucagon and insulin, PMA and insulin, and vehicle solution
A typical auto-radiograph of an SDS-PAGE gel containing a-Gi-2 immunoprecipitated from 
rat hepatocytes that had been labelled with 32P (see sections 2.2.2 and 2.2.3) and then 
challenged with vehicle solution (lane 1), 8-bromo-cAMP (lane 2; 300 pM), PMA (lane 3; 
100 ng/ml), glucagon (lane 4; 10 nM), insulin (lane 5; 10 pM), 8-bromo-cAMP and insulin 
(lane 6), glucagon and insulin (lane 7), PMA and insulin (lane 8), and vehicle solution (lane 
9) for 15 minutes. Where the hepatocytes were challenged with a ligand and insulin, the 
insulin was added first followed immediately by the ligand.

Figure 4.6: Percentage phosphorylation of a-Gi-2 in Sprague Dawley rat hepatocytes:
Effects of 8-bromo-cAMP, PMA, glucagon, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with 8-bromo-cAMP (8BrcAMP; 300 
pM), PMA (100 ng/ml), glucagon (Glue; 10 nM), and insulin (Ins; 10 pM) for 15 minutes. 
Where the hepatocytes were challenged with a ligand and insulin, the insulin was added first 
followed immediately by the ligand. The hepatocytes were harvested and a-G i-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2. The data are expressed as mean
± SEM (n > 4; see table 4.3) where * indicates that the data are significantly different 
(p<0.05) from control (0%) with data tested using a single sample Student's r-test
Figure 4.7: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of insulin on 8-bromo-cAMP, PMA and 
glucagon induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with 8-bromo-cAMP (8Br; 300 pM), PMA (100 ng/ml), glucagon (Glue; 10 
nM), insulin (Ins; 10 pM) for 15 minutes in the presence and absence of insulin (Ins; 10 
pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867. 
The proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting 
gels dried and put down for autoradiography (see section 2.2.5). The level of 
phosphorylation achieved was determined by Cerenkov counting of gel chips that contained
phosphorylated a-Gi-2. The data are expressed as mean ± SEM (n > 4; see table 4.4) where 
* indicates that the data are significantly different (p<0.05) from control (ligand in the 
absence of insulin, 0%) with data tested using a single sample Student's r-test.
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Figure 4.8: Percentage phosphorylation of a-Gi-2 in Sprague Dawley rat hepatocytes:
Effects of forskolin, IBMX, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with forskolin (For, 100 pM), IBMX 
(100 pM), and insulin (Ins; 10 pM) for 15 minutes. Where the hepatocytes were challenged 
with two or more ligands the ligands were added at the same time. The hepatocytes were 
harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The
data are expressed as mean ± SEM (n > 4; see table 4.3) where * indicates that the data are 
significantly different (p<0.05) from control (0%) with data tested using a single sample 
Student's f-test.
Figure 4.9: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of insulin or IBMX on forskolin, and 
IBMX induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with forskolin (For; 100 pM), IBMX (100 pM), and insulin (Ins; 10 pM) for 15 
minutes. Where the hepatocytes were challenged with two or more ligands the ligands were 
added at the same time. The hepatocytes were harvested and a-Gi-2 immunoprecipitated 
with antiserum 1867. The proteins were separated by SDS-PAGE (see sections 2.2.4 and
2.2.5) and the resulting gels dried and put down for autoradiography (see section 2.2.5). 
The level of phosphorylation achieved was determined by Cerenkov counting of gel chips
that contained phosphorylated a-Gi-2. The data are expressed as mean ± SEM (n > 4; see 
table 4.4) where * indicates that the data are significantly different (p<0.05) from control 
(ligand only, 0%) with data tested using a single sample Student's r-test.
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Figure 4.10: Percentage phosphorylation of a-Gi-2 in Sprague Dawley rat hepatocytes:
Effects of forskolin, HA1004, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with forskolin (For; 100 pM), insulin 
(Ins; 10 pM) and HA1004 (1 pM) for 15 minutes. Where the hepatocytes were challenged 
with two or more ligands the ligands were added at the same time. The hepatocytes were 
harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The
data are expressed as mean ± SEM (n > 4; see table 4.3) where * indicates that the data are 
significantly different (p<0.05) from control (0%) with data tested using a single sample 
Student's f-test.
Figure 4.11: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of insulin or HA 1004, on forskolin and 
HA1004 induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with forskolin (For; 100 pM), insulin (Ins; 10 pM) and HA1004 (1 pM) for 15 
minutes. Where the hepatocytes were challenged with two or more ligands the ligands were 
added at the same time. The hepatocytes were harvested and a-Gi-2 immunoprecipitated 
with antiserum 1867. The proteins were separated by SDS-PAGE (see sections 2.2.4 and
2.2.5) and the resulting gels dried and put down for autoradiography (see section 2.2.5). 
The level of phosphorylation achieved was determined by Cerenkov counting of gel chips
that contained phosphorylated a-Gi-2. The data are expressed as mean ± SEM (n > 4; see 
table 4.4) where * indicates that the data are significantly different (p<0.05) from control 
(ligand only, 0%) with data tested using a single sample Student's f-test.
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Figure 4.12: Percentage phosphorylation of a-Gi-2 in Sprague Dawley rat hepatocytes:
Effects of okadaic acid, HA1004, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with insulin (Ins; 10 pM), okadaic acid 
(OA; 1 (xM) and HA1004 (1 pM) for 15 minutes. Where the hepatocytes were challenged 
with two or more ligands die ligands were added at the same time. The hepatocytes were 
harvested and a-G i-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The
data are expressed as mean ± SEM (n ^  4; see table 4.3) where * indicates that the data are 
significantly different (p<0.05) from control (0%) with data tested using a single sample 
Student's r-test.
Figure 4.13: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of insulin, on okadaic acid and HA 1004 
induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with insulin (Ins; 10 |xM), okadaic acid (OA; 1 |iM) and HA1004 (1 jxM) for 15 
minutes. Where the hepatocytes were challenged with two or more ligands the ligands were 
added at the same time. The hepatocytes were harvested and a-Gi-2 immunoprecipitated 
with antiserum 1867. The proteins were separated by SDS-PAGE (see sections 2.2.4 and
2.2.5) and the resulting gels dried and put down for autoradiography (see section 2.2.5). 
The level of phosphorylation achieved was determined by Cerenkov counting of gel chips
that contained phosphorylated a-Gi-2. The data are expressed as mean ± SEM (n > 4; see 
table 4.4) where * indicates that the data are significantly different (p<0.05) from control 
(ligand only, 0%) with data tested using a single sample Student's f-test.
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Figure 4.14: Percentage phosphorylation of a-Gi-2 *n Sprague Dawley rat hepatocytes:
Effects of okadaic acid, PMA, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with PMA (100 ng/ml), insulin (Ins; 10 
pM), and okadaic acid (OA; 1 pM) for 15 minutes. Where the hepatocytes were challenged 
with two or more ligands the ligands were added at the same time. The hepatocytes were 
harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The
data are expressed as mean ± SEM (n > 4; see table 4.3) where * indicates that the data are 
significantly different (p<0.05) from control (0%) with data tested using a single sample 
Student's r-test.
Figure 4.15: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of insulin or okadaic acid, on okadaic acid 
and PMA induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with PMA (100 ng/ml), insulin (Ins; 10 pM), and okadaic acid (OA; 1 pM) for 
15 minutes. Where the hepatocytes were challenged with two or more ligands the ligands 
were added at the same time. The hepatocytes were harvested and a-G i-2  
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2. The data are expressed as mean
± SEM (n > 4; see table 4.4) where * indicates that the data are significantly different 
(p<0.05) from control (ligand only, 0%) with data tested using a single sample Student's t- 
test.
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Figure 4.16: A typical auto-radiograph of immunoprecipitated a-Gi-2 from hepatocytes
from Sprague Dawley rats: Dose response for amylin, 10-12 to 10'6 M
A typical auto-radiograph of an SDS-PAGE gel containing immunoprecipitated a-Gi-2 from 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle (lane 1), amylin 10"11 M (lane 2), amylin 1(H° M ( la n e  3), amylin 10'9 M (lane 4), 
amylin 10-8 M (lane 5), amylin 10"7 M (lane 6), amylin 10-6 M (lane 7), and vehicle (lane 8) 
for 15 minutes. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867. The proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) 
and the resulting gels dried and put down for autoradiography (see section 2.2.5).
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Figure 4.17: Dose response curve for the amylin induced phosphorylation of a-Gi-2 i*1
Sprague Dawley rat hepatocytes
Dose response curve for the amylin induced phosphorylation of a-Gi-2 in Sprague Dawley 
rat hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
amylin (10~11 to 10‘6 M) for 15 minutes. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2- The data are expressed as mean
± SEM (n > 4; see table 4.2) where * indicates that the data are significantly different 
(p<0.05) from control (0%) with data tested using a single sample Student's f-test.
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At a concentration of 1 |iM amylin caused a significant increase in the level of 
phosphorylation of a-Gi-2 when compared to control (0%; see figure 4.18). As amylin is 
considered to be a 'partner' of insulin, and may play a role in the insulin /  glucagon control 
over blood glucose levels and glycogen storage (see sections 1.3.1 and 4.1.2), then the 
action of amylin on glucagon and insulin mediated phosphorylation events was examined.
Glucagon (10 nM) and PMA (100 ng/ml) caused an increase in the level of 
phosphorylation of a-Gi-2, whilst insulin (10 |iM) inhibited the basal and some ligand 
mediated phosphorylations (see section 4.3.2; figures 4.6 and 4.18, and table 4.3). The 
inclusion of amylin with PMA and glucagon had no significant effect (see figure 4.19 and 
table 4.4) but the effect of insulin on amylin induced phosphorylation of a-Gi_2 was to 
significantly enhance it, that is amylin reversed the insulin inhibition of basal 
phosphorylation (see figure 4.19 and table 4.4)
4 .3 .4  Effects o f streptozotocin induced diabetes on the phosphorylation 
o f a - G ^  in Sprague Dawley rat hepatocytes
Male Sprague Dawley rats were injected with streptozotocin (see Appendix 2) to 
induce a model of type I diabetes and hepatocytes were prepared as described in section 
2.2.2. Experiments were then carried out to examine the effect of streptozotocin induced 
diabetes on the phosphorylation of a-Gi.2-
It was found that in hepatocytes from diabetic animals the levels of 
phosphorylation induced by 8-bromo-cAMP (300 |iM), PMA (100 ng/ml), glucagon 
(10 nM) and insulin (10 |xM) were not significantly different from control (0%; see figure 
4.20 and table 4.6) and the reduced levels of 8-bromo-cAMP-, PMA- and glucagon- 
mediated phosphorylation were significantly different from those found in non-diabetic
Table 4.5: Effects of different concentration of amylin on the phosphorylation of a-Gi-2
in Sprague Dawley rat hepatocytes.
Log Amy Cone (M) Mean SEM n= P= Sig Diff
-11 16 8 3 0.187 N
-10 10 4 3 0.154 N
-9 8 1 3 0.003 Y
-8 0 5 4 0.971 N
-7 -9 5 4 0.176 N
-6 15 3 7 0.011 Y
Control, no amylin, was taken as 0 % phosphorylation; Log Amy Cone (M) = Logarithm of 
the concentration of amylin; SEM = standard error of mean; p = significance value returned 
by single sample Student's f-test; n = number of observations; Sig Diff = Significance 
difference test, single sample Student's f-test, against control (0%), Y = significantly 
different (p<0.05), N = not significantly different (p>0.05)
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animals (see figure 4.20 and table 4.6).
Examination of insulin-induced inhibition of ligand-mediated phosphorylation of 
a-Gi-2 showed that insulin was only able to significantly inhibit 8-bromo-cAMP induced 
phosphorylation (see figure 4.21 and table 4.7). When these results were compared with 
those from non-diabetic animals (see figure 4.21 and table 4.7) it was found that, even 
though there had been a loss of the significant effect of insulin on glucagon-mediated 
phosphorylation, the change that occurred was not significant.
Table 4.6: Ligand induced percentage stimulation of the phosphorylation of a-Gi-2 *n
’normal1 and 'type I' diabetic Sprague Dawley rat hepatocytes.
NORMAL
Mean SEM n= P= Sig Dif
8BrcAMP 92 12 10 0.000 Y
PMA 22 4 12 0.000 Y
Glue 37 13 6 0.038 Y
Ins -17 3 18 0.000 Y
8Br+Ins 28 9 3 0.086 N
PMA+Ins 12 7 10 0.145 N
Gluc+Ins 33 4 5 0.001 Y
TYPE I
Sig Dif
Mean SEM n= P= Sig Dif P= N / T I
8BrcAMP 22 7 4 0.054 Y 0.050 Y
PMA 6 2 3 0.076 Y 0.086 Y
Glue -15 6 4 0.076 Y 0.015 Y
Ins -14 6 3 0.125 Y 0.770 N
8Br+Ins 8 6 4 0.296 N 0.106 N
PMA+Ins -8 9 4 0.122 N 0.152 N
Gluc+Ins -2 8 4 0.826 N 0.003 N
Control was taken as 0 % phosphorylation; SEM = Standard error of mean; n = number of 
observations; p = significance value returned by single sample Student's f-test; Sig Dif = 
significant difference by one sample Student's f-test from control (0%), Y = significantly 
different (p<0.05), N = not significantly different (p>0.05); Sig Dif N /  T I  = Comparison 
of the significant difference by two-sample Student's f-test between phosphorylation events 
in 'normal' and 'type I' diabetic Sprague Dawley rat hepatocytes, Y = significantly different 
(p<0.05), N = not significantly different (p>0.05); 8Br = 8BrcAMP = 8-bromo-cAMP, 
300 (iM; PMA = Phorbol 12-myristate 13-acetate, 100 ng/ml; Glue = Glucagon, 10 nM; 
Ins = Insulin, 10 |iM.
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Figure 4.18: Percentage phosphorylation of a-Gi-2 m Sprague Dawley rat hepatocytes:
Effects of amylin, PMA, glucagon, and insulin
Stimulation of a-Gi-2 phosphorylation in Sprague Dawley rat hepatocytes labelled with 32P 
(see sections 2.2.2 and 2.2.3) and then challenged with amylin (Amy; 1 |xM), insulin (Ins; 
10 pM), glucagon (Glue; 10 nM), and PMA (100 ng/ml) for 15 minutes. Where the 
hepatocytes were challenged with two or more ligands the ligands were added at the same 
time. The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867. 
The proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting 
gels dried and put down for autoradiography (see section 2.2.5). The level of 
phosphorylation achieved was determined by Cerenkov counting of gel chips that contained
phosphorylated a-Gi-2. The data are expressed as mean ± SEM (n £ 4; see table 4.3) where 
* indicates that the data are significantly different (p<0.05) from control (0%) with data 
tested using a single sample Student’s f-test.
Figure 4.19: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in Sprague
Dawley rat hepatocytes: Effects of amylin or insulin on amylin, PMA and 
glucagon induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The hepatocytes were 
challenged with amylin (Amy; 1 pM), insulin (Ins; 10 pM), glucagon (Glue; 10 nM), and 
PMA (100 ng/ml) for 15 minutes. Where the hepatocytes were challenged with two or 
more ligands the ligands were added at the same time. The hepatocytes were harvested and 
a-Gi-2 immunoprecipitated with antiserum 1867. The proteins were separated by SDS- 
PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for 
autoradiography (see section 2.2.5). The level of phosphorylation achieved was determined 
by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The data are
expressed as mean ± SEM (n > 4; see table 4.4) where * indicates that the data are 
significantly different (p<0.05) from control (ligand only, 0%) with data tested using a 
single sample Student's f-test.
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Figure 4.20: Percentage phosphorylation of a-Gi-2 in hepatocytes from 'normal' and
streptozotocin treated Sprague Dawley rats: Effects of 8-bromo-cAMP,
PMA, glucagon, and insulin
Stimulation of a-Gi-2 phosphorylation in 'normal' and 'type I' diabetic Sprague Dawley rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 8- 
bromo-cAMP (8Br or 8BrcAMP; 300 jxM), PMA (100 ng/ml), glucagon (Glue; 10 nM), 
and insulin (Ins; 10 |iM) for 15 minutes. Where the hepatocytes were challenged with a 
ligand and insulin the insulin was added first followed immediately by the ligand. The 
hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The 
proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels 
dried and put down for autoradiography (see section 2.2.5). The level of phosphorylation 
achieved was determined by Cerenkov counting of gel chips that contained phosphorylated 
a-Gi-2. Normal refers to animals that were not injected with streptozotocin whilst Type I
refers to animals that were treated. The data are expressed as mean ± SEM (n > 4; see table
4.5) where * indicates that the data are significantly different (p<0.05) from control (0%) 
with data tested using a single sample Student's f-test and t  indicates a significant 
difference, by a two-sample Student's f-test, between streptozotocin treated and untreated 
animals.
Figure 4.21: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in
hepatocytes from 'normal' and streptozotocin treated Sprague Dawley rats: 
Effects of inulin or insulin on 8-bromo-cAMP, PMA and glucagon induced 
phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in 'normal' and 'type Y 
diabetic Sprague Dawley rat hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). 
The hepatocytes were challenged with 8-bromo-cAMP (8Br; 300 |iM), PMA (100 ng/ml), 
glucagon (Glue; 10 nM), insulin (Ins; 10 pM) for 15 minutes in the presence and absence of 
insulin (10 jiM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867. The proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) 
and the resulting gels dried and put down for autoradiography (see section 2.2.5). The 
level of phosphorylation achieved was determined by Cerenkov counting of gel chips that 
contained phosphorylated a-Gi-2. Normal refers to animals that were not injected with 
streptozotocin whilst Type I refers to animals that were treated. The data are expressed as
mean ± SEM (n > 4; see table 4.6) where * indicates that the data are significantly different 
(p<0.05) from control (ligand in the absence of insulin, 0%) with data tested using a single 
sample Student's f-test.
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Table 4.7: Percentage inhibition by insulin of ligand induced phosphorylation of a-Gi-2
in ‘normal and ’type I' diabetic Sprague Dawley rat hepatocytes.
NORMAL
Mean SEM n= P= Sig Dif
8Br by Ins 25 7 3 0.074 N
PMA by Ins -4 9 12 0.681 N
Glue by Ins -14 4 5 0.036 Y
TYPE I
Sig Dif
Mean SEM n= P= Sig Dif P= N / T I
8BrbyIns 12 3 4 0.023 Y 0.105 N
PMA by Ins 18 6 3 0.068 N 0.252 N
Glue by Ins -28 7 3 0.062 N 0.124 N
Control was taken as 0% phosphorylation; SEM = Standard error of mean; n = number of 
observations; p = significance value returned by single sample Student's f-test; Sig Dif = 
significant difference by one sample Student's f-test, Y = significantly different (p<0.05), N 
= not significantly different (p>0.05); Sig Dif N / T I = Comparison of the significant 
difference by two-sample Student's f-test between phosphorylation events in 'normal' and 
'type T diabetic Sprague Dawley rat hepatocytes, Y = significantly different (p<0.05), N = 
not significantly different (p>0.05); 8Br = 8-bromo-cAMP, 300 |iM; PMA = Phorbol 12- 
myristate 13-acetate, 100 ng/ml; Glue = Glucagon, 10 nM; Ins = Insulin, 10 |iM.
4 .3 .5  Two-dimensional phosphopeptide mapping o f  tryptic peptide o f  
a -G i.2  from  ligand treated hepatocytes fro m  * normal* and  
streptozotocin treated Sprague Dawley rats
Samples of phosphorylated a-G i-2 from non-diabetic Sprague Dawley rat 
hepatocytes were digested with trypsin and subjected to two-dimensional peptide mapping 
using the methods described in section 2.2.6 to 2.2.9. The analysis and results for PMA 
and 8-bromo-cAMP treated samples were as outlined in sections 3.3.2 to 3.3.2.1 and 3.4 
(see section 3.3.2.1, and figures 3.6 and 3.7, respectively). PMA-treated samples 
produced three peptides C l, C2 and C3 (see section 3.3.2.1 and figures 3.6 and 3.16) 
whilst 8-bromo-cAMP treated cells produced peptides C l, C2, C3 and AN (see section 
3.3.2.1 and figures 3.7 and 3.16).
The results obtained for the two-dimensional phosphopeptides maps of 
phosphorylated a-Gi-2 from non-diabetic rat hepatocytes that had been exposed to various 
ligands, and various combination of ligands, could be divided into two distinct groups. It 
was found that the compounds either produced the 'three-spot' pattern, that is Cl, C2 and
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Figure 4.22: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with insulin and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
insulin (10 jxM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where insulin produced spots Cl, C2, and C3. Diagrammatic representation of 
the results is shown in figure 3.16. The experiment was performed at least three times with 
similar results.
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Figure 4.23: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with glucagon and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
glucagon (10 nM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where glucagon produced spots C l, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.24: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with 8-bromo-cAMP and insulin and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
8-bromo-cAMP (300 pM) and insulin (10 pM). The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH 1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiment where 8-bromo-cAMP and insulin produced spots Cl, C2, 
C3 and AN. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
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Figure 4.25: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with glucagon and insulin and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
glucagon (10 nM) and insulin (10 pM). The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiment where glucagon and insulin produced spots Cl, C2, C3 
and AN. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
Sprague Dawley, glucagon and insulin, trypsin
Figure 4.26: Phosphopeptide map of a-Gi_2 from Sprague Dawley rat hepatocytes
incubated with forskolin and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
forskolin (100 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where forskolin produced spots C l, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.27: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with IBMX and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
IBMX (100 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH 1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where IBMX produced spots C l, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.28: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with forskolin and IBMX and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
forskolin (100 pM) and IBMX (100 |iM). The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH 1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiment where forskolin and IBMX produced spots Cl, C2, C3 and 
AN. Diagrammatic representation of the results is shown in figure 3.16. The experiment 
was performed at least three times with similar results.
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Figure 4.29: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with forskolin and insulin and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
forskolin (100 p,M) and insulin (10 pM). The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH 1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiment where forskolin and insulin produced spots C l, C2, C3 
and AN. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
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Figure 4.30: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with okadaic acid and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
okadaic acid (1 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where okadaic acid produced spots C l, C2, C3, and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.31: Phosphopeptide map of a-Gi-2 from Sprague Dawley rat hepatocytes
incubated with amylin (1 pM) and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
amylin (1 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where amylin produced spots C l, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.32: Phosphopeptide map of a-Gi_2 from Sprague Dawley rat hepatocytes
incubated with amylin (0.1 pM) and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
amylin (0.1 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where amylin produced spots Cl, C2, and C3. Diagrammatic representation of 
the results is shown in figure 3.16. The experiment was performed at least three times with 
similar results.
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Figure 4.33: Phosphopeptide map of a-Gi_2 from streptozotocin treated Sprague Dawley
rat hepatocytes incubated with vehicle solution and then digested with
trypsin
Hepatocytes from streptozotocin treated (’type I* diabetic) Sprague Dawley rats were 
labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with vehicle solution. 
The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867 before 
being subjected to SDS-PAGE. The protein was recovered from the gel and digested with 
TPCK-treated trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 
32P-labelled tryptic phosphopeptides were then separated on thin-layer cellulose plates by 
electrophoresis at pH1.9 and ascending chromatography. The final position of DNP-lysine 
is marked on each plate, SF represents the position of the solvent front, origin is the point 
of application of the sample, (+) and (-) indicate the orientation of the electric field, and the 
bar at the top of the plate indicates the separation of the negative, neutral and positive 
markers. The autoradiograph shows the result from a typical experiment where vehicle 
produced spots Cl, C2, and C3. Diagrammatic representation of the results is shown in 
figure 3.16. The experiment was performed at least three times with similar results.
zero
SFS F -----
DNP-Lysine
(+)
Origin
Sprague Dawley, diabetic, control, trypsin
Figure 4.34: Phosphopeptide map of a-Gi-2 from streptozotocin treated Sprague Dawley
rat hepatocytes incubated with 8-bromo-cAMP and then digested with
trypsin
Hepatocytes from streptozotocin treated ('type I' diabetic) Sprague Dawley rats were 
labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 8-bromo-cAMP 
(300 pM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-treated trypsin as described in experimental procedures (see sections
2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin-layer 
cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where 8-bromo-cAMP produced spots Cl, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.35: Phosphopeptide map of a-Gi-2 from streptozotocin treated Sprague Dawley
rat hepatocytes incubated with PMA and then digested with trypsin
Hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
PMA (100 ng/ml). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with 
antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered from the 
gel and digested with TPCK-treated trypsin as described in experimental procedures (see 
sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin- 
layer cellulose plates by electrophoresis at pH1.9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where PMA produced spots Cl, C2, and C3. Diagrammatic representation of 
the results is shown in figure 3.16. The experiment was performed at least three times with 
similar results.
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Figure 4.36: Phosphopeptide map of a-Gi-2 from streptozotocin treated Sprague Dawley
rat hepatocytes incubated with glucagon and then digested with trypsin
Hepatocytes from streptozotocin treated ('type I1 diabetic) Sprague Dawley rats were 
labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with glucagon 
(10 nM). The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 
1867 before being subjected to SDS-PAGE. The protein was recovered from the gel and 
digested with TPCK-treated trypsin as described in experimental procedures (see sections
2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides were then separated on thin-layer 
cellulose plates by electrophoresis at pHl .9 and ascending chromatography. The final 
position of DNP-lysine is marked on each plate, SF represents the position of the solvent 
front, origin is the point of application of the sample, (+) and (-) indicate the orientation of 
the electric field, and the bar at the top of the plate indicates the separation of the negative, 
neutral and positive markers. The autoradiograph shows the result from a typical 
experiment where glucagon produced spots C l, C2, C3 and AN. Diagrammatic 
representation of the results is shown in figure 3.16. The experiment was performed at 
least three times with similar results.
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Figure 4.37: Phosphopeptide map of a-Gi-2 from streptozotocin treated Sprague Dawley
rat hepatocytes incubated with insulin and then digested with trypsin
Hepatocytes from streptozotocin treated ('type I' diabetic) Sprague Dawley rats were 
labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with insulin (10 pM). 
The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867 before 
being subjected to SDS-PAGE. The protein was recovered from the gel and digested with 
TPCK-treated trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 
32P-labelled tryptic phosphopeptides were then separated on thin-layer cellulose plates by 
electrophoresis at pH 1.9 and ascending chromatography. The final position of DNP-lysine 
is marked on each plate, SF represents the position of the solvent front, origin is the point 
of application of the sample, (+) and (-) indicate the orientation of the electric field, and the 
bar at the top of the plate indicates the separation of the negative, neutral and positive 
markers. The autoradiograph shows the result from a typical experiment where insulin 
produced spots Cl, C2, and C3. Diagrammatic representation of the results is shown in 
figure 3.16. The experiment was performed at least three times with similar results.
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C3, or produced the ’four-spot' pattern of C l, C2, C3 and AN. The only compounds, 
other than control or PMA, that produced a three-spot pattern were insulin (see figure 4.22) 
and amylin (0.1 pM; see figure 4.32). Glucagon (see figure 4.23), 8-bromo-cAMP plus 
insulin (see figure 4.24), glucagon plus insulin (see figure 4.25), forskolin (see figure 
4.26), IBMX (see figure 4.27), forskolin plus D3MX (see figure 4.28), forskolin plus 
insulin (see figure 4.29), okadaic acid (see figure 4.30), and amylin (1 pM; see figure 4.31) 
all produced the four spot pattern of Cl, C2, C3 and AN.
Samples of phosphorylated a-Gi-2 from hepatocytes of animals that had been 
injected with streptozotocin were also examined by trypsin digestion and two-dimensional 
phospho-peptide mapping. Samples from control (see figure 4.33) and hepatocytes that had 
been incubated with 8-bromo-cAMP (see figure 4.34), PMA (see figure 4.35), glucagon 
(see figure 4.36) and insulin (see figure 4.37) were tested and it was found that control, 
PMA and insulin treated hepatocytes gave peptides Cl, C2 and C3 whilst glucagon and 8- 
bromo-cAMP samples gave peptides Cl, C2, C3 and AN.
4 .4  D iscussion
It has been established that a-G i_2 from Sprague Dawley rat hepatocytes 
undergoes multi-site phosphorylation (see Chapter 3; Morris et al., 1994) and that the level 
of phosphorylation can be increased by agents such as vasopressin, angiotensin II, 
glucagon, PMA, 8-bromo-cAMP and okadaic acid (Bushfield et a l , 1990a; Bushfield et a l , 
1991; Bushfield et al.y 1990b; Bushfield et a l , 1990c; Pyne et a l , 1989b) yet no attempt 
had been made to examine the effects of insulin or amylin on the phosphorylation events in 
'normal' or streptozotocin treated rats.
In the papers by Bushfield and Pyne (Bushfield et a l , 1990a; Bushfield et a l , 
1991; Bushfield et a l , 1990b; Bushfield et a l , 1990c; Pyne et a l , 1989b) the hepatocytes 
exhibited a basal level of phosphorylation and this again was shown to occur in the 
hepatocytes used in these studies. Indeed, Bushfield (Bushfield et a l, 1991) demonstrated 
by the use of the phosphatase inhibitor okadaic acid, that a-Gi-2 was at the centre of a futile 
cycle of phosphorylation and dephosphorylation and again this futile cycle effect was also 
demonstrated with okadaic acid in these studies (see section 4.3.2, table 4.3 and figure 
4.12). Interestingly, two-dimensional phospho-peptide analysis of trypsin digestion 
products of the okadaic acid-induced phosphorylated a-Gi-2 showed that four phospho- 
peptides were produced which corresponded to peptides Cl, C2, C3, and AN (see figure 
4.30; see Chapter 3, sections 3.3.2.1 and 3.4, figure 3.16). This indicated that, even under 
basal conditions, phosphorylation was occurring at two different sites in the protein with the 
AN site possibly experiencing the greater turn-over in phosphorylation as it is not normally 
detected in unstimulated cells.
The incubation of 32p labelled hepatocytes with insulin caused both a time and 
dose-dependent inhibition on the phosphorylation of a-Gi-2 with the maximum effect being
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achieved at about 5 minutes and an effective concentration of 10‘9 M (see figures 4.2 and 
4.4, tables 4.1 and 4.2; section 4.3.1). As it is known that a-Gi-2 exerts a tonic inhibitory 
effect on adenylyl cyclase, and that the phosphorylation of a-Gi-2 caused a loss of this 
inhibitory effect, then the effect of insulin mediated dephosphorylation of a-Gi-2 may be to 
cause an increase in the tonic inhibition of cyclase, and hence a desensitisation of the cAMP 
system.
For insulin to decrease the phosphorylation of a-Gi-2 it could act in one of two 
ways. As resting (basal, control) cells appear to be involved in a futile cycle of 
phosphorylation and dephosphorylation as part of the control of a-Gi-2 activity, then insulin 
may act by either inhibiting a kinase or by stimulating the activity of a phosphatase.
The effect of insulin on the activation of two of the kinases believed to be 
involved in the futile cycle, PKC and PKA, was explored by the use of ligands that had 
either a direct stimulatory effect on the kinases (e.g. PMA or 8-bromo-cAMP), or activated 
a kinase by stimulating the production of a secondary messenger (e.g. forskolin stimulated 
cAMP production). Alternatively, the kinase activity was examined by using inhibitors that 
prevented the degradation of the kinase-activating secondary messengers (e.g. IBMX 
inhibition of phosphodiesterases), or by using kinase inhibitors such as HA1004 (see 
section 1.2.4.1). The role of the phosphatase in the cycle was examined by the use of 
phosphatase inhibitor okadaic acid (see sections 1.2.4.1 and 1.2.4.3) which, in 
hepatocytes, has been shown to produce its half maximal effect on protein 
dephosphorylation at 200 nM, with maximal effect at 1 |iM resulting in the stimulation of 
gluconeogenesis and glucose output (Haystead et al., 1989; see Hardie et al., 1991).
To examine how insulin exerted its effects on the PKC-mediated phosphorylation 
of a-Gi-2 the phorbol ester PMA was used. It was shown that PMA could stimulate the 
phosphorylation of a-Gi-2 and that this occurred, as discussed in Chapter 3, at the same site 
as in unstimulated cells, that is serine 144 (see section 3.3.2.1 and figures 3.5 and 3.6). 
When cells were incubated with both PMA and insulin it was found that even though insulin 
inhibited basal phosphorylation, no change in the phosphorylation occurred (see section 
4.3.2 and figures 4.6 and 4.7). This indicated that insulin did not significantly inhibit the 
activity of PKC, or activate a phosphatase that was specific for the removal of the phosphate 
group on serine 144. It is possible that as PMA-stimulated phosphorylation is only an 
increase of 22 ± 4% (n=12) above control (0%), then the insulin effect is not detectable. 
Alternatively, as PMA stimulates the activity of most of the members of the PKC family, 
other than £ and possibly 0 (see table 1.2), and insulin may only affect one isoform then any 
effect may be masked by the gross activation of the PKCs.
The other kinase that has been implicated in the phosphorylation of a-Gi-2 is 
PKA, although it has been argued that it does not directly phosphorylate the protein as this 
has not been demonstrated in vitro (see section 3.4; Lincoln, 1991). The involvement of
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PKA at some stage in the phosphorylation of a-Gi-2 is indicated by the fact that both 
8-bromo-cAMP, which will activate PKA, and forskolin, which will raise intracellular 
cAMP levels and therefore activate PKA, caused a significant increase in the 
phosphorylation of the protein (see section 4.3.2, table 4.3 and figures 4.6 and 4.8). 
However, as the increased cAMP levels will also cause an increase in Ca2+ influx then these 
ligands will also indirectly activate PKC (see Houslay, 1991a; see section 1.2.4.2). 
Phosphopeptide mapping of tryptic peptides of a-Gi-2 from cells that were treated with 
8-bromo-cAMP, forskolin or IBMX, produced maps that contained four phosphopeptides, 
C l, C2, C3 and AN (see figures 3.5, 3.6 and 3.7; and 4.26, 4.27, and 4.28) and, although 
the presence of peptide AN showed an obvious increase in the incorporation of ^ 2P into 
a-Gi-2, any changes in the labelling of PKC-site represented by peptides Cl, C2 or C3, 
could not be detected due to the unquantifiable nature of the phosphopeptide mapping 
method.
The inclusion of the kinase inhibitor, HA1004, together with forskolin did not 
significantly inhibit the phosphorylation of a-Gi-2 (see section 4.3.2, table 4.3 and figures 
4.10 and 4.11). At the concentration the inhibitor was used, 1 |xM, it is considered to be 
specific for PKA and PKG (see section 1.2.4.1), and its inability to inhibit forskolin- 
stimulated phosphorylation may indicate that it was either failing to enter the cells, although 
this was discounted by the observation that it could affect basal phosphorylation levels (see 
figure 4.11 and table 4.3), or that the inhibitor was effective against PKA-mediated 
phosphorylation but was unable to inhibit any increased PKC activity. The inhibition of 
basal phosphorylation levels by HA1004, besides indicating that the inhibitor could enter 
the cells, suggested that either PKA was actively phosphorylating a-Gi-2 under basal 
conditions, although PKA-mediated phosphorylation, that is peptide AN, was not detected 
in two-dimensional phosphopeptide maps from unstimulated cells unless okadaic acid was 
present; or at the concentration used, HA 1004 was still able to inhibit PKC-mediated 
phosphorylation which is known to occur as part of the futile cycle.
These studies were complemented by the use of the phosphodiesterase inhibitor 
IBMX which elicited a significant phosphorylation of a-Gi-2 in cells where no agonist of 
the cAMP system was added. The increased level of phosphorylation was determined to be 
cAMP-dependent as phosphopeptide mapping revealed the presence of the tryptic peptide 
AN which was only found when cAMP levels were raised (see figure 4.27). However, 
when IBMX was added in conjunction with a stimulator of the cAMP system, such as 
forskolin, it did not cause a significant increase in phosphorylation (see figures 4.8 and 
4.9). The fact that IBMX could not enhance forskolin stimulated phosphorylation indicates 
that, at the concentration of forskolin used (100 |iM), the level of cAMP produced was 
sufficient to fully activate PKA and so cause the phosphorylation of a-Gi-2-
As IBMX was also able to increase the level of a-Gi-2 phosphorylation (see 
figure 4.8), and produce the four spot pattern (see figure 4.27), then this shows that even
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under basal, unstimulated, conditions that cAMP is being produced and that only the 
inhibition of phosphodiesterase activity by IBMX is required to produce an increase in the 
phosphorylation of the protein. This may indicate how easily phosphorylation in the futile 
phosphorylation /  dephosphorylation cycle can be activated as although IBMX is able to 
increase intracellular cAMP levels in hepatocytes, the levels achieved would not be 
sufficient to activate PKA. IBMX may be able to activate PKA if the components of the 
system are compartmentalised. That is, the effects of IBMX were localised, where cAMP 
concentrations could become sufficiently high to activate PKA.
Work by Bushfield et al. (Bushfield et al., 1990b) has shown that the 
phosphorylation of a-Gi-2 caused an inactivation of the protein and the loss of inhibition of 
adenylyl cyclase. As IBMX produced such a phosphorylation then the tonic inhibition of 
adenylyl cyclase would be lost and more cAMP produced, and hence further 
phosphorylation of a-Gi_2. This may demonstrate that the phosphorylation of a-Gi-2 has to 
be tightly controlled otherwise positive feedback could start. The fact that HA1004 also 
inhibited the phosphorylation of a-Gi-2 in hepatocytes again demonstrates that the protein is 
undergoing a futile cycle of phosphorylation and dephosphorylation. In this case the 
inclusion of HA 1004 would inhibit PKA, and possibly PKC, which would result in a 
decrease in the phosphorylation of a-Gi-2 and hence an increase in the tonic inhibition of 
adenylyl cyclase which in turn could produce a decrease in basal cAMP levels and a 
reduction in the activity of PKA or PKC.
The inclusion of insulin with 8-bromo-cAMP, although producing a decrease in 
the level of phosphorylation of a-Gi-2, did not produce a significant inhibition (see figure 
4.6 and 4.7; tables 4.3 and 4.4), but insulin was able to inhibit significantlyt he forskolin 
stimulated phosphorylation of a-Gi-2 (see section 4.3.2, tables 4.3 and 4.4, and figures 
4.6, 4.7, 4.8, and 4.9). As 8-bromo-cAMP directly activates PKA and also causes the 
activation of PKC, then the failure of insulin to inhibit the phosphorylation indicates that its 
point of action must be before the kinase was activated, and hence was also unlikely to be 
by the activation of a phosphatase. As insulin was able to inhibit the forskolin-stimulated 
phosphorylation of a-Gi-2 this suggested that the inhibition may have occurred before the 
activation of the kinase, at the kinase itself or by the stimulation of phosphatase activity, but 
as the 8-bromo-cAMP result indicated that it was before the activation of the kinase, then 
insulin may have produced its effects by inhibiting the production of cAMP by adenylyl 
cyclase, or by increasing the rate of cAMP degradation by the activation a 
phosphodiesterase. Indeed, the insulin-dependent activation of phosphodiesterases has 
already been reported (see sections 1.2.3.1 and 1.4.3.2; Kilgour etal., 1989; see Houslay,
1990) as has the inhibition of adenylyl cyclase (see section 1.4.3.2; see Haring, 1991).
When hepatocytes were incubated with forskolin and IBMX (see table 4.3 and 
figure 4.8) it was found that both compounds did not significantly increase the 
phosphorylation of a-Gi-2 when compared to the compounds on their own, thus indicating
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that PKA may be maximally activated. The inclusion of insulin with forskolin or IBMX 
produced a significant inhibition of phosphorylation (see table 4.3 and figure 4.9) but 
inclusion with forskolin and IBMX did not. This again supported the idea that the 
inhibition occurs before the activation of the kinase and not at the kinase itself because, if 
insulin inhibited the kinase activity, then it would be able to affect PKA activity even when 
the kinase was fully activated.
If insulin were producing the inhibition of forskolin-stimulated phosphorylation 
of a-Gi-2 solely by the activation of a phosphodiesterase then insulin should not be able to 
effect the phosphorylation of a-Gi-2 induced by IBMX, but as it did (see figures 4.8 and 
4.9; tables 4.3 and 4.4) then insulin may have produced its effect by the inhibition of 
adenylyl cyclase activity and therefore suppressing cAMP production. It would appear that, 
as insulin was able to inhibit a-Gi-2 phosphorylation in unstimulated cells, then this would 
produce increased tonic inhibition of adenylyl cyclase activity. This in turn would lead to a 
decrease in cAMP levels and possibly the inhibition of kinase activity. This in effect would 
produce a feedback resulting in the further loss of a-Gi-2 phosphorylation and hence a 
further decrease in adenylyl cyclase activity. Hence it seems likely that insulin may be 
exerting its effects at more than one point in the futile a-Gi-2 phosphorylation cycle, or that 
other cellular control mechanisms are operating to prevent such a feedback occurring in 
unstimulated cells. The failure to detect cAMP-dependent phosphorylation of a-Gi-2 in 
unstimulated cells also suggests that the inhibitory effect of insulin must be operating by 
some other mechanism than just the interaction with some components of the cAMP 
signalling system.
The idea that the phosphorylation of a-G i-2 was connected to the loss of 
inhibition of adenylyl cyclase was proposed by Bushfield et al. (Bushfield et al., 1990b) 
who argued that as the time course of ligand-induced phosphorylation of a-Gi-2 matched the 
time course for the loss of a-Gj inhibition of adenylyl cyclase then the two were connected. 
Other work has shown that the inhibition of adenylyl cyclase by insulin may not be 
mediated by Gj but caused either by the action of an unique G-protein or possibly by the 
phosphorylation of adenylyl cyclase itself (see Haring, 1991). The direct involvement of Gi 
in the attenuation of adenylyl cyclase has been discounted in experiments which show that 
in diabetic animals, which exhibit Gi depleted hepatocyte plasma membranes and show a 
loss of cAMP attenuation, the attenuation can be restored by a drug, metformin, which does 
not affect Gi levels (see Houslay, 1990). This therefore might explain why a feedback of 
the insulin-dependent suppression of adenylyl cyclase activity on a-Gi-2 phosphorylation, 
which then further inhibits adenylyl cyclase, does not occur as a-Gi-2 is not inhibiting 
adenylyl cyclase but has some other function.
Although the insulin-induced inhibition of ligand-mediated a -G i-2 
phosphorylation by a phosphatase has been discounted by insulin's inability to inhibit
185
Chapter 4
8-bromo-cAMP-mediated phosphorylation of a-Gi-2 the possible role of phosphatases was 
still investigated by the use of the phosphatase inhibitor okadaic acid (see section 1.2.4.3).
It was found that exposure of 32P-labelled hepatocytes to okadaic acid 
significantly increased the phosphorylation of a-Gi-2 (see table 4.3 and figure 4.12) and the 
addition of insulin had no effect (see table 4.4 and figure 4.13). As okadaic acid only 
inhibits phosphatases PP1 and PP2A, and not phosphatases PP2B and PP2C (see sections 
1.2.4.3; see Cohen, 1991; Hardie et al., 1991; Haystead et al., 1989), this suggested that 
insulin was producing its inhibitory effect by the activation of either phosphatases PP1 or 
PP2A, although this can be discounted by the 8-bromo-cAMP- and PKC-induced 
phosphorylation where insulin had no effect.
Finally, the effects of glucagon on the phosphorylation of a-Gi-2 were examined. 
It has already been reported (Bushfield et al., 1990b) that glucagon caused an increase in the 
phosphorylation of a-Gi-2 and that this was accompanied by a loss of the ability of a-Gi-2 
to inhibit adenylyl cyclase. In these studies it was found that glucagon did cause a 
phosphorylation of a-G i-2 (see section 4.3.2, table 4.3 and figure 4.6), that the 
phosphorylated protein, when digested with trypsin, produced phospho-peptides Cl, C2, 
C3, and AN, and that insulin enhanced the level of glucagon mediated phosphorylation (see 
section 4.3.2, table 4.4. and figure 4.7). Glucagon has been shown in isolated hepatocytes 
to raise intracellular cAMP levels, and so activate PKA, and also to activate PKC (Tang & 
Houslay, 1992).
What these results showed was that even though insulin was potentially 
increasing the tonic inhibition of adenylyl cyclase by the dephosphorylation of a-Gi-2, that 
the effect of glucagon, by what ever method, not only increased the phosphorylation 
a-Gi-2, and thus removed insulin's inhibitory effect on adenylyl cyclase, but the presence of 
insulin enhanced the level of phosphorylation, hence decreasing the inhibition of adenylyl 
cyclase. This may be another indication of the level of control exerted by insulin and 
glucagon on the metabolism, and hence the blood levels, of glucose. That is, if insulin is 
suppressing the release of glucose from the liver, then the situation can be rapidly reversed, 
and the reversal enhanced, upon exposure of the liver to glucagon by an enhanced level of 
a-Gi-2 phosphorylation and therefore the suppression of its inhibition of adenylyl cyclase. 
In effect insulin may be sensitising the liver to glucagon. As this seems unlikely it may 
indicate that a-Gi_2 is not involved in the insulin-induced inhibition of adenylyl cyclase 
activity, something that has already been suggested from studies in streptozotocin treated 
rats (see section 1.4.3.2; see Houslay, 1990).
The approach that was taken to try and understand the method by which insulin 
inhibited the phosphorylation of a-Gi-2 was limited by only being able to focus on one 
section of the phosphorylation /  dephosphorylation mechanism. When attempts were made 
to examine more than one section the results became confused. What the results did show 
was that insulin was possibly affecting the phosphorylation of a-Gi-2 by more than one
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method in hepatocytes and this maybe viewed as typical of insulin's actions as it has already 
been demonstrated that the activated insulin receptor is able to effect a number of different 
secondary messenger systems (see section 1.4.3.2).
Amylin is a recently discovered polypeptide which is co-secreted with insulin, 
activates adenylyl cyclase and appears, in some ways, to antagonise the effects of insulin 
(see section 4.1.2). It was found that amylin did stimulate the phosphorylation of a-Gj.2 
but that a concentration of 10-6 M was required (see section 4.3.3, table 4.5 and figure 
4.17). Two-dimensional phospho-peptide mapping of a-Gi-2 from hepatocytes that had 
been treated with amylin showed that at 0.1 pM only three phospho-peptides (Cl, C2 and 
C3) were produced upon trypsin digestion, whilst amylin at 1 pM produced a four-spot 
pattern (Cl, C2, C3 and AN; see figures 4.31 and 4.32). This finding fits the data for the 
dose response curve for the activation of adenylyl cyclase by amylin in Bushfield et a l 
(Bushfield et al., 1993) where it was shown that amylin only activates adenylyl cyclase at 
concentrations greater than 10-8 M, hence 1 pM amylin gave the four-spot pattern typical of 
a cAMP / PKA-dependent phosphorylation, whilst amylin at 0.1 pM only produced the 
three spot pattern of unstimulated cells.
When the effect of amylin (1 pM) on ligand-stimulated phosphorylation of a-Gi-2 
in hepatocytes was examined it was found that the only effect was a reversal of insulin's 
inhibition of basal phosphorylation (see tables 4.3 and 4.4 and figures 4.18 and 4.19) thus 
adding further weight to the argument that amylin acts as an antagonist to insulin, although 
if this was truly the case then an inhibition of glucagon-stimulated phosphorylation might be 
expected but this was not found. In addition, as amylin has been shown to stimulate cAMP 
production, although this was only detected in the presence of a phosphodiesterase inhibitor 
(Bushfield et al.y 1993), and at 1 pM produces a four spot phosphopeptide map typical of 
an agonist that activates the cAMP system (see figure 4.31), this again suggested that the 
components of the signalling system maybe compartmentalised so that small localised 
changes in secondary messenger concentrations are sufficient to activate the kinases present 
This may explain the lack of effect of amylin on glucagon induced phosphorylation, that is 
the non-additive effect of cAMP production, in terms of a maximised localised 
phosphorylation which amylin cannot enhance. The greater, although not significantly 
greater, phosphorylation achieved by the gross activators of PKA, such as 8-bromo-cAMP, 
may represent the phosphorylation of total cellular a-Gi-2, whilst glucagon, amylin and 
insulin effects maybe localised.
The effects of streptozotocin-induced diabetes in Sprague Dawley rats was 
examined. It has already been reported that the induction of the diabetes caused changes in 
the expression and levels of phosphorylation of a-Gi-2 (see section 4.1.1; Bushfield et al.y 
1990a). Examination of the tryptic digest products of a-Gi-2 fr°m hepatocytes that had 
been incubated with vehicle (control; see section 4.3.5 and figure 4.33), 8-bromo-cAMP 
(300 pM; see section 4.3.5 and figure 4.33), PMA (100 ng/ml; see section 4.3.5 and figure
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4.35), glucagon (10 nM; see section 4.3.5 and figure 4.36) and insulin (10 pM; see section 
4.3.5 and figure 4.37) showed that the induction of diabetes by streptozotocin did not effect 
the phosphorylation sites of the protein.
Examination of the levels of ligand induced phosphorylation of a-Gi-2 showed 
that 8-bromo-cAMP-, PMA- and glucagon-mediated phosphorylation was significantly 
decreased when compared to control animals that had not been treated with streptozotocin 
(see section 4.3.4, table 4.6 and figure 4.20). These finding agree with those of Bushfield 
et al. (Bushfield et al., 1990a) and most probably indicate a higher level of cold- 
phosphorylation of a-Gi-2 under basal conditions. It does not represent any decrease in 
a-Gi-2 found in streptozotocin-induced diabetes (Bushfield et al.y 1990a) as ligand-induced 
phosphorylated samples were compared to control diabetic animals which would have also 
shown any changes in a-Gi-2 expression.
When the effects of insulin on the phosphorylation of a-Gi-2 in streptozotocin 
treated rats was examined it was found that although some of the effects were now no 
longer significantly different from control the change that had occuiTed were not significant 
(see section 4.3.4, table 4.7 and figure 4.21).
Treatment of rats with streptozotocin not only destroys the (3-cells of the pancreas 
but it also produces a degree of insulin resistance (see section 4.1.1). From the 
phosphorylation study results it would appear that insulin resistance may be occurring as 
some of the insulin effects had lost their significance when compared to control.
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Phosphorylation of a-Gi-2 in hepatocytes from lean (Fa/+) and
obese (Fa/Fa) Zucker rats:
Effects of various agents, insulin and BRL 49653
5 .1  Introduction
As discussed in Chapters 3 and 4, a-Gi-2 from Sprague Dawley rat hepatocytes 
undergoes multi-site phosphorylation by at least two different kinases. Such 
phosphorylation events can be induced by a number of different compounds but are 
basically propagated by the activation of PKC and PKA. It has also been shown that 
insulin caused a dose- and time-dependent inhibition of the phosphorylation of a-Gi-2. 
From such studies it was concluded that insulin may be acting by the simultaneous 
activation of an unidentified kinase and a phosphatase. Furthermore, the induction of 
diabetes in a 'type I’ model by streptozotocin, in the Sprague Dawley rat significantly 
increased the basal phosphorylation of a-Gi-2 but did not effect the insulin-mediated 
inhibition of basal phosphorylation (see Chapter 4).
To complement such studies, the role of insulin in the phosphorylation of a-Gi-2 
was examined in insulin-resistant obese (Fa/Fa) Zucker rats which are routinely used as a 
model of the insulin-resistance seen in type II diabetes (see section 5.1.1). Some 
phosphorylation events relating to a-Gi-2 in lean (Fa/+) and obese (Fa/Fa) Zucker rat 
hepatocytes have already been examined. Such studies showed that vasopressin, 
angiotensin II, and PMA caused an increase in the phosphorylation of a-Gi-2 in the lean but 
not in the obese animals. Associated with this was the loss of the inhibitory function of 
a-Gi-2 in the lean animals and, as the Gi-inhibition of adenylyl cyclase (see section 1.2.2.2) 
could not be detected in hepatocytes from obese Zucker rats, this and the inability to 
phosphorylate a-Gi-2 from obese Zuckers was taken as evidence of increased basal levels of 
phosphorylation of a-Gi-2 (Bushfield et al., 1990c; Houslay et al., 1989). The loss of Gi 
function has been disputed by Young et al. (1991) who have demonstrated that the effect 
may be dependent on the plasma membrane preparation method used in the assessment of 
Gi function.
The expression of G-proteins in obese (Fa/Fa) Zucker rat hepatocytes has been 
examined and it has been reported that there was no change in the level of a-Gi and a 
decrease in the level of a-Gs (Houslay et al., 1989). The antisera used in the study and the 
pertussis toxin a-Gi quantification method detected all isoforms of a-Gi present and hence 
the data may not show any changes in the levels of the particular isoforms present. In 
contrast, experiments carried out using cardiomyocytes from obese Zucker rats, which also 
showed a loss of a-Gi-mediated adenylyl cyclase inhibition, did not show a change in the
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expression of three species of a-Gs but did identify a decrease in the expression of a-Gi_i 
and a-Gi_2 (Eckel, Herberg & Wichelhaus, 1993).
If the phosphorylation of a-Gi-2 is physiologically significant in the control of the 
signalling system then the increased level of basal phosphorylation of a-Gi-2 reported in the 
obese Zucker rat may indicate a dysfunction that occurs in the 'type II' diabetes (see 
Bushfield et al., 1990c). As Bushfield et al. showed that a-Gi-2 is at the centre of a futile 
cycle of phosphorylation and de-phosphorylation in Sprague Dawley rats (Bushfield et al., 
1991) then the dysfunction in the Zucker rats may indicate that the fault is either as a result 
of the activation of a kinase or the deactivation of a phosphatase. Thus it may provide a 
useful point for target ligands in the treatment of ’type H diabetes.
Considerable interest has been expressed by the pharmaceutical industry in 
developing a drug strategy for the treatment of type II diabetes. Type II diabetes represents 
a heterogeneous disease in that the development of the disease may result from different 
initiators but resulting in the appearance of a similar set of clinical symptoms (see section
1.3.1). The treatment of the disease can be divided into two main approaches: the 
achievement of near normal glucose metabolism, that is the abolition of elevated fasting 
glucose levels and the restoration of glucose tolerance; or the prevention of long term 
complications (see section 1.3.1). As the dysfunction that occurs in the insulin signalling 
system is unknown, and as insulin produces a wide range of cellular events by the 
interaction with a number of different signal transduction systems (see table 1.3 and section 
1.4), then there is no clear target point for drug intervention. As a result, most attention has 
been focused on the treatment of the secondary complications and not the correction of 
glucose metabolism.
To date the main drug treatment for type II diabetes has involved the use of 
sulphonylureas and a compound called metformin. The sulphonylureas work by 
stimulating the production of insulin by the pancreas and this may result in several 
complications occurring. First, the increased levels of insulin production only adds to the 
problems already created by the high levels of insulin present and can lead to 
hypoglycaemia, coma and sometimes death; second, the strain on the pancreas is increased, 
as a result of the increased insulin production and this may hasten the failure of the organ so 
that type II diabetes becomes type I as the disease progresses. The method of action of 
metformin is unknown but it may affect glucose absorption and hepatic gluconeogenesis.
A better approach to the treatment of type II diabetes may therefore be to improve 
tissue insulin sensitivity. This would have the benefits of avoiding the risk of 
hypoglycaemia, reducing the strain of excessive insulin production on the pancreas, 
reducing complications resulting from hyperinsulinaemia and hyperglycaemia, and possibly 
restoring amylin secretion to normal physiological levels as the level of hyperinsulinaemia 
decreases (see section 4.1.2). To this end a group of ligands called thiazolidinediones may 
prove beneficial in the treatment of type II diabetes as it has been shown that they can
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increase insulin sensitivity, and decrease hyperinsulinaemia and hyperglycemia (see section
5.1.2).
5 .1 .1  The Zucker rat model o f  'type IV  diabetes
The Zucker rats (Rattus norvegicus) are a strain of rats which resulted from a 
spontaneous mutation when two strains of laboratory rat were mated, and as a result have a 
genetic disposition to obesity, although the exact genetic defect is unknown (see Kasiske, 
O'Donnell & Keane, 1992). The rats were first described in 1961 by Zucker and Zucker 
(Zucker & Zucker, 1961; see also Bray, 1977) and are now well established as a rodent 
model for the insulin resistance as seen in type II diabetes (see Ionescu, Sauter & 
Jeanrenaud, 1985).
The obese (Fa/Fa) Zucker rat displays some of the characteristics associated with 
'type IT diabetes (see section 1.3.1) and it has been found that they are hyperinsulinaemic 
(see Kasiske et al., 1992; Bray, 1977; Stem et al., 1975; Zucker & Antoniades, 1972) but 
are not normally hyperglycaemic (see Ionescu et al., 1985; Bray, 1977; Zucker & 
Antoniades, 1972), although instances have been reported (McCaleb & Sredy, 1992; 
Triscari et al.y 1979); they are glucose tolerant when it is administered intravenously, but 
not orally (see Ionescu et al., 1985); are hypoglucagonaemic (see Bray, 1977) and are 
insulin-resistant (see Kasiske et al., 1992; King et al., 1992; Sherman et al., 1988; Stem et 
al., 1975).
The lack of hyperglycemia may be explained by increased rates of insulin- 
independent glucose uptake and incorporation into lipids in the liver of obese (Fa/Fa) rats 
(Carbd, Lopez-Soriano & Argil6s, 1991). The degree to which hyperinsulinaemia and 
insulin-resistance develops can be dictated by the diet the rats are fed. It has been found that 
animals that have diets low in carbohydrates but high in fat exhibit hyperinsulinaemia, 
insulin resistance in the muscle, and reduced levels of lipogenesis in the adipocytes. In 
contrast, animals on a high carbohydrate diet exhibit a higher level of hyperinsulinaemia, 
increased levels of lipogenesis and are insulin-sensitive in the muscles (Stem et al., 1975). 
In fasting obese (Fa/Fa) rats the insulin levels observed are generally ten-times higher than 
in lean (Fa/+) animals with postprandial levels rising even higher (Kasiske et al., 1992).
The insulin resistance reported in the muscle is believed to represent an 
impairment of the glucose transport process (Sherman et al., 1988) such as a failure of the 
transporter to translocate to the plasma-membrane (King et al., 1992). However, a decrease 
in the auto-phosphorylation of the insulin receptor in the muscle, but not the liver, has also 
been reported (Slieker et al., 1990). Interestingly, streptozotocin-treatment of obese rats, 
which effectively eliminates the hyperinsulinaemia (see section 4.1.1), appears to correct the 
receptor phosphorylation defect (see Kasiske et al., 1992). In addition, a PKC component 
of the insulin resistance has been reported as it was found that in lean (Fa/?) Zucker rat 
hearts and hepatocytes that the phorbol ester, PMA, could stimulate the transport of glucose
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and inhibit the insulin effects on transportation, yet in obese (Fa/Fa) rats this effect was 
abolished. PKC has also been implicated in the alteration in the hormonal responsiveness 
of hepatocytes from lean (Fa/+) and obese (Fa/Fa) Zucker rats where it was found that the 
obese animals showed a decreased responsiveness to PMA treatments and also reduced 
activity of PKC has been found in the heart and liver samples from the obese animals 
(Garcfa-S&nz et al., 1992; Van der Werve et al., 1987)
5 .1 .2  The thiazolidinediones and BRL 49653
A number of pharmaceutical companies are developing compounds that could be 
used in the treatment of type II diabetes. These compounds are based on analogues of 
thiazolidinedione (see Colca & Morton, 1990; Weinstein et al., 1993).
One of the earliest developed compounds was called ciglitazone (5-[4-(l- 
methylcyclohexyl-methoxy)benzyl]thiazolidine-2,4-dione, developed by Takeda Chemical 
Industries, Japan; see figure 5.1). Although originally developed for another purpose, it 
was found that at the high concentrations used during toxicological testing it was able to 
suppress blood glucose levels. Further examination showed that the compound seemed to 
produce its effects by improving insulin sensitivity, and hence possessed hypoglycaemic 
properties. Development of the compound was finally stopped when toxicological 
complications became apparent (see Colca & Morton, 1990).
Using ciglitazone (see figure 5.1) as a starting compound chemical modifications 
have been made to reduce the toxic properties and to improve its biological activity in 
increasing insulin sensitivity (see Colca & Morton, 1990). Examples of the compounds that 
have been produced and have been shown to have hypoglycaemic effects are pioglitazone 
(5-{4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzyl}thiazolidine-2,4-dione; Takeda Chemical 
Industries, Japan; see figure 5.1), CS-045 ((±)-5-[4-(6-hydroxy-2,5,7,8-tetramethyl- 
chroman-2-yl-methoxy)benzyl]-2,4-thiazolidinedione; Sankyo Company Ltd., Japan; see 
figure 5.1); englitazone (also called CP 68,722; (±)-5-[(3,4-dihydro-2-phenylmethyl-2H-l- 
benzopyran-6-yl)methyl]-thiazolidine-2,4-dione; Pfizer, US; see figure 5.1); and BRL 
49653 (5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-thiazolidine-2,4-dione; 
SmithKline Beecham; see figure 5.1). All of these compounds possess the ability to reduce 
hyperinsulinaemia and hyperglycemia, and improve insulin sensitivity in animal models, but 
are only effective after chronic daily dosing over a period of days or weeks.
Pioglitazone (see figure 5.1) has been shown to increases insulin sensitivity in 
obese Wistar rats and obese mice (Kobayashi et al.y 1992; see Hofmann et al., 1992; Colca 
& Morton, 1990). In the obese mice it has been found that the liver's sensitivity to insulin 
was increased and this therefore helped to reduce the levels of hepatic glucose output and 
therefore reduce fasting hyperglycemia, and reduce hyperinsulinaemia (Iwanishi &
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Figure 5.1: Chemical structures of ciglitazone, CS-045, pioglitazone, englitazone (CP
68722) and BRL 49653
Chemical structures of ciglitazone (5-[4-(l-methylcyclohexyl-methoxy)benzyl]thiazolidine- 
2,4-dione), CS-045 ((±)-5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)- 
benzyl]-2,4-thiazolidinedione), pioglitazone (5-{4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzylj- 
thiazolidine-2,4-dione), englitazone (CP 68722; (±)-5-[(3,4-dihydro-2-phenylmethyl-2H-l- 
benzopyran-6-yl)methyl]-thiazolidine-2,4-dione) and BRL 49653 (5-(4-[2-(N-methyl-N-(2- 
pyridyl)amino)ethoxy]benzyl)-thiazoIidine-2,4-dione).
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Kobayashi, 1993; Hofmann et al., 1992; Hofmann, Lorenz & Colca, 1991; Ikeda et al.,
1990). It has been demonstrated that the compound can correct the reduction in glucose 
transporter (GLUT4) expression seen in the fat and muscle of diabetic obese mice, but the 
method by which it increases the liver's sensitivity to insulin is unknown. However, it has 
been shown not to involve changes in the expression of the liver glucose transporter 
GLUT2 which do not change in the diabetic state (Hofmann et al., 1992; Hofmann et al.,
1991). Studies in cultured 3T3-F442A cells have demonstrated that pioglitazone may be 
increasing the expression of GLUT4 in fat cells by stabilising and increasing the half-life of 
it's mRNA (Sandouk, Reda & Hofmann, 1993). Information on its mode of action has 
also come from studies on the muscle of obese Wistar rats and rats on a high-fat diet where 
it has been shown that the compound does not effect insulin binding to its receptor but 
increases the tyrosine kinase activity of the receptor when insulin is present (Iwanishi & 
Kobayashi, 1993; Kobayashi et al., 1992). Additional evidence from cell culture studies of 
brown adipose tissue and observation in diabetic rodents, indicate that it may operate by 
enhancing the growth and differentiation of the tissue (Foellmi, Wyse & Kletzien, 1993).
Englitazone (also called CP 68722; see figure 5.1) was developed by Pfizer and, 
like all the thiazolidinediones, has the effect of reducing hyperinsulinaemia and 
hyperglycemia in animal models of type II diabetes (Bowen et al., 1991; Stevenson et al., 
1990; see Kreutter et al., 1990). Studies on 3T3-L1 adipocytes have shown that unlike 
some of the other compounds it is able to stimulate glucose uptake by the cultured cells in 
the absence of added insulin and that this increase in glucose uptake could be inhibited by 
the inclusion of a protein synthesis inhibitor. This suggests that the compound may 
produce its effects by the stimulation of the synthesis of glucose transporters which were 
able to translocate to the cell membrane (Kreutter et al., 1990). The insulin-independent 
effect of englitazone has also been reported in isolated rat hepatocytes where it was found 
that the compound could produce insulin-like effects on glycogenesis, glucose oxidation 
and glycolysis, but without affecting the auto-phosphorylation of the insulin receptor or the 
phosphorylation IRS1 (see section 1.4.3.1). In addition, the same study showed that 
englitazone also antagonised glucagon responses (McPherson et al., 1993).
CS-045 (see figure 5.1) has again been shown to reduces hyperinsulinaemia and 
hyperglycaemia in animal models of type II diabetes (Fujiwara et al., 1988; see Colca & 
Morton, 1990) and has also proved successful in studies with diabetic humans (Kaneko et 
al., 1993; Suter et al., 1992) although some mild side effects have been reported (Kaneko et 
al., 1993). Again the compound is thought to work by increasing insulin binding in the 
adipocytes and improving the sensitivity to insulin (Fujiwara et al., 1988).
The antihyperglycaemic properties of BRL 49653 (see figure 5.1) have been 
assessed in a number of animal models of diabetes and has been shown to be sixty-times 
more potent than pioglitazone and 100-200 times more potent than CS-045 (Cawthome et 
al., 1993). It has been shown that for the compound to produce any effect that the dosage
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has to be chronic and the application of a single dose has no effect. In the type II diabetes 
models used, diabetic mice (ob/ob and db/db) and obese (Fa/Fa) Zucker rats, it was found 
that the compound reduced hyperinsulinaemia and hyperglycemia and improved glucose 
tolerance. In addition, in none of the animals studied was it found that excessively high 
doses of BRL 49653 caused hypoglycaemia (Cawthome et al., 1993; Young et al., 1993) 
Studies were also carried out using normal Sprague Dawley rats and Sprague Dawley rats 
that had 'type-I’ diabetes induced by the use of alloxan or streptozotocin (see section 4.1.1). 
In all cases it was found that the compound had no effect, although increased insulin 
sensitivity could be observed upon dosing with insulin. This demonstrated that it could not 
affect non-insulin resistant animals and required the presence of insulin to be active.
Examination of the effect of insulin on adipocytes derived from obese mice that 
had been treated with BRL 49653 showed that, when compared to animals that had not been 
treated, the compound increased the number of insulin receptors, improved insulin 
responsiveness, increased GLUT4 expression and translocation to the membrane and did 
not effect glucose uptake in the absence of insulin (Cawthome et al., 1993; Young et al., 
1993).
In the obese (Fa/Fa) Zucker rat it was found that treatment of the animal for 21 
days with BRL 49653 increased insulin sensitivity as measured by a hyperinsulinaemic- 
euglycaemic clamp (Cawthome et al., 1993; Smith et al., 1993). The clamp is performed 
by an intravenous infusion of insulin to elevate the low basal insulin concentration. This 
results in a suppression of glucose production by the liver and an increased uptake of 
glucose by peripheral tissue such as the muscle. To maintain the blood glucose level at the 
pre-insulin-infusion concentration glucose has to be variably administered. In obese Zucker 
rats that had not been treated with BRL 49653 it was found that the infusion of insulin did 
affect blood glucose levels by suppression of glucose output by the liver, and therefore 
additional glucose was required. Animals that had been treated with BRL 49653 also 
required additional glucose to maintain the blood glucose level but the level of glucose 
required was significantly higher hence indicating insulin sensitivity had been restored. In 
obese Zucker rats it was also found that chronic treatment of the animals with BRL 49653 
did not effect the number of insulin receptors present per hepatocyte and did not alter the 
tyrosine kinase activity of the receptor. These observations suggest that the point of action 
of BRL 49653 in the Zucker rat hepatocytes is not at the insulin receptor but at some point 
post-receptor (Smith et al., 1993).
The method by which BRL 49653 produces its effects is unknown although it 
has been established that it does not bind to any of a wide range of cell surface receptors. 
Additional information has come from a study on insulin-resistant (high-fat-fed) rats where 
it was shown that the compound reduced basal insulin levels in the control and insulin 
resistant rats and reversed insulin resistance in the liver and the muscle. It was proposed 
that the correction of insulin resistance resulted from the reduced basal levels and therefore
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removing any desensitisation effects resulting from hyperinsulinaemia (Kraegen et al., 
1993).
5 .2  A im s
It has been established that a-Gi-2 undergoes ligand dependent multi-site 
phosphorylation in Sprague Dawley rat hepatocytes, that insulin affects the basal level of 
phosphorylation and some changes occur when Sprague Dawley rats are made diabetic by 
the use of streptozotocin (see Chapters 3 and 4).
To examine further the effects of diabetes on the expression and phosphorylation 
of a-Gi-2 in more detail it is proposed to carry out a series of experiments on hepatocytes 
from lean (Fa/+) and the insulin resistant obese (Fa/Fa) Zucker rat
The compound BRL 49653 has been shown to be beneficial in restoring insulin- 
sensitivity and therefore reducing hyperinsulinaemia and hyperglycemia in the obese Zucker 
rat (see section 5.1.2). Animals that have been dosed with this compound were also 
examined to see if it affected the phosphorylation characteristics of a-Gi-2.
Finally, hepatocytes from lean and obese Zucker rats, which were and were not 
chronically dosed with BRL 49653, were examined to assess the levels of a-Gi-2 and PKC 
isoforms expression and the distribution of the proteins between the cytosol and membrane 
fractions.
5 .3  R esu lts
5 .3 .1  Treatment o f  Zucker rats with BRL 49653
From previous work carried out at SmithKline Beecham (see Cawthome et al., 
1993; Smith et al., 1993; Young et al., 1993) it has been established that Zucker rats require 
21 days of oral dosing with BRL 49653 at 3 pmole per kilogram for the compound to be 
effective. BRL 49653 was prepared for dosing by dissolving it in a few drops of 1 M 
NaOH and almost making it up to the required volume to which HC1 was added until the 
compound started to precipitate. Finally, one drop of 1 M NaOH was added and the 
solution checked for precipitation of the compound. As a result of the previous studies and 
the nature of the diabetic state in obese Zucker rats, it was decided that animals should be 
fasted for 5 hours prior to experiments.
It is known that the diet fed to obese Zucker rats can affect their diabetic condition 
(Stem et al., 1975) and thus the animals used in these studies had free access to standard 
laboratory rat food (Oxoid rat and mouse breeders diet; H.C. Styles, Bewdley, Worcs. UK; 
see Young et al., 1991) and water.
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5 .3 .2  Phosphorylation o f  a-Gi.2  in lean (Fa/+) and obese (Fa/Fa) Zucker 
rat hepatocytes
Hepatocytes were prepared from lean (Fa/+) and obese (Fa/Fa) Zucker rats as 
described in section 2.2.2 with the changes noted in section 5.3.1. The hepatocytes were 
then labelled with 32P and the phosphorylation experiments carried out as described in 
sections 2.2.3 to 2.2.5.
Two typical autoradiographs of immunoprecipitated a-Gi-2 from hepatocytes of 
lean and obese Zucker rats are shown in figures 5.2 and 5.3. Further analysis of the data 
by Cerenkov counting of the gel chips containing the phosphorylated a-Gi-2 revealed that in 
the lean animals 8-bromo-cAMP (300 pM), PMA (100 ng/ml) and glucagon (10 nM; see 
section 4.1.2) all caused a significant increase in the level of phosphorylation of a-Gi-2 
whilst in the obese animals only 8-bromo-cAMP was effective (see figure 5.4 and table 
5.1). The inclusion of insulin (10 p.M) in the incubation mixture did not result in a 
significant phosphorylation of a-Gi-2 in the lean or the obese animals (see figure 5.4 and 
table 5.1).
However, when insulin was added in conjunction with various ligands it was 
found that insulin significantly inhibited PMA and glucagon stimulation of a-G i-2 
phosphorylation in the lean animals but not 8-bromo-cAMP stimulated, and inhibited 8- 
bromo-cAMP and glucagon stimulated a-Gi-2 phosphorylation in the obese animals but did 
not affect the actions of PMA (see figures 5.5 and table 5.2).
5 .3 .3  Effects o f  chronic dosing o f lean (Fa/+) and obese (Fa/Fa) Zucker 
rats with BRL 49653 on the phosphorylation o f  a - G i .2  in 
hepatocytes
Lean and obese Zucker rats were dosed with BRL 49653 as described in section 
5.3.1. Hepatocytes were then prepared from lean (Fa/+) and obese (Fa/Fa) Zucker rats as 
described in section 2.2.2 with the changes noted in section 5.3.1. The hepatocytes were 
labelled with 32P and the phosphorylation experiments carried out as described in sections
2.2.3 to 2.2.5.
Two typical autoradiographs of immunoprecipitated a-Gi-2 from hepatocytes of 
dosed-lean and dosed-obese Zucker rats are shown in figures 5.6 and 5.7. Further analysis 
of the data by Cerenkov counting of the gel chips containing the phosphorylated a-Gi-2 
revealed that in the dosed-lean animals, 8-bromo-cAMP (300 |xM), and PMA (100 ng/ml; 
see section 4.1.2) both caused a significant increase in the level of phosphorylation of a-Gi. 
2 (see figure 5.8 and table 5.1), whereas glucagon (10 nM; see section 4.1.2) and insulin 
did not have any effect (see figure 5.8 and table 5.1). When these data were compared with 
lean animals that had not been dosed with BRL 49653 it was found that the loss of glucagon 
stimulated phosphorylations of a-Gi-2 was significantly different (see figure 5.8).
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Figure 5.2: A typical auto-radiograph of 32P phosphorylated a-Gi-2 from lean (Fa/+)
Zucker rat hepatocytes that have been challenged with vehicle solution, 
8-bromo-cAMP, PMA, glucagon, insulin, 8-bromo-cAMP and insulin, 
glucagon and insulin, PMA and insulin, and vehicle solution
A typical auto-radiograph of an SDS-PAGE gel containing a-Gi-2 immunoprecipitated from 
lean (Fa/+) Zucker rat hepatocytes that had been labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with vehicle solution (lane 1), 8-bromo-cAMP (lane 2; 300 |xM), 
PMA (lane 3; 100 ng/ml), glucagon (lane 4; 10 nM), insulin (lane 5; 10 jiM), 8-bromo- 
cAMP and insulin (lane 6), glucagon and insulin (lane 7), PMA and insulin (lane 8), and 
vehicle solution (lane 9) for 15 minutes. Where die hepatocytes were challenged with a 
drug and insulin the insulin was added first followed immediately by the drug.

Figure 5.3: A typical auto-radiograph of 32P phosphorylated a-Gi-2 from obese (Fa/Fa)
Zucker rat hepatocytes that have been challenged with vehicle solution, 
8-bromo-cAMP, PMA, glucagon, insulin, 8-bromo-cAMP and insulin, 
glucagon and insulin, PMA and insulin, and vehicle solution
A typical auto-radiograph of an SDS-PAGE gel containing a-Gi-2 immunoprecipitated from 
obese (Fa/Fa) Zucker rat hepatocytes that had been labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with vehicle solution (lane 1), 8-bromo-cAMP (lane 2; 300 pM), 
PMA (lane 3; 100 ng/ml), glucagon (lane 4; 10 nM), insulin (lane 5; 10 pM), 8-bromo- 
cAMP and insulin (lane 6), glucagon and insulin (lane 7), PMA and insulin (lane 8), and 
vehicle solution (lane 9) for 15 minutes. Where the hepatocytes were challenged with a 
drug and insulin the insulin was added first followed immediately by the drug.

Figure 5.4: Percentage phosphorylation of a-Gi-2 in lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes: Effects of 8-bromo-cAMP, PMA, glucagon, and
insulin
Stimulation of a-Gi-2 phosphorylation in lean (Fa/+) and obese (Fa/Fa) Zucker rat 
hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
8-bromo-cAMP (8Br; 8BrcAMP; 300 pM), PMA (100 ng/ml), glucagon (Glue; 10 nM), 
and insulin (Ins; 10 |xM) for 15 minutes. Where the hepatocytes were challenged with a 
ligand and insulin the insulin was added first followed immediately by the ligand. The 
hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The 
proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels 
dried and put down for autoradiography (see section 2.2.5). The level of phosphorylation 
achieved was determined by Cerenkov counting of gel chips that contained phosphorylated
a-Gi-2. The data is expressed as mean ± SEM (n > 4; see table 5.1) where * indicates that 
the data are significantly different (p<0.05) from control (0%) with data tested using a 
single sample Student’s r-test and t  indicates a significant difference between 
phosphorylations in hepatocytes from Fa/+ and Fa/Fa (two sample Student’s r-test where 
p<0.05 was taken as significantly different).
Figure 5.5: Percentage inhibition of ligand induced a-Gi-2 phosphorylation in lean
(Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes: Effects of insulin on 
8 bromo-cAMP, PMA and glucagon induced phosphorylations
Insulin induced inhibition of ligand induced a-Gj-2 phosphorylation in lean (Fa/+) and 
obese (Fa/Fa) Zucker rat hepatocytes labelled with 32P (see sections 2.2.2 and 2.2.3). The 
hepatocytes were challenged with 8-bromo-cAMP (8BrcAMP; 300 pM), PMA (100 ng/ml), 
glucagon (Glue; 10 nM) for 15 minutes in the presence and absence of insulin (Ins; 10 pM). 
The hepatocytes were harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The 
proteins were separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels 
dried and put down for autoradiography (see section 2.2.5). The level of phosphorylation 
achieved was determined by Cerenkov counting of gel chips that contained phosphorylated
a-Gi-2- The data are expressed as mean ± SEM (n > 4; see table 5.2) where * indicates that 
the data are significantly different (p<0.05) from control (ligand in the absence of insulin, 
0%) with data tested using a single sample Student's r-test.
Phosphorylation of alpha-Gi-2 in Zucker
rat hepatocytes140 i
120 -
100 -
80-e
UU4>eu
40-
2 0 -
00
00
Induced inhibition of alpha-Gi-2 phosphorylation 
in Zucker rat hepatocytes
4 0 1
30-
co
2 0 -
10-
- 10 -
-20
8BrcAMP+Ins Gluc+InsPMA+Ins
Fa/+
Fa/Fa
□  Fa/+
□  Fa/Fa
Figure 5.6: A typical auto-radiograph of 32P phosphorylated a-Gi-2 from hepatocytes
from BRL 49653 dosed lean (Fa/+) Zucker rats that have been challenged 
with vehicle solution, 8-bromo-cAMP, PMA, glucagon, insulin, 8-bromo- 
cAMP and insulin, glucagon and insulin, PMA and insulin, and vehicle 
solution
A typical auto-radiograph of an SDS-PAGE gel containing a-Gi-2 immunoprecipitated 
hepatocytes from lean (Fa/+) Zucker rat that had been dosed with BRL 49653. The 
hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle solution (lane 1), 8-bromo-cAMP (lane 2; 300 |xM), PMA (lane 3; 100 ng/ml), 
glucagon (lane 4; 10 nM), insulin (lane 5; 10 pM), 8-bromo-cAMP and insulin (lane 6), 
glucagon and insulin (lane 7), PMA and insulin (lane 8), and vehicle solution (lane 9) for 15 
minutes. Where the hepatocytes were challenged with a drug and insulin, the insulin was 
added first followed immediately by the drug.
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Figure 5.7: A typical auto-radiograph of 32P phosphorylated a-Gi-2 from hepatocytes
from BRL 49653 dosed obese (Fa/Fa) Zucker rats that have been challenged 
with vehicle solution, 8-bromo-cAMP, PMA, glucagon, insulin, 8-bromo- 
cAMP and insulin, glucagon and insulin, PMA and insulin, and vehicle 
solution
A typical auto-radiograph of an SDS-PAGE gel containing a-Gi-2 immunoprecipitated 
hepatocytes from obese (Fa/Fa) Zucker rat that had been dosed with BRL 49653. The 
hepatocytes were labelled with 32P (see sections 2.2.2 and 2.2.3) and then challenged with 
vehicle solution (lane 1), 8-bromo-cAMP (lane 2; 300 |xM), PMA (lane 3; 100 ng/ml), 
glucagon (lane 4; 10 nM), insulin (lane 5; 10 |iM), 8-bromo-cAMP and insulin (lane 6), 
glucagon and insulin (lane 7), PMA and insulin (lane 8), and vehicle solution (lane 9) for 15 
minutes. Where the hepatocytes were challenged with a drug and insulin, the insulin was 
added first followed immediately by the drug.
1 2 3 4 5 6 7 8
■Mi
til -  200
—  68
-  43
-  29
-  18
Chapter 5
Table 5.1: Percentage stimulation of the phosphorylation of a-Gi-2 in lean (Fa/+) and
obese (Fa/Fa) Zucker rat hepatocytes and the effects of BRL 49653.
Mean
Fa/+
SEM n= P= T Mean
Fa/Fa
SEM n= P= T
8BrcAMP 103 25 5 0.016 Y 100 9 5 0.000 Y
PMA 56 14 5 0.017 Y 30 17 5 0.169 N
Glue 40 16 5 0.034 Y -2 25 5 0.945 N
Ins 40 21 5 0.065 N 2 7 5 0.835 N
8Br + Ins 73 23 5 0.037 Y 71 3 5 0.000 Y
PMA + Ins 44 16 5 0.056 N 27 4 5 0.005 Y
Glue + Ins 24 10 5 0.090 N 22 12 5 0.167 N
Fa/+ Dosed Fa/Fa Dosed
Mean SEM n= P= T Mean SEM n= P= T
8BrcAMP 104 19 5 0.006 Y 95 17 4 0.013 Y
PMA 28 8 6 0.021 Y 39 14 5 0.062 N
Glue 8 9 6 0.445 N 27 12 4 0.127 N
Ins 3 6 6 0.620 N 8 8 5 0.406 N
8Br + Ins 75 15 6 0.005 Y 82 18 5 0.012 Y
PMA + Ins 15 18 5 0.466 N 27 5 5 0.011 Y
Glue + Ins 15 8 6 0.114 N 12 4 5 0.051 N
Control was taken as 0% phosphorylation of a-Gi-2- Fa/+ = lean animals; Fa/Fa = obese 
animals; Fa/+ Dosed = Fa/+ animals that had been dosed with BRL 49653; Fa/Fa Dosed = 
Fa/Fa animals that had been dosed with BRL 49653; SEM = standard error of mean; n = 
number of observations; p = significance value returned by single sample Student's r-test; T 
= result of a single sample Student’s r-test where Y = phosphorylation was significantly 
different from control (0%; p<0.05) and N = phosphorylation was not significantly 
different from control (0%; p>0.05); 8Br = 8BrcAMP = 8-bromo-cAMP (300 jjM); PMA = 
Phorbol 12-myristate 13-acetate (100 ng/ml); Glue = Glucagon (10 nM); Ins = Insulin 
(10 jiM).
When the inhibitory effects of insulin on ligand induced phosphorylation of 
a-Gi-2 was examined it was found that insulin (10 jiM) had no effect on the levels of 
phosphorylation induced by 8-bromo-cAMP (300 jxM), PMA (100 ng/ml) or glucagon 
(10 nM; see figures 5.9 and table 5.2). Although these data showed some change from that 
observed in the non-dosed lean the changes that occurred were not significant.
Examination of the data of phosphorylated a-Gi-2 from dosed-obese animals 
showed that 8-bromo-cAMP (300 |xM), and PMA (100 ng/ml) caused a significant increase 
in the level of phosphorylation of a-Gi-2 (see figure 5.10 and table 5.1) whereas glucagon
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(10 nM; see section 4.1.2) and insulin did not (see figure 5.10 and table 5.1). When these 
data were compared with obese animals that had not been dosed with BRL 49653 it was 
found that there was no significant change in the levels of phosphorylation (see figure 
5.10).
When the inhibitory effects of insulin on ligand induced phosphorylation of 
a-Gi_2 in hepatocytes from dosed-obese animals was examined it was found that insulin 
(10 pM) no longer significantly inhibited any ligand induced phosphorylations, and 
although this was a change from the results seen in non-dosed obese animals the change 
was not significant (see figure 5.11 and table 5.2).
5 .3 .4  Two-dimensional phosphopeptide mapping o f  tryptic peptides o f a- 
Gi-2 from  lean (Fa/+) and obese (Fa/Fa) Zucker rats
Hepatocytes from lean and obese Zucker rats were labelled with 32P and
incubated with either vehicle, PMA (100 ng/ml) or 8-bromo-cAMP (300 p,M). The
phosphorylated a-Gj.2 was then collected and treated as outlined in sections 2.2.2 to 2.2.9.
Table 5.2: Percentage inhibition of ligand induced phosphorylation of a-Gi.2 in lean
(Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes by insulin and the effects of BRL 49653 on 
the inhibition.
Mean
Fa/+
SEM n= P= T Mean
Fa/Fa
SEM n= P= T
8Br + Ins 17 7 4 0.109 N 14 2 5 0.006 Y
PMA + Ins 18 5 5 0.026 Y -3 10 5 0.780 N
Glue + Ins 26 6 5 0.013 Y 20 5 3 0.049 Y
Fa/+ Dosed Fa/Fa Dosed
Mean SEM n= P= T Mean SEM n= P= T
8Br + Ins 17 6 5 0.074 N 0 10 4 0.993 N
PMA + Ins 12 12 5 0.401 N 5 7 5 0.534 N
Glue + Ins -10 8 6 0.305 N 10 9 4 0.338 N
Fa/+ = lean animals; Fa/Fa = obese animals; Fa/+ Dosed = Fa/+ animals that had been 
dosed with BRL 49653; Fa/Fa Dosed = Fa/Fa animals that had been dosed with BRL 
49653; SEM = standard error of mean; n = number of observations; p = significance value 
returned by single sample Student's r-test; T = result of a single sample Student's r-test 
where Y = phosphorylation was significantly different from control (0%; p<0.05) and N = 
phosphorylation was not significantly different from control (0%; p>0.05); 8Br = 
8BrcAMP = 8-bromo-cAMP (300 pM); PMA = Phorbol 12-myristate 13-acetate (100 
ng/ml); Glue = Glucagon (10 nM); Ins = Insulin (10 pM).
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Figure 5.8: Percentage phosphorylation of a-Gi_2 in lean (Fa/+) and BRL 49653 dosed
lean (Fa/+) Zucker rat hepatocytes: Effects of 8-bromo-cAMP, PMA,
glucagon, and insulin
Stimulation of a-Gi-2 phosphorylation in 32P labelled hepatocytes (see sections 2.2.2 and
2.2.3) from lean (Fa/+) Zucker rats and lean (Fa/+) Zucker rats that were dosed with BRL 
49653. The hepatocytes were challenged with 8-bromo-cAMP (8Br; 8BrcAMP; 300 pM), 
PMA (100 ng/ml), glucagon (Glue; 10 nM), and insulin (Ins; 10 pM) for 15 minutes. 
Where the hepatocytes were challenged with a ligand and insulin the insulin was added first 
followed immediately by the ligand. The hepatocytes were harvested and a-G i-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2- The data are expressed as mean
± SEM (n > 4; see table 5.1) where * indicates that the data are significantly different 
(p<0.05) from control (0%) with data tested using a single sample Student's r-test and t  
indicates a significant difference between phosphorylations in hepatocytes from Fa/+ and 
Fa/+ drug rats (two sample Student's r-test where p<0.05 was taken as significantly 
different).
Figure 5.9 Percentage inhibition of ligand induced a-Gi-2 phosphorylation in lean 
(Fa/+) and BRL 49653 dosed lean (Fa/+) Zucker rat hepatocytes: Effects of 
insulin on 8-bromo-cAMP, PMA and glucagon induced phosphorylations
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in 32P labelled 
hepatocytes (see sections 2.2.2 and 2.2.3) from lean (Fa/+) Zucker rats and lean (Fa/+) 
Zucker rats that were dosed with BRL 49653. The hepatocytes were challenged with 8- 
bromo-cAMP (8BrcAMP; 300 pM), PMA (100 ng/ml), glucagon (Glue; 10 nM) for 15 
minutes in the presence and absence of insulin (Ins; 10 pM). The hepatocytes were 
harvested and a-Gi-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2- The
data are expressed as mean ± SEM (n ^  4; see table 5.2) where * indicates that the data are 
significantly different (p<0.05) from control (ligand in the absence of insulin, 0%) with data 
tested using a single sample Student's f-test and t  indicates a significant difference between 
phosphorylations in hepatocytes from Fa/+ and Fa/+ drug rats.
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Figure 5.10: Percentage phosphorylation of a-Gi-2 in obese (Fa/Fa) and BRL 49653
dosed obese (Fa/Fa) Zucker rat hepatocytes: Effects of 8-bromo-cAMP,
PMA, glucagon, and insulin
Stimulation of a-Gi-2 phosphorylation in 32P labelled hepatocytes (see sections 2.2.2 and
2.2.3) from obese (Fa/Fa) Zucker rats and obese (Fa/Fa) Zucker rats that were dosed with 
BRL 49653. The hepatocytes were challenged with 8-bromo-cAMP (8Br; 8BrcAMP; 300 
pM), PMA (100 ng/ml), glucagon (Glue; 10 nM), and insulin (Ins; 10 pM) for 15 minutes. 
Where the hepatocytes were challenged with a ligand and insulin the insulin was added first 
followed immediately by the ligand. The hepatocytes were harvested and a-Gi-2 
immunoprecipitated with antiserum 1867. The proteins were separated by SDS-PAGE (see 
sections 2.2.4 and 2.2.5) and the resulting gels dried and put down for autoradiography 
(see section 2.2.5). The level of phosphorylation achieved was determined by Cerenkov 
counting of gel chips that contained phosphorylated a-Gi-2. The data are expressed as mean
± SEM (n > 4; see table 5.1) where * indicates that the data are significantly different 
(p<0.05) from control (0%) with data tested using a single sample Student's r-test and t  
indicates a significant difference between phosphorylations in hepatocytes from Fa/Fa and 
Fa/Fa drug rats (two sample Student’s r-test where p<0.05 was taken as significantly 
different).
Figure 5.11 Percentage inhibition of ligand induced a-Gi-2 phosphorylation in obese 
(Fa/Fa) and BRL 49653 dosed obese (Fa/Fa) Zucker rat hepatocytes: 
Effects of insulin on 8-bromo-cAMP, PMA and glucagon induced 
phosphorylation
Insulin induced inhibition of ligand induced a-Gi-2 phosphorylation in 32P labelled 
hepatocytes (see sections 2.2.2 and 2.2.3) from obese (Fafca) Zucker rats and obese 
(Fa/Fa) Zucker rats that were dosed with BRL 49653. The hepatocytes were challenged 
with 8-bromo-cAMP (8BrcAMP; 300 pM), PMA (100 ng/ml), glucagon (Glue; 10 nM) for 
15 minutes in the presence and absence of insulin (Ins; 10 pM). The hepatocytes were 
harvested and a-G i-2 immunoprecipitated with antiserum 1867. The proteins were 
separated by SDS-PAGE (see sections 2.2.4 and 2.2.5) and the resulting gels dried and put 
down for autoradiography (see section 2.2.5). The level of phosphorylation achieved was 
determined by Cerenkov counting of gel chips that contained phosphorylated a-Gi-2. The
data are expressed as mean ± SEM (n > 4; see table 5.2) where * indicates that the data are 
significandy different (p<0.05) from control (ligand in the absence of insulin, 0%) with data 
tested using a single sample Student’s r-test and t  indicates a significant difference between 
phosphorylations in hepatocytes from Fa/Fa and Fa/Fa drug rats.
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It was found that the trypsin digest of a-Gi-2 derived from hepatocytes from lean 
and obese animals that had been incubated with vehicle or PMA produced phosphopeptides 
that gave a three-spot pattern upon separation (see figures 5.12,5.13, 5.15 and 5.16). The 
phosphopeptides were identified as C l, C2 and C3 (see Chapter 3; see figure 3.16). 
Hepatocytes from lean and obese animals that had been incubated with 8-bromo-cAMP gave 
a four-spot pattern (see figures 5.14 and 5.17) with the phosphopeptides identified as Cl, 
C2, C3 and AN (see Chapter 3; see figure 3.16).
5 .3 .5  Phosphoamino acid analysis o f  ligand stimulated phosphorylation 
o f a-Gi.2  in hepatocytes from lean (Fa/+) Zucker rats
When the hepatocytes were treated with one of 8-bromo-cAMP (300 pM), PMA
(100 ng/ml), or insulin (10 pM) the phosphorylation occurred exclusively on serine residues
(see figure 5.18).
5 .3 .6  Examination o f the levels o f  a-G i .2  expression in lean (Fal+) and 
obese (Fa/Fa) Z ucker rat hepatocytes, m em brane cytosol 
distribution and the effects o f BRL 49653
Hepatocytes from lean and obese Zucker rats were examined by ELISA (see 
section 2.2.16) for the level of a-Gi-2 expression and the distribution of the protein between 
membrane and cytosol fractions (see section 2.2.13). Samples from lean and obese Zucker 
rats that had been dosed with BRL 49653 (see section 5.3.1) were also examined.
It was found that the level of expression of a-Gi-2 per milligram of protein was 
significantly reduced in the obese (Fa/Fa) animals when compared to the non-diabetic lean 
(Fa/+) controls (see table 5.3 and figure 5.19). The effect of BRL 49653 was to decrease 
the level of expression of a-Gi-2 per milligram of protein in the lean animals but did not 
effect the levels in the obese animals (see figure 5.19 and table 5.3).
When the distribution of a-Gi-2 between the membrane and cytosol fractions was 
examined it was found that there was no significant difference in the distribution except in 
the obese animals where significantly more was detected in the membrane (see figure 5.20 
and table 5.4). BRL 49653 had no effect on the distribution of the protein other than to 
abolish the significant distribution in the obese (Fa/Fa) animals but the resulting distribution 
was not significantly different from the non-dosed obese animals.
5 .3 .7  Examination o f  the levels o f  PKC-isoform expression in lean 
(Fa/+) and obese (FalFa) Zucker rat hepatocytes, membrane cytosol 
distribution and the effects o f BRL 49653
Hepatocytes from lean and obese Zucker rats were examined by ELISA (see 
section 2.2.16) for the level of expression of the PKC-isoforms a, (3, 6, e, y, and £. The 
distribution of the proteins between membrane and cytosol fractions (see section 2.2.13),
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Figure 5.12: Phosphopeptide map of a-Gi-2 from lean (Fa/+) Zucker rat hepatocytes
incubated with vehicle solution and then digested with trypsin
Hepatocytes from lean (Fa/+) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with vehicle solution. The hepatocytes were harvested and a- 
Gi-2 immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. The 
protein was recovered from the gel and digested with TPCK-treated trypsin as described in 
experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic phosphopeptides 
were then separated on thin-layer cellulose plates by electrophoresis at pH1.9 and ascending 
chromatography. The final position of DNP-lysine is marked on each plate, SF represents 
the position of the solvent front, origin is the point of application of the sample, (+) and (-) 
indicate the orientation of the electric field, and the bar at the top of the plate indicates the 
separation of the negative, neutral and positive markers. The autoradiograph shows the 
result from a typical experiment where vehicle produced spots C l, C2, and C3. 
Diagrammatic representation of the results is shown in figure 3.16. The experiment was 
performed at least three times with similar results.
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Figure 5.13: Phosphopeptide map of a-Gi-2 from lean (Fa/+) Zucker rat hepatocytes
incubated with PMA and then digested with trypsin
Hepatocytes from lean (Fa/+) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with PMA (100 ng/ml) for 15 minutes. The hepatocytes were 
harvested and a-Gi_2 immunoprecipitated with antiserum 1867 before being subjected to 
SDS-PAGE. The protein was recovered from the gel and digested with TPCK-treated 
trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled 
tryptic phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis 
at pH 1.9 and ascending chromatography. The final position of DNP-lysine is marked on 
each plate, SF represents the position of the solvent front, origin is the point of application 
of the sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top 
of the plate indicates die separation of the negative, neutral and positive markers. The 
autoradiograph shows the result from a typical experiments where PMA produced spots Cl, 
C2, and C3. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
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Figure 5.14: Phosphopeptide map of a-Gi-2 from lean (Fa/+) Zucker rat hepatocytes
incubated with 8-bromo-cAMP and then digested with trypsin
Hepatocytes from lean (Fa/+) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with 300 pM 8-bromo-cAMP for 15 minutes. The hepatocytes 
were harvested and a-Gi-2 immunoprecipitated with antiserum 1867 before being subjected 
to SDS-PAGE. The protein was recovered from the gel and digested with TPCK-treated 
trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled 
tryptic phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis 
at pH 1.9 and ascending chromatography. The final position of DNP-lysine is marked on 
each plate, SF represents the position of the solvent front, origin is the point of application 
of the sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top 
of the plate indicates the separation of the negative, neutral and positive markers. The 
autoradiograph shows the result from typical experiments where 8-bromo-cAMP produced 
spots Cl, C2, C3 and AN. Diagrammatic representation of the results is shown in figure
3.16. The experiment was performed at least three times with similar results.
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Figure 5.15: Phosphopeptide map of a-Gi-2 from obese (Fa/Fa) Zucker rat hepatocytes
incubated with vehicle solution and then digested with trypsin
Hepatocytes from obese (Fa/Fa) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with vehicle solution. The hepatocytes were harvested and 
a-Gi-2 immunoprecipitated with antiserum 1867 before being subjected to SDS-PAGE. 
The protein was recovered from the gel and digested with TPCK-treated trypsin as 
described in experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled tryptic 
phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis at 
pH 1.9 and ascending chromatography. The final position of DNP-lysine is marked on each 
plate, SF represents the position of the solvent front, origin is the point of application of the 
sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top of the 
plate indicates the separation of the negative, neutral and positive markers. The 
autoradiograph shows die result from a typical experiment where vehicle produced spots 
Cl, C2, and C3. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
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Figure 5.16: Phosphopeptide map of a-Gi-2 from obese (Fa/Fa) Zucker rat hepatocytes
incubated with PMA and then digested with trypsin
Hepatocytes from obese (Fa/Fa) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with PMA (100 ng/ml) for 15 minutes. The hepatocytes were 
harvested and a-Gi-2 immunoprecipitated with antiserum 1867 before being subjected to 
SDS-PAGE. The protein was recovered from the gel and digested with TPCK-treated 
trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled 
tryptic phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis 
at pH 1.9 and ascending chromatography. The final position of DNP-lysine is marked on 
each plate, SF represents the position of the solvent front, origin is the point of application 
of the sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top 
of the plate indicates the separation of the negative, neutral and positive markers. The 
autoradiograph shows the result from a typical experiments where PMA produced spots Cl, 
C2, and C3. Diagrammatic representation of the results is shown in figure 3.16. The 
experiment was performed at least three times with similar results.
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Figure 5.17: Phosphopeptide map of a-Gi-2 from obese (Fa/Fa) Zucker rat hepatocytes
incubated with 8-bromo-cAMP and then digested with trypsin
Hepatocytes from obese (Fa/Fa) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with 300 pM 8-bromo-cAMP for 15 minutes. The hepatocytes 
were harvested and a-Gi-2 immunoprecipitated with antiserum 1867 before being subjected 
to SDS-PAGE. The protein was recovered from the gel and digested with TPCK-treated 
trypsin as described in experimental procedures (see sections 2.2.4 - 2.2.9). 32P-labelled 
tryptic phosphopeptides were then separated on thin-layer cellulose plates by electrophoresis 
at pH1.9 and ascending chromatography. The final position of DNP-lysine is marked on 
each plate, SF represents the position of the solvent front, origin is the point of application 
of the sample, (+) and (-) indicate the orientation of the electric field, and the bar at the top 
of the plate indicates the separation of the negative, neutral and positive markers. The 
autoradiograph shows the result from typical experiments where 8-bromo-cAMP produced 
spots Cl, C2, C3 and AN. Diagrammatic representation of the results is shown in figure
3.16. The experiment was performed at least three times with similar results.
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Figure 5.18: Phosphoamino acid analysis of phosphorylated a-Gi-2 from lean (Fa/+)
Zucker rat hepatocytes incubated with 8-bromo-cAMP, PMA and insulin
Hepatocytes from lean (Fa/+) Zucker rats were labelled with 32P (see sections 2.2.2 and
2.2.3) and then challenged with 8-bromo-cAMP (300 pM), PMA (100 ng/ml) and insulin 
(10 pM) for 15 minutes. The hepatocytes were harvested and a-Gi-2 immunoprecipitated 
with antiserum 1867 before being subjected to SDS-PAGE. The protein was recovered 
from the gel and a-Gi-2 from hepatocytes that had been incubated with 8-bromo-cAMP, 
PMA, glucagon and insulin were used for phospho-amino acid analysis as outlined in 
section 2.2.11). The 8-bromo-cAMP sample was applied to position 1, PMA sample to 
position 2, and insulin sample to position 3. The plate was run at pH1.9 in the first 
dimension and rotated 90° anti-clockwise before being run in the second dimension. Pj 
represents phosphate liberated from the peptide as a result of hydrolysis. P-Ser, P-Thr, and 
P-Tyr represent the final position of the applied standards phosphoserine, phosphothreonine 
and phosphotyrosine (see section 2.2.11 and figure 2.2). As can be seen all the samples 
produced phosphoserine therefore confirming that the phosphorylation sites are serines.
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Figure 5.19: Level of a-Gi-2 present in hepatocytes from lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
levels of a-Gi-2 in whole cells. The experiments were also carried out on hepatocytes from 
Zucker rats that had been given BRL 49653 (Fa/+ drug, Fa/Fa drug). The detection 
procedure used was an ELISA with constant protein loading per well, and antiserum 1867 
used as the primary antibody (see section 2.2.16). All experiments were carried out in 
quadruplicate with hepatocytes derived from a minimum of three different animals. Results 
are expressed as mean ± SEM. * denotes significant difference (two sample Student's r-test; 
p<0.05) between the sample and control (Fa/+).
Figure 5.20: Membrane and cytosol distribution of a-Gi-2 in Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
distribution of a-Gi-2 between the membrane and the cytosol fractions (see section 2.2.13). 
The experiments were also carried out on membrane and cytosol samples from Zucker rats 
that had been given BRL 49653 (Fa/+ drug and Fa/Fa drug). The detection procedure used 
was an ELISA with constant protein loading per well, and antiserum 1867 used as the 
primary antibody (see section 2.2.16). All experiments were carried out in quadruplicate 
with hepatocytes derived from a minimum of three different animals and the results are 
expressed as percentage distribution between the two pools. Results are shown as mean ± 
SEM. * denotes significant difference (two sample Student's r-test; p<0.05) between 
cytosol and membrane samples.
Pe
rc
en
t 
Pe
rc
en
t
Levels of alpha Gi-2 present in hepatocytes from Fa/+ 
and Fa/Fa Zucker rats
120 -i Effects of BRL 49653
100 -
80-
60-
40-
2 0 -
Fa/+ Fa/Fa Fa/+ drug Fa/Fa drug
Membrane /  cytosol distribution of alpha-Gi-2 in 
Zucker rat hepatocytes
Effects of BRL 49653
70 “I
60-
50-
4 0 “
30"
2 0 "
10-
Fa/+ Fa/+ Drug Fa/Fa DrugFa/Fa
Membra
Cytosol
Chapter 5
Table 5.3: Summary of ELISA results for the detection of a-Gi-2 and PKC-isoforms in
whole cell preparations of hepatocytes from lean (Fa/+) and obese (Fa/Fa) Zucker rats, and 
the effects of BRL 49653.
Fa/+ Fa/Fa Fa/+drug Fa/Fa drug
a-Gi-2 - 1 1 *
a-PKC NSB NSB NSB NSB
p-PKC NSB NSB NSB NSB
8-PKC - - T T
e-PKC - - T -
y-PKC - - T T
C-PKC - - - -
Fa/+ = lean Zucker rats; Fa/Fa = obese Zucker rats; Fa/+ drug = Fa/+ Zucker rats that have 
been dosed with BRL 49653; Fa/Fa drug = Fa/Fa Zucker rats that have been dosed with 
BRL 49653; - = no change, or for Fa/+ control levels of the protein; "i" = a significant 
decrease in expression of the protein (Fa/Fa compared with Fa/+ and drugged samples 
compared with equivalent non-drugged by two sample Student's r-test where p<0.05 was 
taken as significantly different); NSB = non-specific binding; " T "  = increase in protein 
expression over respective control (Fa/Fa compared to Fa/+; Fa/+ drug to Fa/+; and Fa/Fa 
drug to Fa/Fa by two sample Student's f-test where p<0.05 was taken as significantly 
different) * although sample, Fa/Fa drug, is not significantly different from its control 
(Fa/Fa) the level of a-Gi_2 is still significantly different from Fa/+.
and samples from lean and obese Zucker rats that had been dosed with BRL 49653 (see 
section 5.3.1), were also examined.
The antisera used in the study were raised at the laboratory by Gary Sweeney and 
had proved specific for their respective PKC-isoforms in peptide competition studies in 
Western blotting. It was found that the antisera used for the detection of the PKC-isoforms 
a  and p gave high levels of non-specific binding in ELISAs and so no results were achieved 
for these isoforms. All the other antisera used gave specific responses.
It was found that the level of expression of 8-PKC per milligram of protein was 
the same in lean (Fa/+) and obese (Fa/Fa) animals (see table 5.3 and figure 5.21) and that 
BRL 49653 significantly increased the level of expression of 8-PKC per milligram of 
protein in the lean and obese animals (see figure 5.21 and table 5.3).
When the distribution of 8-PKC between the membrane and cytosol fractions was 
examined it was found that there was a significant difference with more being found in the 
membranes of lean and obese animals, although obesity did not significantly effect the 
distribution (see table 5.4 and figure 5.22). BRL 49653 had no effect on the distribution of 
the protein in the obese (Fa/Fa) animals but did make the distribution in the lean animals no
232
Figure 5.21: Level of 5-PKC present in hepatocytes from lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
levels of 5-PKC in whole cells. The experiments were also carried out on hepatocytes from 
Zucker rats that had been given BRL 49653 (Fa/+ drug, Fa/Fa drug). The detection 
procedure used was an ELISA with constant protein loading per well, and an antiserum 
specific for 8-PKC which was produced in the laboratory (see section 2.2.16). All 
experiments were carried out in quadruplicate with hepatocytes derived from a minimum of 
three different animals. Results are expressed as mean ± SEM. * denotes significant 
difference (two sample Student's r-test; p<0.05) between the sample and control (Fa/+).
Figure 5.22: Membrane and cytosol distribution of 5-PKC in Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
distribution of 8-PKC between the membrane and the cytosol fractions (see section 2.2.13). 
The experiments were also carried out on membrane and cytosol samples from Zucker rats 
that had been given BRL 49653 (Fa/+ drug and Fa/Fa drug). The detection procedure used 
was an ELISA with constant protein loading per well, and an antiserum specific for 8-PKC 
which was produced in the laboratory (see section 2.2.16). All experiments were carried 
out in quadruplicate with hepatocytes derived from a minimum of three different animals 
and the results are expressed as percentage distribution between the two pools. Results are 
shown as mean ± SEM. * denotes significant difference (two sample Student's r-test; 
p<0.05) between cytosol and membrane samples.
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longer significantly different, although the resulting change was not significantly different 
when compared to the non-dosed animals.
The level of expression of e-PKC per milligram of protein was the same in lean 
(Fa/+) and obese (Fa/Fa) animals (see table 5.3 and figure 5.23) and BRL 49653 
significantly increased the level of expression of e-PKC per milligram of protein in the lean 
but not the obese animals (see figure 5.23 and table 5.3).
When the distribution of e-PKC between the membrane and cytosol fractions was 
examined it was found that there was a significant difference with more being found in the 
membranes of lean and obese animals than the cytosol and that obesity significantly affected 
this distribution (see table 5.4 and figure 5.24). BRL 49653 abolished the significantly 
different distributions in both the lean and the obese animals, although the resulting change 
was not significantly different when compared to the non-dosed animals (see table 5.4 and 
figure 5.24).
Table 5.4: Cellular distribution of a-Gi-2 and PKC-isoforms in lean (Fa/+) and obese
(Fa/Fa) Zucker rat hepatocytes and the effects of BRL 49653.
Fa/+ Fa/Fa Fa/+ drug Fa/Fa drug 
Mem Cyto Mem Cyto Mem Cyto Mem Cyto
a-Gi-2
a-PKC NSB NSB NSB- NSB NSB NSB NSB NSB
p-PKC NSB NSB NSB NSB NSB NSB NSB NSB
8-PKC + - + - =t =t + -
e-PKC +* * +* * =t =t =t =t
y-PKC = = = = = = -t +t
C-PKC + - + - + - + -
Fa/+ = lean Zucker rats; Fa/Fa = obese Zucker rats; Fa/+ drug = Fa/+ Zucker rats that have 
been dosed with BRL 49653; Fa/Fa drug = Fa/Fa Zucker rats that have been dosed with 
BRL 49653; Mem = membrane samples; Cyto = cytosol samples; "=" = equivalent levels of 
expression in membrane and cytosol samples; + and - show significant distribution of the 
protein between membrane and cytosol (two sample Student's r-test, significantly different 
if p<0.05); +* and -* indicates that there is a significant difference between membrane and 
cytosol levels of the protein and that there is also a significant difference in the levels 
detected between Fa/+ and Fa/Fa samples (two sample Student's r-test, significantly 
different if p<0.05); t  = although there has been a change it is not significantly different 
from the levels found in the control (two sample Student's r-test, significantly different if 
p<0.05); NSB = non-specific binding.
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Figure 5.23: Level of e-PKC present in hepatocytes from lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
levels of e-PKC in whole cells. The experiments were also carried out on hepatocytes from 
Zucker rats that had been given BRL 49653 (Fa/+ drug, Fa/Fa drug). The detection 
procedure used was an ELISA with constant protein loading per well, and an antiserum 
specific for e-PKC which was produced in the laboratory (see section 2.2.16). All 
experiments were carried out in quadruplicate with hepatocytes derived from a minimum of 
three different animals. Results are expressed as mean ± SEM. * denotes significant 
difference (two sample Student's r-test; p<0.05) between the sample and control (Fa/+).
Figure 5.24: Membrane and cytosol distribution of e-PKC in Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
distribution of e-PKC between the membrane and the cytosol fractions (see section 2.2.13). 
The experiments were also carried out on membrane and cytosol samples from Zucker rats 
that had been given BRL 49653 (Fa/+ drug and Fa/Fa drug). The detection procedure used 
was an ELISA with constant protein loading per well, and an antiserum specific for e-PKC 
which was produced in the laboratory (see section 2.2.16). All experiments were carried 
out in quadruplicate with hepatocytes derived from a minimum of three different animals 
and the results are expressed as percentage distribution between the two pools. Results are 
shown as mean ± SEM. * denotes significant difference (two sample Student's r-test; 
p<0.05) between cytosol and membrane samples.
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The level of expression of y-PKC per milligram of protein was the same in lean 
(Fa/+) and obese (Fa/Fa) animals (see table 5.3 and figure 5.25) and BRL 49653 
significantly increased the level of expression of y-PKC per milligram of protein in the lean 
and the obese animals (see figure 5.25 and table 5.3).
When the distribution of y-PKC between the membrane and cytosol fractions was 
examined it was found that there was no significant difference in the distribution of the 
protein in any of the samples other than in the dosed-obese animals where significantly 
more was found in the cytosol (see table 5.4 and figure 5.26).
The level of expression of £-PKC per milligram of protein was the same in lean 
(Fa/+) and obese (Fa/Fa), and dosed-lean and dosed-obese animals (see table 5.3 and figure 
5.27).
When the distribution of £-PKC between the membrane and cytosol fractions was 
examined it was found that there was significandy more £-PKC in the membrane and that 
dosing with BRL 49653 had no effect (see figure 5.28 and table 5.4).
5 .4  D iscussion
As discussed in Chapters 3 and 4, a-Gi-2 from Sprague Dawley rat hepatocytes 
undergoes ligand stimulated and inhibited phosphorylations and these phosphorylations 
occur at multiple sites on the protein. It was also found that the induction of type I diabetes 
with streptozotocin caused a change in the phosphorylation characteristics of the protein.
The work carried out in this chapter was to examine whether a-G i-2 in 
hepatocytes derived from lean (Fa/+) and obese (Fa/Fa) Zucker rats also underwent 
phosphorylation and if the diabetic state of the obese Zuckers affected these events.
It was found that a-Gi-2 from lean Zucker rats did indeed undergo ligand induced 
phosphorylation by 8-bromo-cAMP (300 pM), PMA (100 ng/ml), glucagon (10 nM) and 
insulin (10 pM; see section 5.3.2, figure 5.4 and table 5.1). However, in hepatocytes from 
the obese animals only 8-bromo-cAMP (300 pM) and PMA (100 ng/ml) were able to affect 
significantly the levels of phosphorylation (see section 5.3.2, figure 5.4 and table 5.1).
The work of Bushfield et al. (1990c) has suggested that a-Gi-2 from obese 
Zucker rats was unable to undergo ligand induced phosphorylation as the protein was 
already fully phosphorylated under basal conditions and this level of phosphorylation 
explained the loss of Gi inhibition of adenylyl cyclase (Bushfield et al., 1990c). The results 
presented above for the 8-bromo-cAMP induced phosphorylations of a-Gi-2 are clearly in 
disagreement with these findings and no explanation can be offered.
The finding that glucagon stimulated phosphorylation of a-Gi-2 in the obese 
animals was no longer significantly different from control (see section 5.3.2, figure 5.4 and 
table 5.1) was in agreement with the general findings of Bushfield et al. (1990c), although 
they did not test glucagon. The change observed in the glucagon stimulation of
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Figure 5.25: Level of y-PKC present in hepatocytes from lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
levels of y-PKC in whole cells. The experiments were also carried out on hepatocytes from 
Zucker rats that had been given BRL 49653 (Fa/+ drug, Fa/Fa drug). The detection 
procedure used was an ELISA with constant protein loading per well, and an antiserum 
specific for y-PKC which was produced in the laboratory (see section 2.2.16). All 
experiments were carried out in quadruplicate with hepatocytes derived from a minimum of 
three different animals. Results are expressed as mean ± SEM. * denotes significant 
difference (two sample Student's r-test; p<0.05) between the sample and control (Fa/+).
Figure 5.26: Membrane and cytosol distribution of y-PKC in Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
distribution of y-PKC between the membrane and the cytosol fractions (see section 2.2.13). 
The experiments were also carried out on membrane and cytosol samples from Zucker rats 
that had been given BRL 49653 (Fa/+ drug and Fa/Fa drug). The detection procedure used 
was an ELISA with constant protein loading per well, and an antiserum specific for y-PKC 
which was produced in the laboratory (see section 2.2.16). All experiments were carried 
out in quadruplicate with hepatocytes derived from a minimum of three different animals 
and the results are expressed as percentage distribution between the two pools. Results are 
shown as mean ± SEM. * denotes significant difference (two sample Student's r-test; 
p<0.05) between cytosol and membrane samples.
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Figure 5.27: Level of £-PKC present in hepatocytes from lean (Fa/+) and obese (Fa/Fa)
Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
levels of £-PKC in whole cells. The experiments were also carried out on hepatocytes from 
Zucker rats that had been given BRL 49653 (Fa/+ drug, Fa/Fa drug). The detection 
procedure used was an ELISA with constant protein loading per well, and an antiserum 
specific for £-PKC which was produced in the laboratory (see section 2.2.16). All 
experiments were carried out in quadruplicate with hepatocytes derived from a minimum of 
three different animals. Results are expressed as mean ± SEM. * denotes significant 
difference (two sample Student's r-test; p<0.05) between the sample and control (Fa/+).
Figure 5.28: Membrane and cytosol distribution of £-PKC in Zucker rat hepatocytes
Samples from lean (Fa/+) and obese (Fa/Fa) Zucker rat hepatocytes were examined for the 
distribution of £-PKC between the membrane and the cytosol fractions (see section 2.2.13). 
The experiments were also carried out on membrane and cytosol samples from Zucker rats 
that had been given BRL 49653 (Fa/+ drug and Fa/Fa drug). The detection procedure used 
was an ELISA with constant protein loading per well, and an antiserum specific for £-PKC 
which was produced in the laboratory (see section 2.2.16). All experiments were carried 
out in quadruplicate with hepatocytes derived from a minimum of three different animals 
and the results are expressed as percentage distribution between the two pools. Results are 
shown as mean ± SEM. * denotes significant difference (two sample Student's r-test; 
p<0.05) between cytosol and membrane samples.
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phosphorylation between the lean and the obese animals was not significant and so no real 
importance can be attached to this finding. This again adds weight to the idea that the 
dysfunction that was occurring was in some way related to a PKC isoform as it has been 
shown that glucagon can stimulate both PKC and PKA (Tang & Houslay, 1992) and if part 
of the dysfunction that occurs in type II diabetes was in the activation of a PKC-isoform 
then a reduction in the phosphorylation of a-Gj-2 may be expected but this would be 
partially masked by the activation of PKA. Alternatively, as discussed for streptozotocin- 
induced diabetes (see Chapter 4), a-Gi-2 may have already been phosphorylated possibley 
as a result of the hyperinsulinaemic condition of the animals and hence further 
phosphorylation was not possible.
Examination of the level of expression of a-Gi-2 per milligram of protein in lean 
and obese Zucker rats by ELISA (see section 5.3.6, figure 5.19 and table 5.3) showed that 
the hepatocytes of obese animals contained significantly less a-Gi-2 than those from the 
lean. Indeed, it was also found that there was significantly more a-Gi-2 hi the membranes 
of obese animals (see section 5.3.6, table 5.5 and figure 5.20). The decrease in the level of 
expression of a-Gi-2 does not affect the comparison of the phosphorylation results between 
the lean and obese animals as the data in the phosphorylation experiments were normalised 
to control, unstimulated, hepatocytes. What this result may indicate is that the increase in 
basal phosphorylation observed in the hepatocytes (Bushfield et al.y 1990c) may not reflect 
an increase in kinase activity but a decrease in the level of available substrate, that is a-Gi-2. 
In addition, the loss of Gi inhibition of adenylyl cyclase action may be because of the 
decreased level of a -G i-2 expression and not as a result of deactivation due to 
phosphorylation.
As the level of a-Gi-2 present was compared between lean and obese animals in 
terms of milligrams of protein then the decrease in a-Gi-2 expression in the obese animals 
may not have occurred if the overall protein content has increased. As the obese animals are 
hyperinsulinaemic (see section 5.1.1) and insulin can stimulate protein synthesis (see 
section 1.4 and table 1.3; see Hollenberg & Jacobs, 1990) then the decrease in a-Gi-2 per 
milligram of protein may be as a result of the stimulation of the synthesis of some other 
proteins. This idea seems unlikely as no increase in protein synthesis has been reported in 
the obese Zucker rats, and as the animals also display insulin resistance (see section 5.1.1) 
then the increased levels of insulin may not be able to stimulate protein synthesis.
From the analysis of tryptic phosphopeptides of a-Gi-2 it was shown that the 
stimulation of phosphorylation by PMA and 8-bromo-cAMP in the hepatocytes from lean 
and obese Zucker rats produced the same peptides, and that these could be identified as Cl, 
C2 and C3 for PMA and vehicle, and Cl, C2, C3 and AN for 8-bromo-cAMP (see section
5.3.4, figures 5.12 to 5.17; see Chapter 3 for the identification of peptides). These are the 
same peptides as produced from ligand stimulated phosphorylations of a-Gi-2 Sprague 
Dawley rat hepatocytes and therefore the PKC-mediated and PKA-dependent
243
Chapter 5
phosphorylation is occurring in Zucker rats is occurring at presumably identical sites (see 
Chapter 3 and section 3.4). This also indicates that the same a-Gi-2 phosphorylation 
system is in operation in the Zucker rats and hence a-Gi-2 is most probably at the centre of a 
futile phosphorylation / dephosphorylation cycle (see Houslay, 1991b).
In Sprague Dawley rat hepatocytes it was demonstrated that insulin caused the 
inhibition of ligand induced phosphorylation of a-Gi-2 (see Chapter 4). Examination of this 
effect in Zucker rats revealed that insulin caused a significant inhibition of PMA and 
glucagon-stimulated phosphorylations in hepatocytes from lean animals and 8-bromo-cAMP 
and glucagon-stimulated phosphorylation in the obese animals (see section 5.3.2, figure 5.5 
and table 5.2). The ability of insulin to inhibit glucagon-stimulated a-Gi-2 phosphorylation 
in the lean and the obese animals suggested that although insulin-resistance can be detected 
in the obese animals the resistance does not effect insulin's actions on a -G i-2 
phosphorylation which in turn may indicate that a-Gi-2 is not involved in the insulin 
signalling that affects glucose metabolism.
The expression of PKC isoforms has been examined in hepatocytes from 
Sprague Dawley rats that have had type I diabetes induced by streptozotocin (Tang et al., 
1993). From these studies it was found that only a, pH, e and £ isoforms were present in 
the hepatocytes of untreated animals, and pi, y, 8 and r| were not, and the induction of 
diabetes caused an increase in the expression of pn in the cytoplasm and membrane, and an 
increase of e in the membrane (Tang et al., 1993). Hence it was possible that some of the 
changes in the phosphorylation characteristics of a-Gi-2 observed between the lean and 
obese Zucker rats may be explained in terms of different levels of expression or distribution 
of the PKC isoforms. In order to address this the levels of expression and the distribution 
between membrane and cytosol fractions of some of the PKC-isoforms were examined by 
ELISA using antisera raised in the laboratory (see section 5.3.7). This was set up as a 
preliminary study with the realisation that the work would have to be fully quantified by 
Western blotting. From this work it became apparent that no results could be achieved for a  
and p PKC-isoforms as the antisera displayed a high level of non-specific binding to the 
ELISA plates (see table 5.4). This was disappointing as p-PKC expression had already 
been shown to change in a type I model of diabetes and may therefore play a significant role 
in insulin signalling (Tang et al., 1993). The antisera for 8 , e, y and £ isoforms of PKC 
demonstrated specific binding and the results showed that there was no difference in the 
level of expression, per milligram of protein, of any of the isoforms in the lean or the obese 
rats (see section 5.3.7, table 5.3 and figures 5.21, 5.23, 5.25, and 5.27). These results 
differ from the work of Tang et al. (Tang et al., 1993) in that 8 and y PKC were not detected 
in Sprague Dawley rat hepatocytes and the level of e-PKC expression had increased upon 
the induction of type I diabetes.
When the distribution between membrane and cytosolic fractions was examined it 
was found that significantly more 8, e and £ PKC was in the membrane fraction of the lean
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animals and that this distribution was only affected for e-PKC in obese animals where the 
kinase had translocated from the membrane to the cytosol. These result suggested that 
e-PKC may play some role in insulin signal transduction as this isoform has been implicated 
in a type I model (hypoinsulinaemic), where increased expression in the membrane was 
found (Tang et al., 1993; see section 5.3.7, table 5.4 and figures 5.22, 5.24, 5.26, and 
5.28).
As discussed in section 5.1.2, BRL 49653 has a potential use in the treatment of 
type II, insulin-independent, diabetes. The use of this compound in these studies served 
two main functions. First, the mode of action of the drug is unknown and it was thought 
that experiments examining the effect of the drug on the phosphorylation, expression and 
distribution of a-Gi-2 and also any effects on PKC distribution and expression, in lean and 
obese Zucker rats may indicate a method of action; and second, the compound already has 
recognised beneficial effects in the Zucker rat model of diabetes such as reducing 
hyperinsulinaemia and restoring insulin sensitivity, so it was therefore thought its use may 
aid the understanding of how insulin effects the phosphorylation of a-Gi-2.
When the effects of chronic dosing of BRL 49653 on a-Gi-2 expression, and 
phosphorylation, in hepatocytes from lean Zucker rats was examined it was found that the 
compound significantly reduced the level of expression to that found in the obese animals 
and the phosphorylation characteristic now resembled those in the obese animals. It was 
found that glucagon- and insulin-stimulated phosphorylations were no longer significantly 
different from control and that the resulting level of phosphorylation was significantly 
different from non-dosed lean animals (see sections 5.3.3 and 5.3.6, figures 5.8 and 5.19 
and tables 5.1 and 5.3). When the inhibitory effects of insulin on ligand induced 
phosphorylation of a-Gi-2 was examined it was found that insulin was now only able to 
significantly inhibit 8-bromo-cAMP stimulated phosphorylation, was no longer able to 
inhibit PMA induced phosphorylation although the change was not significantly different, 
and was no longer able to inhibit glucagon stimulated phosphorylation and in this case the 
change was significantly different (see section 5.3.3, figure 5.9 and table 5.2). 
Comparisons of the distribution of a-Gi-2 between the membrane and cytosolic fractions of 
hepatocytes from lean rats showed that the compound had no effect.
In the obese animals it was found that the chronic dosing with the compound had 
no effect on the expression of a-Gi-2 (see section 5.3.6, figure 5.19 and table 5.3) but it did 
abolish the significant membrane / cytosol distribution of a-Gi-2 (see section 5.3.6, figure 
5.20 and table 5.4). The chronic dosing with compound did not have any significant effect 
on the phosphorylation characteristics of a-Gi-2 (see section 5.3.3, figures 5.10 and 5.11, 
and tables 5.1 and 5.2).
The effect of BRL 49653 on the expression and cellular distribution of PKC 
isoforms was limited. The only significant effects produced were increased expressions of 
5-PKC and y-PKC in both the lean and obese animals and of e-PKC in lean. The
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compound had no effect on the membrane /  cytosol distribution of the PKC isoforms in the 
cell (see section 5.3.7, tables 5.3 and 5.4, and figures 5.21 to 5.28).
From the results presented it appears that BRL 49653 may be producing its 
effects by either deactivating an isoform of PKC or activating a phosphatase. This idea is 
supported by the observation that, except for the change in the insulin-mediated inhibition of 
8-bromo-cAMP stimulated phosphorylation of a-Gi-2 in obese Zuckers, the compound only 
seems to affect phosphorylation events where PKC activation is involved. What the results 
do show is that as BRL 49653 is able to improve insulin sensitivity and therefore reduce 
hyperinsulinaemia and improve glucose tolerance in the obese animals and that the function 
of insulin mediated effects on the phosphorylation of a-Gi-2 must not be connected with 
glucose homeostasis but with some other element of insulin signalling. In addition, as the 
obese Zucker rat is insulin-resistant and it can be shown that insulin can effect the ligand 
induced phosphorylation of a-Gi-2 when the cAMP-dependent phosphorylation event is 
activated, then insulin must still be able to effect cAMP mediated events, again this points to 
some dysfunction in the PKC-dependent pathway which may be associated with insulin 
signalling and glucose homeostasis.
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General conclusions
A growing body of evidence is accumulating which suggests that the 
phosphorylation of heterotrimeric G-proteins (see section 1.2.2) occurs and that it may play 
a role in regulating the function of these key signalling proteins. In particular, in vivo 
phosphorylation has been reported for a-Gi (isoform not identified), a-Gi-2 and a-Gz in 
platelets and hepatocytes (Bushfield et al., 1991; Bushfield et al., 1990b; Carlson et a l, 
1989; Lounsbury et a l, 1991; Lounsbury et a l, 1993; Pyne et a l, 1989b) and also for a- 
Gs in vitro (Pyne et a l, 1992). Indeed, in the hepatocytes it has been shown that the 
phosphorylation of a-Gi-2 causes a deactivation of the tonic GTP-mediated inhibitory 
function of this protein but not receptor-mediated Gi inhibition of adenylyl cyclase 
(Bushfield et a l, 1991; Bushfield et a l, 1990b; Pyne et a l, 1989b). In vitro studies of 
heterotrimeric G-protein phosphorylation have shown that the phosphorylation causes a 
decrease in the GTPase activity of the protein and it may be this that causes the change in the 
G-protein activity (Sauvage e ta l, 1991).
Prior to this work it had been shown that the phosphorylation of a-Gi-2 occurred 
in hepatocytes and it had been suggested that this may occur at two different sites (Bushfield 
et a l, 1990; Bushfield et a l, 1990; Bushfield et a l, 1991) one of which was PKC- 
mediated and the other as a result of increased intracellular cAMP levels. In these studies it 
was definitely shown to be the case with PKC-mediated phosphorylation occurring at one 
site and a second cAMP-dependent phosphorylation occurring at a second, unidentified site.
Work by Bushfield et a l  (1991) demonstrated that a-Gi-2 was at the centre of a 
futile cycle of phosphorylation and dephosphorylation. The work presented in this thesis 
has added further details to this cycle and it was shown that the cycle occurred both at the 
PKC site and the cAMP-dependent site. The cAMP-dependent phosphorylation of a-Gi-2 
also occurred when the cAMP system was not being directly stimulated, that is when either 
the degradation of cAMP, or the dephosphorylation of a-Gi-2, was inhibited then the 
phosphopeptides maps contained the cAMP-dependent phosphopeptide AN (see Chapter 4). 
This showed that the phosphorylation of a-Gi-2 is in a state of dynamic flux which has the 
advantage that the level of phosphorylation of the protein can be rapidly changed and 
therefore affect whether the protein is active, and hence possibly affect adenylyl cyclase 
activity or some other cellular event
The phosphorylation of a-Gi-2 by PKC, which is activated by DAG which is 
produced as part of the inositol phosphate signal transduction system (see sections 1.2.3.2 
and 1.2.4.2), may represent another example of cross-talk (see section 1.2.3.3) between the 
signal transduction systems if a-Gi-2 is involved in the inhibition of adenylyl cyclase. The 
result of this phosphorylation would be a reduction in the inhibition of adenylyl cyclase and
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this would have two effects. First, is that basal levels of cAMP may increase and second, 
and possibly more importantly, the removal of the tonic inhibition would mean that the 
cAMP generating system was sensitised and so able to respond to cAMP generating signals 
more quickly. Indeed if a-Gi-2 serves to elicit actions other than the inhibition of adenylyl 
cyclase activity but some other component of cellular signalling then the result of the 
phosphorylation may act to sensitise or desensitise the signalling pathway.
Two of the major hormones responsible for altering hepatocytes functions are 
glucagon and insulin (see sections 4.1.2 and 1.4.1). It had already been demonstrated that 
glucagon caused an increase in the level of phosphorylation of a-Gi-2 and these findings 
were confirmed in this study (Bushfield et al.y 1990b). However, in hepatocytes from 
normal, non-diabetic, Sprague Dawley rats insulin caused a time and dose-dependent 
inhibition of basal phosphorylation but was unable to inhibit 8-bromo-cAMP or PMA 
induced phosphorylation. Interestingly, insulin caused an enhancement of the level of 
phosphorylation produced by glucagon (see Chapter 4). The method by which insulin was 
effecting such a control over the a-Gi-2 futile phosphorylation /  dephosphorylation cycle 
was not fully resolved but the data did indicate that insulin may be affecting the cycle at 
more than one point (see Chapter 4), that is, affecting both phosphorylation and 
dephosphorylation. This is not unusual for insulin as it has already been shown to stimulate 
both kinases and phosphatases (see section 1.4.3.1; see Avurch et al.y 1990; Dent et al., 
1990)
Insulin causes the inhibition of glucose release and a stimulation of the storage of 
glucose as glycogen and glucagon effectively reverses this process. The effects of glucagon 
are generated mainly through cAMP dependent mechanisms, although it has also been 
shown to stimulate PKC activity (Tang & Houslay, 1992; see sections 1.2.4.2 and 4.1.2). 
As glucagon and insulin have an antagonistic relationship in glucose homeostasis then the 
effects of one compound may also act to inhibit signal transduction systems controlled by 
the other and this is effectively what is happening in the glucagon and insulin mediated 
effects on a-Gi-2 phosphorylation, that is glucagon caused the phosphorylation of a-Gi-2 
whilst insulin caused a dephosphorylation.
Recently another hormone, amylin, has been implicated in the regulation of 
glucose metabolism (see section 4.1.2). It has been suggested that amylin attenuates the 
actions of insulin (see Rink et al.t 1993; Westermark et a l, 1992) and here it was found that 
amylin increased basal levels of a-Gi-2 phosphorylation and blocked insulin's action in the 
inhibition a-Gi-2 phosphorylation. The role of amylin in diabetes and glucose metabolism 
is starting to attract attention and it may be found that in the treatment of type I (insulin- 
dependent diabetes) that amylin should also be administered (see Rink et al.t 1993; 
Westermark et al., 1992). From the results presented it is clear the amylin does effect the 
phosphorylation of a-Gi-2, although at rather high (10-5 M) concentrations, and thus may
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play some role in modulating the signal transduction systems in hepatocytes (see 
Chapter 4).
From the work in Chapter 3 it was found that the phosphorylation of a-Gi-2 
always occurred on serine and that compounds that stimulated PKC activity caused the 
production of three phosphopeptides on trypsin digestion, namely C l, C2 and C3 (see 
section 3.3.2 and figures 3.5, 3.6 and 3.16), whilst agents that stimulated the cAMP- 
pathway produced four phosphopeptides, Cl, C2, C3 and AN (see sections 3.3.2 and
4.3.5, and figures 3.7, and 4.23 to 4.31). Although the ligands that stimulated cAMP- 
dependent phosphorylation of a-Gi-2 also produced phosphopeptide maps which contained 
the PKC-dependent phosphopeptides Cl, C2, and C3, it was unclear, due to difficulties in 
quantifying the phosphorylation at the different sites by two-dimensional phosphopeptide 
mapping, if phosphorylation was occurring at only peptide AN in the presence of cAMP or 
if phosphorylation was occurring at both sites. However, phosphorylation at the PKC site 
may have been occurring as it seems that none of the cAMP-dependent phosphorylations 
were free from PKC activation as a result of cAMP-induced increases in intracellular Ca2+ 
levels which in turn results in the activation of PKC (see Houslay, 1991a; see section 
1.2.4.2; Tang & Houslay, 1992).
The in vitro phosphorylation of a-G i-2 has shown that the protein can be 
phosphorylated by PKC but not PKA (Lincoln, 1991; Sauvage et al., 1991), so it therefore 
seems likely that the protein is able to undergo in vivo phosphorylation by PKC but not 
PKA (see section 3.1.1). Hence it is possible that PKC may directly phosphorylate the 
protein. The phosphorylation motifs for PKC are known, although there is degeneracy and 
the situation regarding isoform specificities needs to be resolved. However, in conjunction 
with the trypsin and V8 digests and the secondary digestion of the tryptic peptides with V8, 
it was possible to predict two potential phosphorylation sites for PKC as serines 47 and 
144, with serine 144 being the more favoured based on potential phosphopeptide 
production on enzymatic cleavage (see Chapter 3). The idea that the protein only possesses 
one PKC phosphorylation site is supported by the stoichiometry data for PKC mediated 32P 
labelling of a-Gi-2 produced by Bushfield et a l (1991).
The identification of the cAMP-dependent site was not possible for two main 
reasons. First, the data available from enzymatic digests were limited as the 
phosphorylation process seemed to produce a protein that was less susceptible to V8 
cleavage, and second, the identity of the kinase is unknown (see Chapter 3). What can be 
said is that the phosphorylation site is not likely to be serines 47 or 144, as these serines do 
not produce phosphopeptides with the necessary mass-charge ratio characteristics. 
Although it has not been shown in vitro that a-Gi-2 can undergo phosphorylation by PKA 
(Lincoln, 1991; Sauvage et a l , 1991), the work did demonstrate that not only was the 
phosphorylation cAMP-dependent but that PKA was also involved since PKA inhibitor, 
HA 1004, could prevent cAMP-dependent phosphorylation of a-Gj_2, but there is still the
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possibility that the inhibitor may have also affected PKC-mediated phosphorylations. The 
difficulty of digesting a-G i-2 that had been phosphorylated by a cAMP-dependent 
mechanism with V8 indicated that the phosphorylation caused either a conformational 
change in the protein so that some of the V8 cleavage sites were now masked from the 
enzyme, or that the phosphorylation occurred at a site near a V8 cleavage site and therefore 
inhibited a cleavage that was important for the initial digestion of the protein, and the 
exposure of further V8 cleavage sites to complete digestion.
Both PKC and cAMP-dependent phosphorylations of a-Gi-2 resulted in the 
deactivation of the protein and a loss of Gi-mediated inhibition of adenylyl cyclase 
(Bushfield et al.y 1990b). Nevertheless, analysis of both the phosphopeptide mapping data 
and the stoichiometry data of 32P labelling of a-Gi-2, clearly indicated the presence of two 
phosphorylation sites. Deactivation of a-Gi-2 seems to correlate with the phosphorylation 
of the PKC site (Bushfield et al., 1990b), thus the effect on a-Gi-2 function due to the 
phosphorylation at the cAMP-dependent site still has to be found. As the stoichiometry data 
(Bushfield et al,y 1991) and phosphopeptide mapping analysis suggest that 
phosphorylations occur at both sites on the same protein, then this may indicate that the 
degree of deactivation of a-Gi-2 is now greater as the action of two separate phosphatases, 
or the action of the same phosphatase at two different sites is required to produce a protein 
that can be activated to inhibit adenylyl cyclase. This may mean that the 'double' 
phosphorylation of a-Gi-2 results in an increased level of deactivation of the protein, that is 
the protein requires a greater degree of dephosphorylation to be in a form that can be 
activated. Alternatively, the phosphorylation of the PKC site may be required to expose the 
PKA-dependent site for phosphorylation, or the phosphorylation at the PKA-dependent site 
may confer stability of the phosphorylated state and hence activation potential of the protein.
Unstimulated hepatocytes show phosphorylation at the PKC site only. This 
demonstrated that, in unstimulated cells, part of the pool of a-Gi-2 was inactivated as 
regards being available to provide tonic inhibition of adenylyl cyclase. This suggested that 
the cells possesses a greater ability to inhibit the activity of adenylyl cyclase than is used. It 
is possible that this offers an explanation for the mechanism by which insulin exerts a small 
inhibition on adenylyl activity in intact cells but not in some isolated membranes (see 
Houslay, 1990; Young et al.t 1991). Such a phosphatase driven dephosphorylation of a- 
Gi-2 could provide a mechanism for a problem which has taxed investigators for many 
years.
The idea that the phosphorylation of a-Gi-2 affects its ability to inhibit adenylyl 
cyclase came from the observation that the rate of the phosphorylation of a-Gi-2 is identical 
to the rate of loss of adenylyl cyclase inhibition in hepatocytes (Bushfield et al., 1990b). It 
has also been suggested that a-Gi is not involved in the insulin-mediated inhibition of 
adenylyl cyclase activity because even though a-Gi and the inhibition of adenylyl cyclase 
are lost in diabetic rats a drug, metformin, which reverses the loss of adenylyl cyclase
250
Chapter 6
inhibition, has no effect on a-Gi levels hence indicating that a-Gi is not responsible for 
adenylyl cyclase inhibition (Houslay, 1990). As it has been shown that in diabetic rats the 
level of a -G i-2 is reduced and the remaining a -G i-2 has undergone increased 
phosphorylation (Bushfield et al., 1990a; Bushfield et al., 1990b) then a mechanism by 
which metformin may be working is to decrease the level of phosphorylation of the 
remaining a-Gi-2 and therefore restore a-Gi-2-mediated inhibition of adenylyl cyclase. 
Alternatively, if a-Gi-2 is not involved in adenylyl cyclase inhibition then the function of the 
phosphorylation events concerning a-Gi-2 are unknown in terms of the effect on signalling 
in hepatocytes, although the phosphorylation may still have some effect on a-Gi-2 function 
as it has been shown that the phosphorylation of a-Gi can decrease its GTPase activity 
(Sauvage etal., 1991).
Interestingly, when hepatocytes from non-diabetic Sprague Dawley rats were 
simultaneously challenged with insulin and glucagon it was found that insulin, instead of 
inhibiting the phosphorylation event, caused an increase in the level of 32P incorporated into 
the protein (see Chapter 4). This was an unexpected effect as it had been found that insulin 
inhibited most other ligands which promoted cAMP-dependent phosphorylation of a-Gi-2. 
What this effect may again demonstrate is the importance of the control of glucose 
homeostasis. If cells were exposed to insulin, and therefore glucose release suppressed, 
and a sudden requirement was made for glucose then this mechanism may provide a method 
for the rapid reversal of cellular glucose handling. That is, the exposure of cells to both 
glucagon and insulin caused a greater level of phosphorylation of a-Gi-2 and therefore 
attenuated the inhibition of cAMP production which, in turn, might result in an increased 
adenylyl cyclase activity and an enhancement of the effects of glucagon on glucose 
metabolism. The existence of this type of mechanism seems unlikely as the involvement of 
the phosphorylation of a-Gi-2 in glucose homeostasis is contradicted by the correction of 
glucose handling by metformin (see Houslay, 1990) and BRL 49653 (see section 5.1.2) in 
diabetic rats where it has been shown that although the improvements occur there is no 
effect on either a-Gi-2 expression, which has been depleted, or on a-Gi-2 phosphorylation.
If the phosphorylation of a-Gi-2 does indeed play a role in intracellular signalling, 
and cellular events mediated by insulin action then some change in a-Gi-2 maY occur in the 
diabetic condition, and indeed changes in the phosphorylation characteristics and level of 
expression of a-Gi-2 in hepatocytes taken from animal models of diabetes have already been 
reported (Bushfield et al., 1990a; Bushfield et al., 1990b; Bushfield et al., 1990c; Gawler et 
a l , 1987).
To examine further these ideas two animal models of diabetes, namely the 
streptozotocin induced type I diabetes in Sprague Dawley rats (see section 4.1.1) and the 
obese Zucker as model of insulin-resistance in type II diabetes (see section 5.1.1) were 
used. It has already been reported that in both models of diabetes the level of expression of 
a-Gi-2 is decreased and its phosphorylation characteristics changed (Bushfield etal., 1990a;
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Bushfield et al., 1990b; Bushfield et al.y 1990c; Gawler et aLy 1987). The changes in 
expression of a-G i-2 observed in the type II model and some of the changes in 
phosphorylation characteristics found in both models were again confirmed by these 
studies.
In the type I model it was found that diabetes significantly decreased the levels of 
phosphorylation induced by 8-bromo-cAMP, PMA and glucagon. Furthermore, insulin no 
longer inhibited basal phosphorylation levels although the change was not significant (see 
Chapter 4). When the data on insulin induced inhibition of ligand induced phosphorylations 
were examined it was found that there was no significant change from the non-diabetic 
animals, although insulin was now able to inhibit significantly 8-bromo-cAMP induced 
phosphorylation. The reduced levels of ligand induced phosphorylations may indicate that 
a-Gi-2 has already been phosphorylated prior to the start of experiment and the phosphatase 
activity of the futile phosphorylation /  dephosphorylation has decreased, hence no increase 
in the level of phosphorylation can be achieved. Alternatively, the increased levels of basal 
phosphorylation may result from the loss of insulin stimulated dephosphorylation as the 
animal is hypoinsulinaemic. Such increased levels of basal phosphorylation does not 
appear to make sense in physiological terms if a-Gi-2 is involved in adenylyl cyclase 
inhibition as the effect would be to increase the effectiveness of cAMP dependent 
mechanisms which in turn may compound the glucose metabolism problems.
In the lean Zucker rat, which acted as a control for the type II model obese Zucker 
rats, it was found that insulin did not affect the basal level of phosphorylation of a-Gi-2. 
Furthermore, 8 -bromo-cAMP, PMA and glucagon significantly stimulated the 
phosphorylation and these results only differed from the non-diabetic Sprague Dawley rats 
in that insulin did not inhibit basal phosphorylation. In the obese animals the 
phosphorylation induced by glucagon and insulin were affected to a small extent but the 
changes were not significant when compared to the lean rats. Examination of the insulin- 
mediated inhibition of ligand stimulated phosphorylation of a-Gi-2 showed that in the lean 
animals insulin inhibited the action of both PMA, and glucagon, and in the obese rats 
insulin inhibited 8-bromo-cAMP and glucagon (see Chapter 5). These findings contrasted 
strongly with the studies in Sprague Dawley rat hepatocytes where it was found that the 
only effect of insulin was to cause an enhancement of the glucagon-mediated stimulation of 
a-Gi.2 phosphorylation.
The difference between the phosphorylation characteristics of a-Gi-2 the lean 
Zucker rats and the non-diabetic Sprague Dawley rats was surprising as it was expected that 
both animals would give a similar result. An explanation may be that as the lean Zucker rats 
still carries one of the recessive genes which is responsible for obesity then both 'normal' 
genes are required for the full and correct functioning of the insulin signal transduction 
system. Alternatively, the difference between the results in the lean Zucker rat and the non­
diabetic Sprague Dawley may not reflect the presence of the single copy of the recessive
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gene in the Zucker rat but may just show a difference in the two animals' insulin signalling 
systems.
Although the insulin-resistance in the obese Zucker rat did not significantly effect 
insulin-dependent modulations of ot-Gi_2 phosphorylation, the fact that insulin was still able 
to inhibit both 8-bromo-cAMP and glucagon stimulated phosphorylation but no longer the 
PMA induced phosphorylation, indicated that a fault in the insulin resistant state, and hence 
possibly part of the control of glucose metabolism, may involve PKC either in its 
expression or activation. Examination of the level of expression of some of the isoforms of 
PKC present in hepatocytes revealed that in the isoforms tested (8, e, y, and 0  that the only 
significant change that occurred was in the distribution of e-PKC between the membrane 
and cytosol fractions. Interestingly this isoform has also been implicated in changes seen in 
streptozotocin induced diabetes in Sprague Dawley rats (Tang et al., 1993).
To explore further the relationship between a-Gi-2 phosphorylation, insulin, and 
insulin resistance, obese Zucker rats were dosed with the compound BRL 49653 (see 
section 5.1.2) which is known to have beneficial effects in improving insulin sensitivity and 
restoring glucose tolerance in animal models of type n  diabetes (Cawthome et al., 1993; 
Kraegen et al., 1993; Smith et al., 1993; Young et al., 1993). It was found that BRL 
49653 changed the phosphorylation characteristics of a-Gi-2 in lean Zucker rats so that they 
now resembled those found in the obese. More significantly, it changed the effects of 
insulin on ligand induced phosphorylation in the lean animals so that they were now 
approaching the profile seen in the non-diabetic Sprague Dawleys (see Chapters 4 and 5). 
In the obese animals the dosing with BRL 49653 did not seem to have any significant effect 
on the phosphorylation of a-Gi-2 or on insulin's effects on drug induced phosphorylation. 
These results further support the idea that there may be some residual effect of the one 
recessive 'obesity' gene in the lean Zucker rats and, more interestingly, that the 
phosphorylation of a-Gi-2 is n°t directly involved in glucose metabolism, because if it were 
then the changes in the phosphorylations seen between the lean and obese animals should be 
corrected as BRL 49653 corrects glucose metabolism.
In summary, the phosphorylation of a-Gi-2 in rat hepatocytes occurs at two 
different sites, one of which, the PKC site, is most probably serine 144. The effect of such 
phosphorylations may be to cause a loss of tonic GTP-mediated Gi inhibition of adenylyl 
cyclase (Bushfield et al., 1991; Bushfield et al., 1990b; Pyne et al., 1989b). Insulin 
inhibits basal phosphorylation of a-Gi-2 in the Sprague Dawley rats but not in the Zucker 
rats. The results from the type II model indicated that insulin resistance may occur as a 
result of an alteration in the PKC mediated phosphorylation of a-Gi-2, although it was also 
demonstrated that even though the animals were insulin resistant that some of the insulin 
effects of ligand induced phosphorylations were still active. A study with the compound 
BRL 49653, which is known to improve insulin sensitivity and glucose handling in animal 
models of type II diabetes, did not significantly alter the phosphorylation characteristics of
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a-Gi_2 other than to change the phosphorylation events in the control, non-diabetic animals 
so that they now resembled those found in diabetic obese animals. This drug study did 
indicate that although changes in a-Gi-2 phosphorylation did occur in animal models of type 
II diabetes, and that as these changes could not be corrected by a compound that could 
improve glucose handling, then the phosphorylation of a-Gi-2 must be involved in some 
other aspect of insulin signalling in rat hepatocytes other than glucose homeostasis.
254
Appendix 1 
Phosphate buffered saline (PBS)
0.14 M NaCl 8.0 gdnr3
2.7 mM KC1 0.2 gdnr3
1.5 mM KH2PO4 0.2 gdnr3
8.1 mM Na2HP04 1.15 gdnr3
Appendix 2
Diabetic Sprague Dawley rats
Diabetes was induced in male Sprague-Dawley rats (225 - 250 g) by a single 
intraperitoneal injection of streptozotocin (50 mg/kg, 0.3 ml) in 0.1 M sodium citrate, 
pH4.5. Animals were killed three to four days after injection, and were judged to be 
diabetic if blood glucose levels exceeded 12 mM.
Perfusion buffers
Stock Krebs (1 dm3)
113 mM NaCl 6.92 g dm-3
4.7 mM KC1 0.32 g dm-3
1.18 mM MgS04.7H20 0.29 gdnr3
1.18 mM k h 2p o 4 0.16 g dm-3
25 mM NaHCC>3 2.10 gdnr3
Krebs plus EDTA
Stock Krebs (100 ml) plus ethylenediaminetetra-acetic acid (EDTA, a
small quantity -  0.5 mM).
Krebs plus glucose
Stock Krebs (200 ml) plus 10 mM glucose (0.36 g).
Krebs plus Ca2+
Stock Krebs (100 ml) plus 2.5 mM CaCl2 (27.75 mg).
Heparin solution
1 mg / ml heparin in 0.9% (w/v) NaCl solution.
Appendix 3
Low phosphate Krebs buffers
Stock low phosphate Krebs (1 dm?)
113 mM N ad 6.92 g dm-3
4.7 mM KC1 0.32 g dm-3
1.18 mM MgS04.7H20 0.29 g dm-3
50 |iM KH2PO4 6.8 mg dm”3
25 mM NaHC03 2.10  g dm”3
25 mM HEPES* 5.96 g dm-3
(*N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid)
Low phosphate Krebs (Incubation buffer)
Stock low phosphate Krebs (200 ml) plus:
2.5% (w/v) Bovine serum albumin (BSA)
2.5 mM CaCl2 55.5 mg
10 mM glucose 0.36 g
Siliconisation of conical flasks
To clean, dry, 25 ml conical flasks 10 - 20 ml of dimethyldichlorosilane solution 
(2% in 1,1,1 trichloroethane; Fisons) was added. The flask was swirled to coat all internal 
surfaces and the solution transferred to the next flask. The flasks were dried in an oven at 
65#C for 30 minutes and then rinsed twice with distilled water before being dried again. 
The flasks were stored until required.
Appendix 4
Immunoprecipitation buffers
Solubilising buffer
1% (v/v) Triton xlOO
10 mM EDTA 1.86 g / 500 ml
100 mM NaH2P04.2H20 7.8 g / 500 ml
100 pM Na3V04 9 mg /  500 ml
50 mM HEPES, pH 7.2 7.1 g / 500 ml
[stored at 4°C]
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Just before use add:
10 (ig/ml Leupeptin
10 (xg/ml Aprotinin
2 mM Phenylmethyl sulfonyl fluoride (PMSF)*
10 nM Okadaic acid (stock [lO'4 M] dissolved in dimethyl sulphoxide)
(* 500 jil PMSF at 35 mg/ml in ethanol to 50 ml solubilising buffer)
Wash buffer plus sodium lauryl sulphate (SDS)
Wash buffer plus 0.1% (w/v) sodium lauryl sulphate (SDS)
Wash buffer
1% (v/v) Triton xlOO 
100 mM NaCl 
50 mM NaH2P04.2H20  
50 mM HEPES, pH 7.2
5.844 g dm-3 
7.8 g dm-3 
11.92 g dm-3
[pH when cold]
Appendix 5
Buffers fo r  SDS~PAGE
Lower gel buffer
1.5 M Tris - HC1, pH8.8 181.65 g dm*3
Upper gel buffer
0.5 M Tris - HC1, pH6.8 60.55 g dm-3
Main gel SDS
1.5 M Tris - HC1, pH8.8 181.65 gdnr3
10% (w/v) sodium lauryl sulphate (SDS)
Stacking gel SDS
0.5 M Tris - HC1, pH6.8 60.55 gdnr3
10% (w/v) sodium lauryl sulphate (SDS)
Acrylamide Solution
30% (w/v) acrylamide : N,N'-methylenebisacrylamide 
([37.5 : 1]; [29.29 g/100 m l: 0.78 g/100 ml])
Running buffer
25 mM Tris 3.0 gdnr3
192 mM glycine 14.4 gdnr3
0.1 % (w/v) sodium lauryl sulphate (SDS)
Main Gel Mix [10%] (two plates)
30 ml water
17.25 ml lower gel buffer
24 ml acrylamide solution
0.92 ml main gel SDS
240 Ml 10% (w/v) ammonium persulphate
36 Ml N,N,N’,N' - tetramethylethylenediamine (TEMED)
Stacking Gel
24 ml water
9.6 ml upper gel buffer
6 ml acrylamide
400 Ml stacking gel SDS
180 Ml 10% (w/v) ammonium persulphate
60 Ml N,N,N',N' - tetramethylethylenediamine (TEMED)
Laemmli buffer
1A ml water
2 ml upper gel buffer
2 ml stacking gel SDS
4 ml 50% (v/v) glycerol
0 .6 ml 2p-mercaptoethanol
0 .0 0 1% (w/v) bromophenol blue
Appendix 6
Pre-flashing
X-ray film (Fuji RX) was pre-flashed for maximum sensitivity and accuracy 
(Bonner & Laskey, 1974; Lasey & Mills, 1975; Randerath, 1970) by using an Amersham 
RPN2051 pre-flash unit. The makers instructions were followed with regards to calibration 
and use, and are breifly outlined below.
Calibration
The flash gun was switched on and fired three or four times to prime the unit. 
One sheet of X-ray film was placed on a white background and using a card with a 2 x 5 cm
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hole different areas of the film were exposed to the flash with the gun placed at various 
heights above the card. This process was repeated for a range of heights starting at 10 cm 
and increasing in 10 cm steps to a height of 1 m. The film was then developed in the 
normal manner.
The film was scanned using a Shimadzu CS-9000 densitometer set at 540 nm. 
The machine was set at zero on an unexposed but developed region of the film. Each 
exposed region of the film was scanned and the exposure that gave an increase of 0.15 
absorbance units above back ground was taken as optimum distance for pre-flashing. 
Under the darkroom conditions used this was found to be 80 cm above the surface of the 
film.
Pre-flashing
The flash gun was fired three or four times to prime the unit and the gun placed 
80 cm above the X-ray film which had been placed on a white background. The gun was 
fired once and then the film was used in the normal manner.
Appendix 7
Buffers fo r  phospho-peptide and phospho-amino acid analysis 
Ammonium bicarbonate solution
50 mM ammonium bicarbonate 400 mg /  100 ml
Electrophoresis buffer (pH 1.9)
50 ml Formic acid (88%)
156 ml Glacial acetic acid 
1794 ml Deionized water
Electrophoresis buffer (pH 35)
10 ml Pyridine 
100 ml Glacial acetic acid 
1890 ml Deionized water
Electrophoresis buffer (pH 4.72)
100 ml n-Butanol
50 ml Pyridine
50 ml Glacial acetic acid
1800 ml Deionized water
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Phospho-chromatography buffer
750 ml n-Butanol
500 ml Pyridine
150 ml Glacial acetic acid
600 ml Deionized water
Marker dyes:
5 mg / ml e - dinitrophenyl (DNP) lysine (yellow, positive marker)
5 mg / ml DNP-DL-Glutamic acid (yellow, neutral marker)
1 mg/ml xylene cyanol FF (blue, negative marker)*
(* xylene cyanol FF made up in water containing 30 - 50%
pH 4.72 buffer)
Dyes mixed 1 : 1 : 1  before application.
Appendix 8
Excel Macros
Calculation o f mass - charge ratios
The Macro is called from the cell in the next column to the peptide (see end of 
appendix). The Macro consists of three subroutines; a main routine that calls the other two 
routines, calculates the mass - charge ratio and produces the final report; a routine that 
calculates the amino acid composition and charge of the peptide; and a third routine that 
calculates the peptide mass. Notes in {) brackets represent comments for guidance and not 
part of the program.
Main control and report subroutine
The function of the subroutine is to call the other routines for the calculation of 
the constituent amino acids of the peptide and its associated charge, and the routine for the 
calculation of the peptide's mass. The column heading, A, and row numbers represent the 
positioning of the program on the Excel spreadsheet
Once the charge and mass have been calculated this subroutine checks to see if the 
peptide contains a serine (if it does not this is reported and the calculation stopped) or if it 
contains more than one serine and hence more than one potential phosphorylation site. If 
the peptide contains multiple phosphorylation sites the program inserts new lines into the 
calculation spreadsheet and copies in the peptide sequence. Finally the program calculates 
the mass - charge ratio and reports the peptide charge, mass and mass - charge ratio. If 
multiple phosphorylation sites exist then the changes in charge, mass and mass - charge 
ratio are also reported (see below for example of output).
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1
2
3
4
5
6
7
8
9
1 0
1 1
1 2
1 3
1 4
1 5
1 6
1 7
1 8
1 9
20
21
2 2
2 3
2 4
2 5
2 6
2 7
2 8
2 9
3 0
31
3 2
3 3
3 4
3 5
3 6
3 7
3 8
3 9
4 0
41
4 2
4 3
4 4
4 5
4 6
4 7
A
CalMr
=ECHO(FALSE)
-CALCULATION^,FALSE,100,0.001 .TRUE, FALSE,'TRUE,TRUE,TRUE) 
=FORMULA("=Mr!Charge(RC[-1])") {Calls routine to calculate charge}
=SELECT(HR[0]C[1]H) {Position for responce}
=FORMULA("=Mr!MW(RC[-2])") {Calls routine to calculate molecular charge} 
=SELECT("R[0]C[1]H) {Position for responce}
=FORMULA("=RC[-2]*(RC[-1]A(-2/3))*100") {Calcs, mass - charge ratio}
-FORMAT.NUMBER("0.00")
=IF(Ser>1)
-ALERT("Peptide contains "&Ser&" serines.",2)
=FOR("Loop",2,Ser,1)
-SELECT ("R[1 ]C[-3]")
=INSERT(2)
=SELECT("R[-1]C")
-COPY()
=SELECT("R[1]C")
=PASTE()
=SELECT("RC[1]")
=CANCELCOPY()
=INSERT(2)
=FORMULA("=R[-1]C+1")
=SELECT("RC[1]")
=INSERT(2)
-FORMULA("=R[-1]C-80")
=SELECT("RC[1]")
=INSERT(2)
= FORMULA(" = (RC[-2]*(RC[-1  ] A(-2 /3)))*1  00")
-FORMAT.NUMBER("0.00")
=NEXT()
=ELSE()
-EN D .IF0
=CALCULATION(1,FALSE,100,0.001,TRUE,FALSE,TRUE,TRUE,TRUE)
= IF (S er< 1) {Lines 34 - 46 check to see  if the peptide contains a}
=SELECT("RC[-2]") {serine and if not reports it.}
-FORMULAf")
=SELECT("RC[1}")
-F O R M U L A D
=SELECT("RCIin
=FORMULA("")
=SELECT("RCI-3]")
=ALERT("There are no serines in this peptidei",3)
=ELSE()
-EN D .IF0
=ECHO(TRUE)
=SELECT("R[1 ]C[-2]")
=RETURN() {End}
{Lines 10 -32 check to see  if the peptide} 
{contains more than one serine, if it does} 
{then a new line is inserted with a copy of} 
{the peptide. Changes in the charge, mass} 
{and mass - charge ratio are also calculated} 
{and reported.}
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Subroutine for the calculation of the constituents and charge of the peptide
This subroutine is called by the above control routine and calculates the amino 
acid constituents of the peptide and its associated charge. At the end of the calculation the 
control returns to the main control subroutine and the next section of the program is 
operated. The column heading, C, and row numbers represent the positioning of the 
program on the Excel spreadsheet.
1 Charge
2 =RESULT(1)
3 =SET.NAME("AlaM,0)
4 =SET.NAME(MArg",0)
5 =SET.NAME("Asn"tO)
6 =SET.NAME("AspH,0)
7 =SET.NAME(MCys"tO)
8 =SET.NAME("Glu",0)
9 =SET.NAME(MGln",0)
1 0 =SET.NAME("Gly",0)
1 1 =SET.NAME("His",0)
1 2  =SET.NAME(MlleH,0)
1 3  =SET.NAME("Leu"fO)
1 4 =SET.NAME(MLys",0)
1 5 =SET.NAME(MMet",0)
1 6 =SET.NAME("Phe'\0)
1 7 =SET.NAME(’,Pro",0)
1 8 =SET.NAME(MSer",0)
1 9 =SET.NAME("Thr",0)
2 0 =SET.NAME("Trp",0)
21 =SET.NAME(MTyrM,0)
2 2 =SET.NAME(MVaP,0)
2 3 =ARGUMENT ("PEPM,2)
2 4 =LEN(PEP)
2 5 -FO R("Counter"f1 ,C24,1)
2 6  =MID(PEP,Counter,1)
2 7  =IF($C$26="A N)
2 8 =SET.NAME("AlaH,Ala+1)
2 9 =ELSE()
3 0  =END.IF()
31 =IF($C$26="R")
3 2 =SET.NAME("Arg",Arg+1) 
3 3 =ELSE()
3 4  =END.IF()
3 5  =IF ($C $26= "N H)
3 6 =SET.NAME("Asn",Asn+1)
3 7 =ELSE()
3 8  =END.IF()
3 9  =IF($C$26="D")
4 0 =SET.NAME(”Asp",Asp+1)
41 =ELSE()
4 2  =END.IF()
4 3  =IF($C$26="C")
{Lines 3 - 22 sets the amino acid counters to zero.}
{Number of amino acids in the peptide.}
{Lines 25 - 107 takes the first amino acid (single} 
{letter code) and determines which amino acid i t } 
{is. When found it adds one to the score of the}
{total number of amino acids of that type found in } 
{the peptide. When line 107 is reached the } 
{program returns to line 25 and the process is 
{repeated for the next letter. This process} 
{continues until all the amino acids in the peptide} 
{have been checked.}
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4 4
4 5
4 6
4 7
4 8
4 9
5 0
51
5 2
5 3
5 4
5 5
5 6
5 7
5 8
5 9
6 0
61
6 2
6 3
6 4
6 5
66
6 7
68
6 9
7 0
71
7 2
7 3
7 4
7 5
7 6
7 7
7 8
7 9
8 0
81
8 2
8 3
8 4
8 5
86
8 7
88
8 9
9 0
91
9 2
9 3
9 4
9 5
9 6
=SET.NAME("Cys"fCys+1) 
=ELSE()
=END.IF()
= IF($C$26="E") 
=SET.NAME(MGlu'\Glu+1) 
=ELSE()
=END.IF()
=IF($C$26="Q")
=SET.NAME(MGlrTfGln+1)
=ELSE()
=END.IF() 
= IF ($C $26= ,,G ,,) 
=SET.NAME(MGlyH,Gly+1) 
=ELSE()
=END.IF()
=IF($C$26="H ")
=SET.NAME(MHisH,His+1)
=ELSE()
=END.IF()
= I F ( $ C $ 2 6 = T )
=SET.NAME(HlleM,lle+1)
=ELSE()
=END.IF()
= IF($C$26="L") 
»SET.NAME("Leu",Leu+1) 
■ELSE()
-END.IFQ 
= IF ($C $26*"K H) 
=SET.NAME(HLys",Lys+1) 
=ELSE()
=END.IF()
= IF ($ C $ 2 6 = ,,M',) 
=SET.NAME(MM er\M et+1) 
=ELSE()
=END.IF()
= IF ($C $26= "F M) 
=SET.NAME("Phe"fPhe+1) 
=ELSE()
=END.IF()
= IF($C$26="P") 
=SET.NAME(MProM,Pro+1) 
=ELSE()
=END.IF()
= IF ($C $26= HS") 
=SET.NAME(MSer",Ser+1) 
=ELSE()
=END.IF() 
= IF ($ C $ 2 6 = ,,TH) 
=SET.NAME(MThr"fThr+1) 
=ELSE()
=END.IF()
= IF ($ C $ 2 6 = ”W") 
=SET.NAME(MTrp '\Trp+1)
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9 7 =ELSE()
9 8  =END.IF()
9 9  = IF($C$26="Y")
1 0 0  =SET.NAME(MTyrM yr+1)
101 =ELSE()
1 0 2  =END.IF()
1 0 3  = IF ($C $26= HV")
1 0 4  =SET.NAME("Var,Val+1)
1 0 5  =ELSE()
1 0 6  =END.IF()
1 0 7  =NEXT()
1 0 8  = (A rg*1)  + (C y s * -1 )  + (L y s* 1 )  + (H is* 1 )  + ( ( S e r - 1 ) * - 1 )
1 0 9  =RETURN(C108)
{Line 108 calculates the charge of the peptide and this value is returned by line 109 to 
the main control program}
Subroutine for the calculation o f the molecular weight of the peptide
This subroutine calculates the mass of the peptide. The column heading, E, and 
row numbers represent the positioning of the program on the Excel spreadsheet.
E
1 MW
2 =RESULT(1)
3 =Ala*89 {Lines 3 - 22 calculate the mass of the }
4 =A rg*174 {individual amino acids in the peptide based }
5 =Asn*132 {on the known numbers of the different}
6 =Asp*133 {amino acids calculated in the l a s t }
7 =C ys*121 {subroutine.}
8 =Glu*147
9 =Gln*146
1 0 =Gly*75
1 1 = H is*155
1 2 = I le*131
1 3 =Leu*131
1 4 = Lys*146
1 5 = M et*149
1 6 = P h e* 1 65
1 7 = P ro * 1 15
1 8 = T h r* 1 1 9
1 9 =T rp* 2 0 4
2 0 =Tyr*1 81
21 =V al*117
2 2 = S e r* 1 85
2 3 =SUM(E3:E22) {Calculates mass of peptide}
2 4 = E 2 3 - (1 8 * (L E N (P E P ) -1 ) ) {Subtracts the mass of water lost in forming 
the peptide.}
2 5 =RETURN(E24) {Reports the final mass.}
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Calculation and output of results
The Macro is activated from cell C2 on the spread sheet.
C2
IP!
A I B  C I D E
1 No. Peptide Charge Maes Ratio
2
3
1
2
MHESKRGD p» 
HSSWG M KA?VJ?
4 3 SRE
5
After the Macro has run it reports the charge (3), mass (1038) and mass - charge 
ratio (2.93, [this actually represents the mass - charge ratio multiplied by 100]) of the 
peptide in cells C2, D2 and E2, respectively.
C3
A I B c I D E
1 No. Peptide Charge Mass Ratio
2 1 MHESKRGD 3 1 0 3 8 2 .9 3
3 2 HSSWG MKAAA
4 3 SRE
5
When the Macro is activated in cell C3 to calculate the mass - charge ratio of the 
second peptide (HSSWGMKAA) it finds that it contains two serines and this is reported.
Peptide  conta ins  2 se r ines .sNo. Pep
1 MH
2 HSS
3 SRE
Once the report has been acknowledged the Macro continues with the calculation, 
inserts a new row and pastes a copy of the peptide in B4. The mass - charge ratios are then 
reported in the usual fashion with the changes in mass and charge as a result of an extra 
phosphorylation event being taken into account.
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A 1 B C D E
1 No. Peptide Charge Maes Ratio
2 1 MHESKRGD 3 1 0 3 8 2 .9 3
3 2 HSSWG MKAAA 1 1 2 0 4 0 .8 8
4 HSSWG MKAAA 2 1 1 2 4 1.85
5 3 SRE
Finally the mass charge ratio of the last peptide is calculated by activating the 
Macro in C5.
A 1 B C D E 1
1 No. Peptide Charge Mass Ratio
2 1 MHESKRGD 3 1 0 3 8 2 .9 3
3 2 HSSWGMKAAA 1 1 2 0 4 0 .8 8
4 HSSWG MKAAA 2 1 1 2 4 1.85
5 3 SRE 4 7 0 1.65
Calculation o f Mann - Whitney U value
This Excel macro calculates the Mann - Whitney U value for two sets of data in 
an argument where the data sets are expressed in terms of standard Excel arrays (e.g. 
A2:E2, A3:F3). The value reported is the U value for which the corresponding p value can 
be found by using any standard set of statistical tables. The column heading, A, and row 
numbers represent the positioning of the program on the Excel spreadsheet
1 ManWhit
2 =RESULT(1)
3 =ECHO(FALSE)
4 =ARGUMENT ("Arrayl H,8)
5 =ARGUMENT("Array2",8)
6 =SET.NAME("U",0)
7 =SET.NAME("EqualPlace".0)
8 =SET.NAME("lowH,0)
9 =SET.NAME("Ur\0)
I 0 =SET.N AM E(" Final U'\0)
I I  =COUNT(Array1)
1 2  =COUNT(Array2)
13  =SET.NAME("SumRank",0)
14  =SET.NAME(HTotalEquaP\0)
15  =IF(A11 <=A12)
1 6 =FOR.CELL("TestCell",Arrayl .TRUE)
1 7 =SET.NAME("EqualPlace",-0.5)
1 8 =FOR.CELL("CCeN"f(Array1 ,Array2) .TRUE) 
19  =IF(TestCell=CCell)
2 0 =SET.NAME("EqualPlace",EqualPlace+0.5)
21 =ELSE()
2 2  =END.IF()
2 3 =NEXT()
{Lines 4 and 5 difine the argument array} 
{Lines 6 - 1 0  defines names and sets to zero}
{n1= for Array 1} 
{n2= for Array 2}
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2 4 =SET.NAME("TotalEquar,TotalEqual+EqualPlace)
2 5 =NEXT()
2 6 =FOR.CELL("CurrentCellM,Arrayl .TRUE)
2 7  =RANK(CurrentCell,(Arrayl ,Array2),1)
2 8 =SET.NAME("SumRank"fSumRank+A27)
2 9 =NEXT()
3 0 =SET.NAME(MSumRank",SumRank+TotalEqual)
31 =ELSE()
3 2 =F0R.CELL(MTestCeir,Array2,TRUE)
3 3 =SET.NAME("EqualPlaceV0.5)
3 4 =FOR.CELL("CCeir, (Arrayl ,Array2),TRUE)
3 5 =IF(TestCell=CCell)
3 6 =SET.NAME(MEqualPlace"fEqualPlace+0.5)
3 7 =ELSE()
3 8  =END.IF()
3 9 =NEXT()
4 0 =SET.NAME("TotalEquar,TotalEqual+EqualPlace)
41 =NEXT()
4 2 =F0R.CELL(MCurrentCeir,Array2 .TRUE)
4 3 =RANK(CurrentCell,(Array 1 ,Array2),1)
4 4 =SET.NAME("SumRankM,SumRank+A43)
4 5 =NEXT()
4 6 =SET.NAME("SumRank",SumRank+TotalEqual)
4 7  =END.IF()
4 8  =IF(A11 <A12)
4 9 =SET.NAME(MUM, U+(A11 *A12)+((A11 *(A11+1 ))/2)-Sum Rank)
5 0 =SET.NAME(HUI",UI+(A11 *A12)-A49)
51 =ELSE()
5 2 -S E T .N A M E fU ", U+(A11 *A12)+((A12*(A12+1 ))/2)-Sum Rank) 
5 3 =SET.NAME(MU r,U I+(A 11 *A12)-A52)
5 4  =END.IF()
5 5  =IF(U<UI)
5 6 =SET.NAME(MFinalU”tFinalU+U)
5 7 =ELSE()
5 8 =SET.NAME("FinalU",FinalU+UI)
5 9  =END.IF()
6 0 =ECHO(TRUE)
61 =RETURN(FinalU)
(Lines 1 5 - 3 1  ranks the two sets of data and calculates the sum of the ranking if n1<n2} 
(Lines 32 - 47 ranks the two sets of data and calculates the sum of the ranking if n1>n2} 
(Lines 48 - 54 calculates the U values depending on whether n1<n2 or n1^n2}
(Lines 55 - 61 determine which (U1 or U) is the smallest U value and reports it}
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Appendix 9
B uffer A
10 mM Tris - HC1, pH7.4 1.20 gdm-3
1 mM EDTA 0.37 g dm*3
1 mM EGTA 0.37 gdm-3
10 mM (3-glycerophosphate 2.17 gdm"3
2 mM Benzamidine 0.31 gdm-3
1 mM Phospho - serine 0.20 gdm-3
1 mM Phospho - threonine 0.22 gdm-3
0.25 M Sucrose 25.65 gdm-3
Just before use mix:
25 ml Buffer A
300 |il PMSF (17 mg / ml, dissolved in methanol)
25 |il Aprotinin (stock: 10 mg/ml)
25 |xL Leupeptin (stock: 10 mg/ml)
2.5 pi Okadaic acid (stock [10*4 M] dissolved in dimethyl sulphoxide)
Appendix 10
Solutions fo r  Western Blotting
Blot Electrode Buffer (BEB)
25 mM Tris 3.0 gdnr3
192 mM Glycine 14.4 g dm-3
20% (v/v) Methanol 200 ml dm-3
Tris - Buffered - Saline - Tween (TSB-T)
10 mM Tris - HC1, pH 7.4 1.21 gdnr3
140 mM NaQ 8.18 gdnr3
0.1 % (v/v) Polyoxyethylene sorbitan monolaurat (Tween 20)
High - Salt - Tris Buffer (HST)
10 mM Tris - HC1, pH 7.4 1.21 gdnr3
1 M NaCl 58.4 gdnr3
0.5% (v/v) Tween 20
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Developing solution
Solution:- 0.4% (w/v) 3-Amino-9-ethylcarbazol (AEC) in dimethyl formamide.
0.4 ml 0.4% (w/v) AEC
9.5 ml 50 mM Sodium acetate pH 5 (pH with glacial acetic acid)
5 |il Tween 20
3 pi H20 2
Ponceau S stain
0.1 % (w/v) Ponceau S in 3% (w/v) trichloro-acetic acid.
Appendix 11 
Solutions fo r  enzyme - linked immuno - assays (ELISA)
0.1 M sodium carbonate buffer (pH9.6)
Appendix 12
Calculations o f peptides and mass - charge ratios fo r  a-G i.2  
Primary sequence of rat a -G ^
K Q N K I I H E D G Y S E E E C R Q Y R A V V Y S N T I Q S i r i A I V K A f l G N L Q I D F A D P Q R  1 0 0
A D D A R Q L F A L S C A A E E Q G H L P E D L S G Y I R R L V A D H G Y Q A C F G R S R E Y Q L N  1 5 0
D S A A Y Y L N D L E R I A Q S D Y I P T Q Q D Y L R T R V K T T G I V E T H F T F K D L H F K H F  2 0 0
D V G G Q R S E R K K V I H C F E G Y T A I I F C V A L S A Y D L V L A E D E E M N R I I H E S r i K L  2 5 0
F D S I C N N K V F T D T S I I L F L N K K D L F E E K I T Q S P L T I C F P E Y T G A N K Y D E A  3 0 0
A S Y I Q S K F E D L N K R K D T K E I Y T H F T C A T D T K N Y Q F V F D A V T D V I I K N N L K  3 5 0
D C G L F  3 5 5
Sodium carbonate 
Sodium hydrogen carbonate
1.7 g dm-3 
2.68 gdm-3
Developing solution 
Citric acid buffer (pH6)
18 mM Citric acid 
65 mM Na2HPQ4
3.78 gdm-3 
9.23 g dm-3
Developing solution
6 mg orthophenylenediamine
15 ml Citric acid buffer (pH6)
5 pi H ^
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Possible trypsin and V8 peptides
Using the method outlined in chapter 3 it is possible to predict the serines that 
possess the best kinase motifs and the peptides that will be produced that contain them on 
enzymatic cleavage. The table below lists the predicted peptides. (Please see chapter 3 for a 
more complete explanation.)
Trypsin Try +V8
Ser Poss (V8) Sequence c MW mr Sequence c MW mr Poss(mr)
16 Y 11A-21K 3 1299 2.52 15R-20D 2 829 2.27 N
16 N 11A - 17K 2 812 2.30
16 N 16S - 21K 2 801 2.32
16 N 16S - 17K 1 313 2.17
44 N 30A - 46K 3 1712 2.10
44 N 33E - 46K 2 1494 1.53
44 N 36L - 46K 1 1137 0.92
47 Y 30A - 67R 7 4270 2.66 44S - 58E 4 1779 2.72 Y
47 44S - 59D 4 1894 2.61 N
47 34V-58E 5 2774 2.53 N
47 34V-59D 5 2889 2.47 N
47 44S - 63E 4 2331 2.28 N
47 34V-63E 5 3325 2.24 N
47 44S-64E 4 2460 2.20 N
47 34V-64E 5 3454 2.19 N
47 34V-65E 5 3583 2.14 N
47 44S - 65E 4 2589 2.12 N
47 N 47S - 67R 4 2576 2.13
47 Y 33E - 67R 6 3972 2.39 44S - 58E 4 1779 2.72 Y
47 44S - 59D 4 1894 2.61 Y
47 34V-58E 5 2774 2.53 Y
47 34V-59D 5 2889 2.47 Y
47 44S - 63E 4 2331 2.28 N
47 34V - 63E 5 3325 2.24 N
47 44S - 64E 4 2460 2.20 N
47 34 V - 64E 5 3454 2.19 N
47 34V-65E 5 3583 2.14 N
47 44S - 65E 4 2589 2.12 N
47 Y 36L-67R 5 3615 2.12 44S - 58E 4 1779 2.72 Y
47 44S - 59D 4 1894 2.61 Y
47 44S - 63E 4 2331 2.28 Y
47 44S-64E 4 2460 2.20 Y
47 44S - 65E 4 2589 2.12 Y
47 N 36L - 54K 3 2054 1.86
47 N 36L-51K 2 1666 1.42
47 N 47 S - 54K 2 1014 1.98
47 N 47S - 5 IK 1 627 1.37
47 N 36L-51K 2 1666 1.42
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144 Y 106Q-177R 5 8288 1.22 131L-146E 4 2694 2.07 Y
144 123D-146E 4 2809 2.01 Y
144 124L-159D 4 3328 1.79 Y
144 123D-159D 4 3443 1.75 Y
144 117Q-146E 4 3465 1.75 Y
144 116E-146E 4 3594 1.70 Y
144 124L-167D 5 5139 1.68 Y
144 135H-146E 2 1427 1.58 Y
144 117Q-159D 4 4099 1.56 Y
144 124L-159D 4 4226 1.53 Y
144 116E-159D 4 4228 1.53 Y
144 116E-167D 5 6039 1.51 Y
144 123D-159D 4 4341 1.50 Y
144 123D-174D 5 6100 1.50 Y
144 123D-161E 4 4583 1.45 Y
144 117Q-174D 5 6756 1.40 Y
144 116E-174D 5 6885 1.38 Y
144 117Q-159D 4 4997 1.37 Y
144 116E-159D 4 5126 1.35 Y
144 117Q-161E 4 5239 1.33 Y
144 116E-161E 4 5368 1.30 Y
144 135H-151D 2 2060 1.24 Y
144 135H-167D 3 3871 1.22 Y
144 135H-159D 2 2958 0.97 N
144 Y 130R-177R 5 5727 1.56 135H - 146E 2 1427 1.58 Y
144 135H-151D 2 2060 1.24 N
144 135H-167D 3 3871 1.22 N
144 135H-174D 3 4717 1.07 N
144 135H-159D 2 2958 0.97 N
144 135H - 161E 2 3200 0.92 N
144 Y 131L-177R 4 5571 1.27 135H-146E 2 1427 1.58 Y
144 135H-151D 2 2060 1.24 N
144 135H-159D 2 2958 0.97 N
144 135H - 161E 2 3200 0.92 N
144 N 144S-177R 3 4129 1.17
144 N 144S - 162R 2 2400 1.12
144 N 144S-145R 1 341 2.05
144 Y 106Q-162R 4 6559 1.14 124L-146E 4 2694 2.07 Y
144 123D-146E 4 2809 2.01 Y
144 124L -15 ID 4 3328 1.79 Y
144 123D -15ID 4 3443 1.75 Y
144 117Q-146E 4 3465 1.75 Y
144 116E-146E 4 3594 1.70 Y
144 135H-146E 2 1427 1.58 Y
144 117Q-151D 4 4099 1.56 Y
144 124L-159D 4 4226 1.53 Y
144 116E-151D 4 4228 1.53 Y
144 123D-159D 4 4341 1.50 Y
144 123D-161E 4 4583 1.45 Y
144 117Q-159D 4 4997 1.37 Y
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144 116E-159D 4 5126 1.35 Y
144 117Q-161E 4 5239 1.33 Y
144 116E-161E 4 5368 1.30 Y
144 135H-151D 2 2060 1.24 Y
144 135H-159D 2 2958 0.97 N
144 N 106Q-145R 3 4500 1.10
144 Y 130R - 162R 4 3998 1.59 135H-146E 2 1427 1.58 N
144 135H- 15 ID 2 2060 1.24 N
144 135H-159D 2 2958 0.97 N
144 135H - 161E 2 3200 0.92 N
144 N 130R - 145R 3 1939 1.93
144 Y 131L-162R 3 3842 1.22 135H-146E 2 1427 1.58 Y
144 135H -15 ID 2 2060 1.24 Y
144 135H-159D 2 2958 0.97 N
144 135H - 161E 2 3200 0.92 N
144 N 131L - 145R 2 1783 1.36
207 Y 194D- 243R 5 5900 1.53 202V-217E 4 2040 2.49 Y
207 202V-232D 3 3565 1.29 N
207 202V - 238E 3 4091 1.17 N
207 202V-239D 3 4206 1.15 N
207 202V - 208E 1 812 1.15 N
207 202V - 240E 3 4335 1.13 N
207 202V - 241E 3 4465 1.11 N
207 Y 194D-211K 5 2259 2.90 195L-208E 2 1731 1.39 N
207 202V - 208E 1 812 1.15 N
207 Y 194D - 210K 4 2131 2.42 195L-208E 2 1731 1.39 N
207 202V - 208E 1 812 1.15 N
207 Y 194D - 209R 3 2002 1.89 195L-208E 2 1731 1.39 N
207 202V - 208E 1 812 1.15 N
207 Y 199M - 243R 4 5260 1.32 202V-217E 4 2040 2.49 Y
207 202V - 232D 3 3565 1.29 N
207 202V - 238E 3 4091 1.17 N
207 202V-239D 3 4206 1.15 N
207 202V - 208E 1 812 1.15 N
207 202V - 240E 3 4335 1.13 N
207 202V - 24IE 3 4465 1.11 N
207 N 207S - 243R 3 4368 1.12
207 Y 199M-211K 4 1618 2.90 202V - 208E 1 812 1.15 N
207 Y 199M - 210K 3 1490 2.30 202V - 208E 1 812 1.15 N
207 Y 199M - 209R 2 1362 1.63 202V-208E 1 812 1.15 N
207 N 207S-211K 3 727 3.71
207 N 207S - 210K 2 599 2.82
207 N 207S - 209R 1 470 1.65
247 N 244M - 258K 3 1877 1.97
247 N 244M - 249K 2 842 2.24
306 Y 297Y - 33IK 6 4242 2.29 300A-319E 5 2452 2.75 Y
306 299E - 319E 5 2581 2.66 Y
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306 300A-316D 4 2093 2.44 Y
306 299E - 316D 4 2222 2.35 Y
306 300A - 329D 5 3605 2.13 N
306 299E - 329D 5 3734 2.08 N
306 300A - 309E 1 1223 0.87 N
306 300A-310D 1 1338 0.82 N
306 299E-309E 1 1352 0.82 N
306 299E - 310D 1 1467 0.77 N
306 Y 297Y-318K 5 2730 2.56 300A- 316D 4 2093 2.44 N
306 299E - 316D 4 2222 2.35 N
306 300A - 309E 1 1223 0.87 N
306 300A- 310D 1 1338 0.82 N
306 299E - 309E 1 1352 0.82 N
306 299E - 310D 1 1467 0.77 N
306 Y 297Y-315K 4 2385 2.24 300A - 309E 1 1223 0.87 N
306 300A-310D 1 1338 0.82 N
306 299E-309E 1 1352 0.82 N
306 299E - 310D 1 1467 0.77 N
306 Y 297Y - 314R 3 2257 1.74 300A-309E 1 1223 0.87 N
306 300A-310D 1 1338 0.82 N
306 299E - 309E 1 1352 0.82 N
306 299E - 310D 1 1467 0.77 N
306 Y 297Y - 313K 2 2101 1.22 300A-309E 1 1223 0.87 N
306 300A-310D 1 1338 0.82 N
306 299E - 309E 1 1352 0.82 N
306 299E - 310D 1 1467 0.77 N
306 N 297Y - 307K 0 1354 0.00
Remaining peptides
From the data presented in chapter 3, that is V8 cleavage of the tryptic peptide 
increases its mass - charge ratio, then it is possible to eliminate all peptides from the above 
table that are either not cleaved by V8 or whose mass - charge ratio decreases. This leaves 
the following peptides as candidates. (Please see chapter 3 for a more complete 
explanation.)
Trypsin Try +V8
Ser Poss (V8) Sequence c MW mr Sequence c MW mr Poss(mr)
47 Y 30A - 67R 7 4270 2.66 44S - 58E 4 1779 2.72 Y
47 Y 33E - 67R 6 3972 2.39 44S - 58E 4 1779 2.72 Y
47 44S - 59D 4 1894 2.61 Y
47 34V-58E 5 2774 2.53 Y
47 34V-59D 5 2889 2.47 Y
47 Y 36L - 67R 5 3615 2.12 44S - 58E 4 1779 2.72 Y
47 44S - 59D 4 1894 2.61 Y
47 44S - 63E 4 2331 2.28 Y
47 44S - 64E 4 2460 2.20 Y
47 44S - 65E 4 2589 2.12 Y
144 Y 106Q - 177R 5 8288 1.22 131L-146E 4 2694 2.07 Y
273
144 123D - 146E 4 2809 2.01 Y
144 124L - 159D 4 3328 1.79 Y
144 123D - 159D 4 3443 1.75 Y
144 117Q-146E 4 3465 1.75 Y
144 116E-146E 4 3594 1.70 Y
144 124L - 167D 5 5139 1.68 Y
144 135H - 146E 2 1427 1.58 Y
144 117Q-159D 4 4099 1.56 Y
144 124L - 159D 4 4226 1.53 Y
144 116E-159D 4 4228 1.53 Y
144 116E-167D 5 6039 1.51 Y
144 123D - 159D 4 4341 1.50 Y
144 123D - 174D 5 6100 1.50 Y
144 123D - 161E 4 4583 1.45 Y
144 117Q-174D 5 6756 1.40 Y
144 116E-174D 5 6885 1.38 Y
144 117Q-159D 4 4997 1.37 Y
144 116E-159D 4 5126 1.35 Y
144 117Q-161E 4 5239 1.33 Y
144 116E-161E 4 5368 1.30 Y
144 135H-151D 2 2060 1.24 Y
144 135H-167D 3 3871 1.22 Y
144 Y 130R - 177R 5 5727 1.56 135H-146E 2 1427 1.58 Y
144 Y 131L-177R 4 5571 1.27 135H-146E 2 1427 1.58 Y
144 Y 106Q-162R 4 6559 1.14 124L-146E 4 2694 2.07 Y
144 123D - 146E 4 2809 2.01 Y
144 124L -15 ID 4 3328 1.79 Y
144 123D -15 ID 4 3443 1.75 Y
144 117Q-146E 4 3465 1.75 Y
144 116E-146E 4 3594 1.70 Y
144 135H - 146E 2 1427 1.58 Y
144 117Q-151D 4 4099 1.56 Y
144 124L - 159D 4 4226 1.53 Y
144 116E-151D 4 4228 1.53 Y
144 123D - 159D 4 4341 1.50 Y
144 123D - 161E 4 4583 1.45 Y
144 117Q-159D 4 4997 1.37 Y
144 116E-159D 4 5126 1.35 Y
144 117Q- 161E 4 5239 1.33 Y
144 116E-161E 4 5368 1.30 Y
144 135H -15 ID 2 2060 1.24 Y
144 Y 131L-162R 3 3842 1.22 135H-146E 2 1427 1.58 Y
144 135H- 151D 2 2060 1.24 Y
207 Y 194D - 243R 5 5900 1.53 202V-217E 4 2040 2.49 Y
207 Y 199M - 243R 4 5260 1.32 202V-217E 4 2040 2.49 Y
306 Y 297Y - 33 IK 6 4242 2.29 300A-319E 5 2452 2.75 Y
306 299E - 319E 5 2581 2.66 Y
306 300A-316D 4 2093 2.44 Y
306 299E - 316D 4 2222 2.35 Y
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Ser = serine number in primary sequence; Poss (V8) = whether the peptide contains a 
sequence that can be cleaved by V8 (Y = Yes; N = No); Trypsin Sequence = proposed 
tryptic peptide, number is the position in the primary amino acid sequence, letter the amino 
acid; c = charge on peptide; MW = molecular weight; mr = mass - charge ratio (multiplied 
by 100); Try + V8 Sequence = proposed V8 peptide cleaved from corresponding tryptic 
peptide; Poss (mr) = change in mass - charge ratio of the trypsin peptide upon V8 cleavage, 
Y = increase, N = decrease. See text in Chapter 3, sections 3.1.2 and 3.1.4, for description 
of technique for prediction of peptides, and kinase motifs. See sections 2.2.12 and 3.1.4, 
for description of mass - charge ratio calculations.
Appendix 13
Estimation of a-G& loaded per t.l.c. plate
Each t.l.c plate had approximately 100 c.p.m. of 32P labelled a-Gi_2 peptides 
loaded onto it. As this figure was determined by Cerenkov, which has a 50% efficiency, 
then it is assumed that 200 d.p.m. was applied to the plate. As the time required to process 
the peptides took approximately one half life (14.3 days) then it is assumed that the loading 
was in the region of 400 d.p.m. Note: It has been assumed that 32P is in excess of cold 
phosphate and no consideration is taken into account for cold labelling.
Using the equations:
_f“ .lN
dt ti/2
Where -dN/dt = the number of atoms decaying per small increment of time, N = 
total number of radioactive atoms present at a given time, X = the decay constant of the 
isotope and ti/2 = half life of 32P, which equals 14.3 days or 20592 minutes.
Therefore using the above equations and rearranging:
N =  400
(0.693/20592) 
Therefore:
N = 11.8 x 106 atoms
Avogadro's number = 6.02 x 1023
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Therefore as stiochiometry of labelling is approximately 1 mol 32P / mol a-Gi-2 
(Bushfield et a/., 1990) then there is approximately 20 x 10-18 moles or 20 amoles of 
a -G i-2 -
As 10 - 100 pmoles are required for sequencing then the experiment only 
produces one ten-millionth of the amount required although the level of peptide actually 
present are most probably higher it still seems likely that the pmole range will not be 
reached.
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